Age at Treatment=62.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-F1;Tissue=Prostate Tumour;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-F1;Tissue=Prostate Tumour;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-F1;Tissue=Prostate Tumour;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-F1;Tissue=Prostate Tumour;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-F1;Tissue=Prostate Tumour;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-B1;Tissue=Blood;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-B1;Tissue=Blood;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-B1;Tissue=Blood;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-B1;Tissue=Blood;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-B1;Tissue=Blood;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-B1;Tissue=Blood;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-B1;Tissue=Blood;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-B1;Tissue=Blood;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-F1;Tissue=Prostate Tumour;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-F1;Tissue=Prostate Tumour;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-F1;Tissue=Prostate Tumour;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-F1;Tissue=Prostate Tumour;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-F1;Tissue=Prostate Tumour;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-F1;Tissue=Prostate Tumour;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-F1;Tissue=Prostate Tumour;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-F1;Tissue=Prostate Tumour;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-F1;Tissue=Prostate Tumour;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-F1;Tissue=Prostate Tumour;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-F1;Tissue=Prostate Tumour;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-F1;Tissue=Prostate Tumour;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-F1;Tissue=Prostate Tumour;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-F1;Tissue=Prostate Tumour;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-F1;Tissue=Prostate Tumour;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0486-F1;Tissue=Prostate Tumour;donor_id=CPCG0486;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0487-B1;Tissue=Blood;donor_id=CPCG0487;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0487-B1;Tissue=Blood;donor_id=CPCG0487;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0487-B1;Tissue=Blood;donor_id=CPCG0487;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0487-B1;Tissue=Blood;donor_id=CPCG0487;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0487-B1;Tissue=Blood;donor_id=CPCG0487;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0487-B1;Tissue=Blood;donor_id=CPCG0487;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0487-B1;Tissue=Blood;donor_id=CPCG0487;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0487-B1;Tissue=Blood;donor_id=CPCG0487;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0489-B1;Tissue=Blood;donor_id=CPCG0489;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0489-B1;Tissue=Blood;donor_id=CPCG0489;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0489-B1;Tissue=Blood;donor_id=CPCG0489;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0489-B1;Tissue=Blood;donor_id=CPCG0489;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0489-B1;Tissue=Blood;donor_id=CPCG0489;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0489-B1;Tissue=Blood;donor_id=CPCG0489;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0489-B1;Tissue=Blood;donor_id=CPCG0489;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0489-B1;Tissue=Blood;donor_id=CPCG0489;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0489-F1;Tissue=Prostate Tumour;donor_id=CPCG0489;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0489-F1;Tissue=Prostate Tumour;donor_id=CPCG0489;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0489-F1;Tissue=Prostate Tumour;donor_id=CPCG0489;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0489-F1;Tissue=Prostate Tumour;donor_id=CPCG0489;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0489-F1;Tissue=Prostate Tumour;donor_id=CPCG0489;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0489-F1;Tissue=Prostate Tumour;donor_id=CPCG0489;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-B1;Tissue=Blood;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-B1;Tissue=Blood;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-B1;Tissue=Blood;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-B1;Tissue=Blood;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-B1;Tissue=Blood;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-B1;Tissue=Blood;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-B1;Tissue=Blood;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-B1;Tissue=Blood;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-F1;Tissue=Prostate Tumour;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-F1;Tissue=Prostate Tumour;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-F1;Tissue=Prostate Tumour;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-F1;Tissue=Prostate Tumour;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-F1;Tissue=Prostate Tumour;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-F1;Tissue=Prostate Tumour;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-F1;Tissue=Prostate Tumour;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-F1;Tissue=Prostate Tumour;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-F1;Tissue=Prostate Tumour;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-F1;Tissue=Prostate Tumour;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-F1;Tissue=Prostate Tumour;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-F1;Tissue=Prostate Tumour;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-F1;Tissue=Prostate Tumour;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-F1;Tissue=Prostate Tumour;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-F1;Tissue=Prostate Tumour;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0490-F1;Tissue=Prostate Tumour;donor_id=CPCG0490;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-B1;Tissue=Blood;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-B1;Tissue=Blood;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-B1;Tissue=Blood;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-B1;Tissue=Blood;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-B1;Tissue=Blood;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-B1;Tissue=Blood;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-B1;Tissue=Blood;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-B1;Tissue=Blood;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-F1;Tissue=Prostate Tumour;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-F1;Tissue=Prostate Tumour;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-F1;Tissue=Prostate Tumour;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-F1;Tissue=Prostate Tumour;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-F1;Tissue=Prostate Tumour;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-F1;Tissue=Prostate Tumour;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-F1;Tissue=Prostate Tumour;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-F1;Tissue=Prostate Tumour;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-F1;Tissue=Prostate Tumour;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-F1;Tissue=Prostate Tumour;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-F1;Tissue=Prostate Tumour;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-F1;Tissue=Prostate Tumour;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-F1;Tissue=Prostate Tumour;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-F1;Tissue=Prostate Tumour;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-F1;Tissue=Prostate Tumour;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0492-F1;Tissue=Prostate Tumour;donor_id=CPCG0492;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-F1;Tissue=Prostate Tumour;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-F1;Tissue=Prostate Tumour;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-F1;Tissue=Prostate Tumour;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-F1;Tissue=Prostate Tumour;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-F1;Tissue=Prostate Tumour;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-F1;Tissue=Prostate Tumour;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-F1;Tissue=Prostate Tumour;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-F1;Tissue=Prostate Tumour;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-F1;Tissue=Prostate Tumour;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-F1;Tissue=Prostate Tumour;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-F1;Tissue=Prostate Tumour;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-F1;Tissue=Prostate Tumour;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-F1;Tissue=Prostate Tumour;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-F1;Tissue=Prostate Tumour;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-F1;Tissue=Prostate Tumour;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-F1;Tissue=Prostate Tumour;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-B1;Tissue=Blood;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-B1;Tissue=Blood;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-B1;Tissue=Blood;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-B1;Tissue=Blood;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-B1;Tissue=Blood;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-B1;Tissue=Blood;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-B1;Tissue=Blood;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-B1;Tissue=Blood;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-F1;Tissue=Prostate Tumour;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-F1;Tissue=Prostate Tumour;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-F1;Tissue=Prostate Tumour;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-F1;Tissue=Prostate Tumour;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-F1;Tissue=Prostate Tumour;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-F1;Tissue=Prostate Tumour;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-F1;Tissue=Prostate Tumour;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-F1;Tissue=Prostate Tumour;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-F1;Tissue=Prostate Tumour;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-F1;Tissue=Prostate Tumour;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-F1;Tissue=Prostate Tumour;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-F1;Tissue=Prostate Tumour;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-F1;Tissue=Prostate Tumour;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-F1;Tissue=Prostate Tumour;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-F1;Tissue=Prostate Tumour;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.9;Sample=CPCG0496-F1;Tissue=Prostate Tumour;donor_id=CPCG0496;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-B1;Tissue=Blood;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-B1;Tissue=Blood;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-B1;Tissue=Blood;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-B1;Tissue=Blood;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-B1;Tissue=Blood;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-B1;Tissue=Blood;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-B1;Tissue=Blood;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-B1;Tissue=Blood;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-F1;Tissue=Prostate Tumour;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-F1;Tissue=Prostate Tumour;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-F1;Tissue=Prostate Tumour;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-F1;Tissue=Prostate Tumour;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-F1;Tissue=Prostate Tumour;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-F1;Tissue=Prostate Tumour;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-F1;Tissue=Prostate Tumour;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-F1;Tissue=Prostate Tumour;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-F1;Tissue=Prostate Tumour;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-F1;Tissue=Prostate Tumour;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-F1;Tissue=Prostate Tumour;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-F1;Tissue=Prostate Tumour;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-F1;Tissue=Prostate Tumour;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-F1;Tissue=Prostate Tumour;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-F1;Tissue=Prostate Tumour;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0498-F1;Tissue=Prostate Tumour;donor_id=CPCG0498;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-B1;Tissue=Blood;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-B1;Tissue=Blood;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-B1;Tissue=Blood;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-B1;Tissue=Blood;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-B1;Tissue=Blood;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-B1;Tissue=Blood;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-B1;Tissue=Blood;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-B1;Tissue=Blood;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-F1;Tissue=Prostate Tumour;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-F1;Tissue=Prostate Tumour;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-F1;Tissue=Prostate Tumour;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-F1;Tissue=Prostate Tumour;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-F1;Tissue=Prostate Tumour;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-F1;Tissue=Prostate Tumour;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-F1;Tissue=Prostate Tumour;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-F1;Tissue=Prostate Tumour;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-F1;Tissue=Prostate Tumour;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-F1;Tissue=Prostate Tumour;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-F1;Tissue=Prostate Tumour;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-F1;Tissue=Prostate Tumour;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-F1;Tissue=Prostate Tumour;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-F1;Tissue=Prostate Tumour;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-F1;Tissue=Prostate Tumour;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0499-F1;Tissue=Prostate Tumour;donor_id=CPCG0499;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-B1;Tissue=Blood;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-B1;Tissue=Blood;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-B1;Tissue=Blood;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-B1;Tissue=Blood;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-B1;Tissue=Blood;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-B1;Tissue=Blood;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-B1;Tissue=Blood;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-B1;Tissue=Blood;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-F1;Tissue=Prostate Tumour;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-F1;Tissue=Prostate Tumour;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-F1;Tissue=Prostate Tumour;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-F1;Tissue=Prostate Tumour;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-F1;Tissue=Prostate Tumour;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-F1;Tissue=Prostate Tumour;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-F1;Tissue=Prostate Tumour;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-F1;Tissue=Prostate Tumour;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-F1;Tissue=Prostate Tumour;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-F1;Tissue=Prostate Tumour;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-F1;Tissue=Prostate Tumour;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-F1;Tissue=Prostate Tumour;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-F1;Tissue=Prostate Tumour;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-F1;Tissue=Prostate Tumour;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-F1;Tissue=Prostate Tumour;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0500-F1;Tissue=Prostate Tumour;donor_id=CPCG0500;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-B1;Tissue=Blood;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-B1;Tissue=Blood;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-B1;Tissue=Blood;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-B1;Tissue=Blood;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-B1;Tissue=Blood;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-B1;Tissue=Blood;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-B1;Tissue=Blood;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-B1;Tissue=Blood;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-F1;Tissue=Prostate Tumour;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-F1;Tissue=Prostate Tumour;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-F1;Tissue=Prostate Tumour;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-F1;Tissue=Prostate Tumour;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-F1;Tissue=Prostate Tumour;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-F1;Tissue=Prostate Tumour;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-F1;Tissue=Prostate Tumour;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-F1;Tissue=Prostate Tumour;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-F1;Tissue=Prostate Tumour;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-F1;Tissue=Prostate Tumour;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-F1;Tissue=Prostate Tumour;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-F1;Tissue=Prostate Tumour;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-F1;Tissue=Prostate Tumour;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-F1;Tissue=Prostate Tumour;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-F1;Tissue=Prostate Tumour;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0502-F1;Tissue=Prostate Tumour;donor_id=CPCG0502;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-B1;Tissue=Blood;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-B1;Tissue=Blood;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-B1;Tissue=Blood;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-B1;Tissue=Blood;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-B1;Tissue=Blood;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-B1;Tissue=Blood;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-B1;Tissue=Blood;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-B1;Tissue=Blood;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-F1;Tissue=Prostate Tumour;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-F1;Tissue=Prostate Tumour;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-F1;Tissue=Prostate Tumour;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-F1;Tissue=Prostate Tumour;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-F1;Tissue=Prostate Tumour;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-F1;Tissue=Prostate Tumour;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-F1;Tissue=Prostate Tumour;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-F1;Tissue=Prostate Tumour;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-F1;Tissue=Prostate Tumour;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-F1;Tissue=Prostate Tumour;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-F1;Tissue=Prostate Tumour;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-F1;Tissue=Prostate Tumour;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-F1;Tissue=Prostate Tumour;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-F1;Tissue=Prostate Tumour;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-F1;Tissue=Prostate Tumour;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0503-F1;Tissue=Prostate Tumour;donor_id=CPCG0503;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-B1;Tissue=Blood;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-B1;Tissue=Blood;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-B1;Tissue=Blood;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-B1;Tissue=Blood;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-B1;Tissue=Blood;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-B1;Tissue=Blood;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-B1;Tissue=Blood;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-B1;Tissue=Blood;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-F1;Tissue=Prostate Tumour;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-F1;Tissue=Prostate Tumour;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-F1;Tissue=Prostate Tumour;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-F1;Tissue=Prostate Tumour;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-F1;Tissue=Prostate Tumour;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-F1;Tissue=Prostate Tumour;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-F1;Tissue=Prostate Tumour;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-F1;Tissue=Prostate Tumour;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-F1;Tissue=Prostate Tumour;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-F1;Tissue=Prostate Tumour;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-F1;Tissue=Prostate Tumour;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-F1;Tissue=Prostate Tumour;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-F1;Tissue=Prostate Tumour;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-F1;Tissue=Prostate Tumour;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-F1;Tissue=Prostate Tumour;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0504-F1;Tissue=Prostate Tumour;donor_id=CPCG0504;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-B1;Tissue=Blood;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-B1;Tissue=Blood;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-B1;Tissue=Blood;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-B1;Tissue=Blood;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-B1;Tissue=Blood;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-B1;Tissue=Blood;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-B1;Tissue=Blood;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-B1;Tissue=Blood;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-F1;Tissue=Prostate Tumour;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-F1;Tissue=Prostate Tumour;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-F1;Tissue=Prostate Tumour;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-F1;Tissue=Prostate Tumour;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-F1;Tissue=Prostate Tumour;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-F1;Tissue=Prostate Tumour;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-F1;Tissue=Prostate Tumour;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-F1;Tissue=Prostate Tumour;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-F1;Tissue=Prostate Tumour;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-F1;Tissue=Prostate Tumour;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-F1;Tissue=Prostate Tumour;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-F1;Tissue=Prostate Tumour;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-F1;Tissue=Prostate Tumour;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-F1;Tissue=Prostate Tumour;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-F1;Tissue=Prostate Tumour;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0507-F1;Tissue=Prostate Tumour;donor_id=CPCG0507;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-B1;Tissue=Blood;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-B1;Tissue=Blood;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-B1;Tissue=Blood;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-B1;Tissue=Blood;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-B1;Tissue=Blood;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-B1;Tissue=Blood;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-B1;Tissue=Blood;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-B1;Tissue=Blood;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-F1;Tissue=Prostate Tumour;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-F1;Tissue=Prostate Tumour;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-F1;Tissue=Prostate Tumour;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-F1;Tissue=Prostate Tumour;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-F1;Tissue=Prostate Tumour;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-F1;Tissue=Prostate Tumour;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-F1;Tissue=Prostate Tumour;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-F1;Tissue=Prostate Tumour;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-F1;Tissue=Prostate Tumour;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-F1;Tissue=Prostate Tumour;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-F1;Tissue=Prostate Tumour;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-F1;Tissue=Prostate Tumour;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-F1;Tissue=Prostate Tumour;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-F1;Tissue=Prostate Tumour;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-F1;Tissue=Prostate Tumour;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0508-F1;Tissue=Prostate Tumour;donor_id=CPCG0508;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-F1;Tissue=Prostate Tumour;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-F1;Tissue=Prostate Tumour;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-F1;Tissue=Prostate Tumour;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-F1;Tissue=Prostate Tumour;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-F1;Tissue=Prostate Tumour;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-F1;Tissue=Prostate Tumour;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-F1;Tissue=Prostate Tumour;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-F1;Tissue=Prostate Tumour;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-F1;Tissue=Prostate Tumour;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-F1;Tissue=Prostate Tumour;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-F1;Tissue=Prostate Tumour;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-F1;Tissue=Prostate Tumour;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-F1;Tissue=Prostate Tumour;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-F1;Tissue=Prostate Tumour;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-F1;Tissue=Prostate Tumour;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-F1;Tissue=Prostate Tumour;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.2;Sample=CPCG0514-B1;Tissue=Blood;donor_id=CPCG0514;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.2;Sample=CPCG0514-B1;Tissue=Blood;donor_id=CPCG0514;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.2;Sample=CPCG0514-B1;Tissue=Blood;donor_id=CPCG0514;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.2;Sample=CPCG0514-B1;Tissue=Blood;donor_id=CPCG0514;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.2;Sample=CPCG0514-B1;Tissue=Blood;donor_id=CPCG0514;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.2;Sample=CPCG0514-B1;Tissue=Blood;donor_id=CPCG0514;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.2;Sample=CPCG0514-B1;Tissue=Blood;donor_id=CPCG0514;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.2;Sample=CPCG0514-B1;Tissue=Blood;donor_id=CPCG0514;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.2;Sample=CPCG0514-F1;Tissue=Prostate Tumour;donor_id=CPCG0514;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.2;Sample=CPCG0514-F1;Tissue=Prostate Tumour;donor_id=CPCG0514;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.2;Sample=CPCG0514-F1;Tissue=Prostate Tumour;donor_id=CPCG0514;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.2;Sample=CPCG0514-F1;Tissue=Prostate Tumour;donor_id=CPCG0514;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.2;Sample=CPCG0514-F1;Tissue=Prostate Tumour;donor_id=CPCG0514;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.2;Sample=CPCG0514-F1;Tissue=Prostate Tumour;donor_id=CPCG0514;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-B1;Tissue=Blood;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-B1;Tissue=Blood;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-B1;Tissue=Blood;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-B1;Tissue=Blood;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-B1;Tissue=Blood;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-B1;Tissue=Blood;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-B1;Tissue=Blood;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-B1;Tissue=Blood;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-F1;Tissue=Prostate Tumour;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-F1;Tissue=Prostate Tumour;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-F1;Tissue=Prostate Tumour;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-F1;Tissue=Prostate Tumour;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-F1;Tissue=Prostate Tumour;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-F1;Tissue=Prostate Tumour;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-F1;Tissue=Prostate Tumour;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-F1;Tissue=Prostate Tumour;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-F1;Tissue=Prostate Tumour;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-F1;Tissue=Prostate Tumour;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-F1;Tissue=Prostate Tumour;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-F1;Tissue=Prostate Tumour;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-F1;Tissue=Prostate Tumour;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-F1;Tissue=Prostate Tumour;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-F1;Tissue=Prostate Tumour;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0519-F1;Tissue=Prostate Tumour;donor_id=CPCG0519;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-B1;Tissue=Blood;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-B1;Tissue=Blood;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-B1;Tissue=Blood;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-B1;Tissue=Blood;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-B1;Tissue=Blood;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-B1;Tissue=Blood;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-B1;Tissue=Blood;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-B1;Tissue=Blood;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-F1;Tissue=Prostate Tumour;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-F1;Tissue=Prostate Tumour;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-F1;Tissue=Prostate Tumour;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-F1;Tissue=Prostate Tumour;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-F1;Tissue=Prostate Tumour;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-F1;Tissue=Prostate Tumour;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-F1;Tissue=Prostate Tumour;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-F1;Tissue=Prostate Tumour;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-F1;Tissue=Prostate Tumour;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-F1;Tissue=Prostate Tumour;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-F1;Tissue=Prostate Tumour;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-F1;Tissue=Prostate Tumour;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-F1;Tissue=Prostate Tumour;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-F1;Tissue=Prostate Tumour;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-F1;Tissue=Prostate Tumour;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0520-F1;Tissue=Prostate Tumour;donor_id=CPCG0520;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-B1;Tissue=Blood;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-B1;Tissue=Blood;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-B1;Tissue=Blood;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-B1;Tissue=Blood;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-B1;Tissue=Blood;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-B1;Tissue=Blood;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-B1;Tissue=Blood;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-B1;Tissue=Blood;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-F1;Tissue=Prostate Tumour;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-F1;Tissue=Prostate Tumour;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-F1;Tissue=Prostate Tumour;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-F1;Tissue=Prostate Tumour;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-F1;Tissue=Prostate Tumour;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-F1;Tissue=Prostate Tumour;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-F1;Tissue=Prostate Tumour;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-F1;Tissue=Prostate Tumour;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-F1;Tissue=Prostate Tumour;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-F1;Tissue=Prostate Tumour;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-F1;Tissue=Prostate Tumour;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-F1;Tissue=Prostate Tumour;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-F1;Tissue=Prostate Tumour;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-F1;Tissue=Prostate Tumour;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-F1;Tissue=Prostate Tumour;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0521-F1;Tissue=Prostate Tumour;donor_id=CPCG0521;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-B1;Tissue=Blood;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-B1;Tissue=Blood;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-B1;Tissue=Blood;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-B1;Tissue=Blood;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-B1;Tissue=Blood;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-B1;Tissue=Blood;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-B1;Tissue=Blood;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-B1;Tissue=Blood;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-F1;Tissue=Prostate Tumour;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-F1;Tissue=Prostate Tumour;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-F1;Tissue=Prostate Tumour;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-F1;Tissue=Prostate Tumour;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-F1;Tissue=Prostate Tumour;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-F1;Tissue=Prostate Tumour;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-F1;Tissue=Prostate Tumour;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-F1;Tissue=Prostate Tumour;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-F1;Tissue=Prostate Tumour;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-F1;Tissue=Prostate Tumour;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-F1;Tissue=Prostate Tumour;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-F1;Tissue=Prostate Tumour;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-F1;Tissue=Prostate Tumour;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-F1;Tissue=Prostate Tumour;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-F1;Tissue=Prostate Tumour;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0522-F1;Tissue=Prostate Tumour;donor_id=CPCG0522;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-B1;Tissue=Blood;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-B1;Tissue=Blood;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-B1;Tissue=Blood;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-B1;Tissue=Blood;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-B1;Tissue=Blood;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-B1;Tissue=Blood;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-B1;Tissue=Blood;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-B1;Tissue=Blood;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-F1;Tissue=Prostate Tumour;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-F1;Tissue=Prostate Tumour;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-F1;Tissue=Prostate Tumour;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-F1;Tissue=Prostate Tumour;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-F1;Tissue=Prostate Tumour;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-F1;Tissue=Prostate Tumour;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-F1;Tissue=Prostate Tumour;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-F1;Tissue=Prostate Tumour;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-F1;Tissue=Prostate Tumour;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-F1;Tissue=Prostate Tumour;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-F1;Tissue=Prostate Tumour;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-F1;Tissue=Prostate Tumour;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-F1;Tissue=Prostate Tumour;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-F1;Tissue=Prostate Tumour;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-F1;Tissue=Prostate Tumour;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0523-F1;Tissue=Prostate Tumour;donor_id=CPCG0523;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-B1;Tissue=Blood;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-B1;Tissue=Blood;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-B1;Tissue=Blood;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-B1;Tissue=Blood;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-B1;Tissue=Blood;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-B1;Tissue=Blood;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-B1;Tissue=Blood;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-B1;Tissue=Blood;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-F1;Tissue=Prostate Tumour;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-F1;Tissue=Prostate Tumour;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-F1;Tissue=Prostate Tumour;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-F1;Tissue=Prostate Tumour;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-F1;Tissue=Prostate Tumour;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-F1;Tissue=Prostate Tumour;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-F1;Tissue=Prostate Tumour;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-F1;Tissue=Prostate Tumour;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-F1;Tissue=Prostate Tumour;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-F1;Tissue=Prostate Tumour;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-F1;Tissue=Prostate Tumour;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-F1;Tissue=Prostate Tumour;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-F1;Tissue=Prostate Tumour;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-F1;Tissue=Prostate Tumour;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-F1;Tissue=Prostate Tumour;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0524-F1;Tissue=Prostate Tumour;donor_id=CPCG0524;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-B1;Tissue=Blood;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-B1;Tissue=Blood;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-B1;Tissue=Blood;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-B1;Tissue=Blood;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-B1;Tissue=Blood;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-B1;Tissue=Blood;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-B1;Tissue=Blood;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-B1;Tissue=Blood;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-F1;Tissue=Prostate Tumour;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-F1;Tissue=Prostate Tumour;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-F1;Tissue=Prostate Tumour;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-F1;Tissue=Prostate Tumour;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-F1;Tissue=Prostate Tumour;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-F1;Tissue=Prostate Tumour;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-F1;Tissue=Prostate Tumour;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-F1;Tissue=Prostate Tumour;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-F1;Tissue=Prostate Tumour;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-F1;Tissue=Prostate Tumour;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-F1;Tissue=Prostate Tumour;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-F1;Tissue=Prostate Tumour;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-F1;Tissue=Prostate Tumour;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-F1;Tissue=Prostate Tumour;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-F1;Tissue=Prostate Tumour;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.0;Sample=CPCG0525-F1;Tissue=Prostate Tumour;donor_id=CPCG0525;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-B1;Tissue=Blood;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-B1;Tissue=Blood;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-B1;Tissue=Blood;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-B1;Tissue=Blood;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-B1;Tissue=Blood;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-B1;Tissue=Blood;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-B1;Tissue=Blood;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-B1;Tissue=Blood;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-F1;Tissue=Prostate Tumour;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-F1;Tissue=Prostate Tumour;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-F1;Tissue=Prostate Tumour;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-F1;Tissue=Prostate Tumour;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-F1;Tissue=Prostate Tumour;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-F1;Tissue=Prostate Tumour;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-F1;Tissue=Prostate Tumour;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-F1;Tissue=Prostate Tumour;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-F1;Tissue=Prostate Tumour;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-F1;Tissue=Prostate Tumour;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-F1;Tissue=Prostate Tumour;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-F1;Tissue=Prostate Tumour;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-F1;Tissue=Prostate Tumour;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-F1;Tissue=Prostate Tumour;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-F1;Tissue=Prostate Tumour;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0526-F1;Tissue=Prostate Tumour;donor_id=CPCG0526;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-B1;Tissue=Blood;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-B1;Tissue=Blood;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-B1;Tissue=Blood;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-B1;Tissue=Blood;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-B1;Tissue=Blood;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-B1;Tissue=Blood;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-B1;Tissue=Blood;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-B1;Tissue=Blood;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-F1;Tissue=Prostate Tumour;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-F1;Tissue=Prostate Tumour;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-F1;Tissue=Prostate Tumour;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-F1;Tissue=Prostate Tumour;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-F1;Tissue=Prostate Tumour;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-F1;Tissue=Prostate Tumour;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-F1;Tissue=Prostate Tumour;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-F1;Tissue=Prostate Tumour;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-F1;Tissue=Prostate Tumour;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-F1;Tissue=Prostate Tumour;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-F1;Tissue=Prostate Tumour;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-F1;Tissue=Prostate Tumour;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-F1;Tissue=Prostate Tumour;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-F1;Tissue=Prostate Tumour;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-F1;Tissue=Prostate Tumour;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0527-F1;Tissue=Prostate Tumour;donor_id=CPCG0527;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-B1;Tissue=Blood;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-B1;Tissue=Blood;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-B1;Tissue=Blood;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-B1;Tissue=Blood;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-B1;Tissue=Blood;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-B1;Tissue=Blood;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-B1;Tissue=Blood;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-B1;Tissue=Blood;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-F1;Tissue=Prostate Tumour;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-F1;Tissue=Prostate Tumour;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-F1;Tissue=Prostate Tumour;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-F1;Tissue=Prostate Tumour;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-F1;Tissue=Prostate Tumour;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-F1;Tissue=Prostate Tumour;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-F1;Tissue=Prostate Tumour;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-F1;Tissue=Prostate Tumour;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-F1;Tissue=Prostate Tumour;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-F1;Tissue=Prostate Tumour;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-F1;Tissue=Prostate Tumour;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-F1;Tissue=Prostate Tumour;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-F1;Tissue=Prostate Tumour;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-F1;Tissue=Prostate Tumour;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-F1;Tissue=Prostate Tumour;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0528-F1;Tissue=Prostate Tumour;donor_id=CPCG0528;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-B1;Tissue=Blood;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-B1;Tissue=Blood;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-B1;Tissue=Blood;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-B1;Tissue=Blood;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-B1;Tissue=Blood;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-B1;Tissue=Blood;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-B1;Tissue=Blood;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-B1;Tissue=Blood;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-F1;Tissue=Prostate Tumour;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-F1;Tissue=Prostate Tumour;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-F1;Tissue=Prostate Tumour;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-F1;Tissue=Prostate Tumour;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-F1;Tissue=Prostate Tumour;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-F1;Tissue=Prostate Tumour;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-F1;Tissue=Prostate Tumour;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-F1;Tissue=Prostate Tumour;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-F1;Tissue=Prostate Tumour;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-F1;Tissue=Prostate Tumour;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-F1;Tissue=Prostate Tumour;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-F1;Tissue=Prostate Tumour;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-F1;Tissue=Prostate Tumour;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-F1;Tissue=Prostate Tumour;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-F1;Tissue=Prostate Tumour;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0529-F1;Tissue=Prostate Tumour;donor_id=CPCG0529;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-B1;Tissue=Blood;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-B1;Tissue=Blood;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-B1;Tissue=Blood;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-B1;Tissue=Blood;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-B1;Tissue=Blood;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-B1;Tissue=Blood;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-B1;Tissue=Blood;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-B1;Tissue=Blood;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-F1;Tissue=Prostate Tumour;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-F1;Tissue=Prostate Tumour;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-F1;Tissue=Prostate Tumour;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-F1;Tissue=Prostate Tumour;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-F1;Tissue=Prostate Tumour;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-F1;Tissue=Prostate Tumour;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-F1;Tissue=Prostate Tumour;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-F1;Tissue=Prostate Tumour;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-F1;Tissue=Prostate Tumour;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-F1;Tissue=Prostate Tumour;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-F1;Tissue=Prostate Tumour;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-F1;Tissue=Prostate Tumour;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-F1;Tissue=Prostate Tumour;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-F1;Tissue=Prostate Tumour;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-F1;Tissue=Prostate Tumour;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0531-F1;Tissue=Prostate Tumour;donor_id=CPCG0531;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-B1;Tissue=Blood;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-B1;Tissue=Blood;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-B1;Tissue=Blood;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-B1;Tissue=Blood;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-B1;Tissue=Blood;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-B1;Tissue=Blood;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-B1;Tissue=Blood;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-B1;Tissue=Blood;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-F1;Tissue=Prostate Tumour;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-F1;Tissue=Prostate Tumour;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-F1;Tissue=Prostate Tumour;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-F1;Tissue=Prostate Tumour;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-F1;Tissue=Prostate Tumour;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-F1;Tissue=Prostate Tumour;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-F1;Tissue=Prostate Tumour;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-F1;Tissue=Prostate Tumour;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-F1;Tissue=Prostate Tumour;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-F1;Tissue=Prostate Tumour;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-F1;Tissue=Prostate Tumour;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-F1;Tissue=Prostate Tumour;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-F1;Tissue=Prostate Tumour;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-F1;Tissue=Prostate Tumour;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-F1;Tissue=Prostate Tumour;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0532-F1;Tissue=Prostate Tumour;donor_id=CPCG0532;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-B1;Tissue=Blood;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-B1;Tissue=Blood;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-B1;Tissue=Blood;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-B1;Tissue=Blood;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-B1;Tissue=Blood;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-B1;Tissue=Blood;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-B1;Tissue=Blood;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-B1;Tissue=Blood;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-F1;Tissue=Prostate Tumour;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-F1;Tissue=Prostate Tumour;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-F1;Tissue=Prostate Tumour;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-F1;Tissue=Prostate Tumour;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-F1;Tissue=Prostate Tumour;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-F1;Tissue=Prostate Tumour;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-F1;Tissue=Prostate Tumour;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-F1;Tissue=Prostate Tumour;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-F1;Tissue=Prostate Tumour;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-F1;Tissue=Prostate Tumour;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-F1;Tissue=Prostate Tumour;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-F1;Tissue=Prostate Tumour;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-F1;Tissue=Prostate Tumour;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-F1;Tissue=Prostate Tumour;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-F1;Tissue=Prostate Tumour;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0533-F1;Tissue=Prostate Tumour;donor_id=CPCG0533;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-B1;Tissue=Blood;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-B1;Tissue=Blood;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-B1;Tissue=Blood;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-B1;Tissue=Blood;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-B1;Tissue=Blood;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-B1;Tissue=Blood;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-B1;Tissue=Blood;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-B1;Tissue=Blood;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-F1;Tissue=Prostate Tumour;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-F1;Tissue=Prostate Tumour;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-F1;Tissue=Prostate Tumour;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-F1;Tissue=Prostate Tumour;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-F1;Tissue=Prostate Tumour;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-F1;Tissue=Prostate Tumour;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-F1;Tissue=Prostate Tumour;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-F1;Tissue=Prostate Tumour;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-F1;Tissue=Prostate Tumour;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-F1;Tissue=Prostate Tumour;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-F1;Tissue=Prostate Tumour;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-F1;Tissue=Prostate Tumour;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-F1;Tissue=Prostate Tumour;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-F1;Tissue=Prostate Tumour;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-F1;Tissue=Prostate Tumour;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0534-F1;Tissue=Prostate Tumour;donor_id=CPCG0534;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-B1;Tissue=Blood;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-B1;Tissue=Blood;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-B1;Tissue=Blood;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-B1;Tissue=Blood;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-B1;Tissue=Blood;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-B1;Tissue=Blood;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-B1;Tissue=Blood;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-B1;Tissue=Blood;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-F1;Tissue=Prostate Tumour;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-F1;Tissue=Prostate Tumour;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-F1;Tissue=Prostate Tumour;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-F1;Tissue=Prostate Tumour;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-F1;Tissue=Prostate Tumour;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-F1;Tissue=Prostate Tumour;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-F1;Tissue=Prostate Tumour;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-F1;Tissue=Prostate Tumour;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-F1;Tissue=Prostate Tumour;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-F1;Tissue=Prostate Tumour;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-F1;Tissue=Prostate Tumour;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-F1;Tissue=Prostate Tumour;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-F1;Tissue=Prostate Tumour;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-F1;Tissue=Prostate Tumour;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-F1;Tissue=Prostate Tumour;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0537-F1;Tissue=Prostate Tumour;donor_id=CPCG0537;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-B1;Tissue=Blood;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-B1;Tissue=Blood;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-B1;Tissue=Blood;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-B1;Tissue=Blood;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-B1;Tissue=Blood;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-B1;Tissue=Blood;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-B1;Tissue=Blood;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-B1;Tissue=Blood;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-F1;Tissue=Prostate Tumour;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-F1;Tissue=Prostate Tumour;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-F1;Tissue=Prostate Tumour;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-F1;Tissue=Prostate Tumour;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-F1;Tissue=Prostate Tumour;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-F1;Tissue=Prostate Tumour;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-F1;Tissue=Prostate Tumour;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-F1;Tissue=Prostate Tumour;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-F1;Tissue=Prostate Tumour;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-F1;Tissue=Prostate Tumour;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-F1;Tissue=Prostate Tumour;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-F1;Tissue=Prostate Tumour;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-F1;Tissue=Prostate Tumour;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-F1;Tissue=Prostate Tumour;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-F1;Tissue=Prostate Tumour;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0539-F1;Tissue=Prostate Tumour;donor_id=CPCG0539;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-B1;Tissue=Blood;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-B1;Tissue=Blood;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-B1;Tissue=Blood;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-B1;Tissue=Blood;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-B1;Tissue=Blood;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-B1;Tissue=Blood;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-B1;Tissue=Blood;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-B1;Tissue=Blood;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-F1;Tissue=Prostate Tumour;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-F1;Tissue=Prostate Tumour;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-F1;Tissue=Prostate Tumour;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-F1;Tissue=Prostate Tumour;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-F1;Tissue=Prostate Tumour;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-F1;Tissue=Prostate Tumour;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-F1;Tissue=Prostate Tumour;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-F1;Tissue=Prostate Tumour;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-F1;Tissue=Prostate Tumour;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-F1;Tissue=Prostate Tumour;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-F1;Tissue=Prostate Tumour;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-F1;Tissue=Prostate Tumour;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-F1;Tissue=Prostate Tumour;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-F1;Tissue=Prostate Tumour;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-F1;Tissue=Prostate Tumour;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0540-F1;Tissue=Prostate Tumour;donor_id=CPCG0540;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-B1;Tissue=Blood;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-B1;Tissue=Blood;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-B1;Tissue=Blood;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-B1;Tissue=Blood;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-B1;Tissue=Blood;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-B1;Tissue=Blood;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-B1;Tissue=Blood;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-B1;Tissue=Blood;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-F1;Tissue=Prostate Tumour;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-F1;Tissue=Prostate Tumour;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-F1;Tissue=Prostate Tumour;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-F1;Tissue=Prostate Tumour;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-F1;Tissue=Prostate Tumour;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-F1;Tissue=Prostate Tumour;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-F1;Tissue=Prostate Tumour;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-F1;Tissue=Prostate Tumour;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-F1;Tissue=Prostate Tumour;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-F1;Tissue=Prostate Tumour;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-F1;Tissue=Prostate Tumour;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-F1;Tissue=Prostate Tumour;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-F1;Tissue=Prostate Tumour;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-F1;Tissue=Prostate Tumour;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-F1;Tissue=Prostate Tumour;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0545-F1;Tissue=Prostate Tumour;donor_id=CPCG0545;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0556;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0556-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0556;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0556-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0556;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0556-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0556;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0556-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0556;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0556-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0556;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0556-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-B1;Tissue=Blood;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-B1;Tissue=Blood;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-B1;Tissue=Blood;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-B1;Tissue=Blood;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-B1;Tissue=Blood;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-B1;Tissue=Blood;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-B1;Tissue=Blood;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-B1;Tissue=Blood;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-F1;Tissue=Prostate Tumour;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-F1;Tissue=Prostate Tumour;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-F1;Tissue=Prostate Tumour;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-F1;Tissue=Prostate Tumour;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-F1;Tissue=Prostate Tumour;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-F1;Tissue=Prostate Tumour;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-F1;Tissue=Prostate Tumour;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-F1;Tissue=Prostate Tumour;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-F1;Tissue=Prostate Tumour;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-F1;Tissue=Prostate Tumour;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-F1;Tissue=Prostate Tumour;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-F1;Tissue=Prostate Tumour;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-F1;Tissue=Prostate Tumour;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-F1;Tissue=Prostate Tumour;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-F1;Tissue=Prostate Tumour;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000922;PreTreatment PSA=9.6;Sample=CPCG0563-F1;Tissue=Prostate Tumour;donor_id=CPCG0563;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-B1;Tissue=Blood;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-B1;Tissue=Blood;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-B1;Tissue=Blood;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-B1;Tissue=Blood;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-B1;Tissue=Blood;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-B1;Tissue=Blood;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-B1;Tissue=Blood;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-B1;Tissue=Blood;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-F1;Tissue=Prostate Tumour;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-F1;Tissue=Prostate Tumour;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-F1;Tissue=Prostate Tumour;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-F1;Tissue=Prostate Tumour;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-F1;Tissue=Prostate Tumour;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-F1;Tissue=Prostate Tumour;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-F1;Tissue=Prostate Tumour;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-F1;Tissue=Prostate Tumour;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-F1;Tissue=Prostate Tumour;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-F1;Tissue=Prostate Tumour;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-F1;Tissue=Prostate Tumour;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-F1;Tissue=Prostate Tumour;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-F1;Tissue=Prostate Tumour;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-F1;Tissue=Prostate Tumour;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-F1;Tissue=Prostate Tumour;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0568-F1;Tissue=Prostate Tumour;donor_id=CPCG0568;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-B1;Tissue=Blood;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-B1;Tissue=Blood;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-B1;Tissue=Blood;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-B1;Tissue=Blood;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-B1;Tissue=Blood;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-B1;Tissue=Blood;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-B1;Tissue=Blood;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-B1;Tissue=Blood;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-F1;Tissue=Prostate Tumour;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-F1;Tissue=Prostate Tumour;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-F1;Tissue=Prostate Tumour;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-F1;Tissue=Prostate Tumour;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-F1;Tissue=Prostate Tumour;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-F1;Tissue=Prostate Tumour;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-F1;Tissue=Prostate Tumour;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-F1;Tissue=Prostate Tumour;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-F1;Tissue=Prostate Tumour;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-F1;Tissue=Prostate Tumour;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-F1;Tissue=Prostate Tumour;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-F1;Tissue=Prostate Tumour;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-F1;Tissue=Prostate Tumour;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-F1;Tissue=Prostate Tumour;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-F1;Tissue=Prostate Tumour;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.5;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.2;Sample=CPCG0569-F1;Tissue=Prostate Tumour;donor_id=CPCG0569;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-B1;Tissue=Blood;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-B1;Tissue=Blood;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-B1;Tissue=Blood;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-B1;Tissue=Blood;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-B1;Tissue=Blood;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-B1;Tissue=Blood;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-B1;Tissue=Blood;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-B1;Tissue=Blood;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-F1;Tissue=Prostate Tumour;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-F1;Tissue=Prostate Tumour;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-F1;Tissue=Prostate Tumour;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-F1;Tissue=Prostate Tumour;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-F1;Tissue=Prostate Tumour;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-F1;Tissue=Prostate Tumour;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-F1;Tissue=Prostate Tumour;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-F1;Tissue=Prostate Tumour;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-F1;Tissue=Prostate Tumour;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-F1;Tissue=Prostate Tumour;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-F1;Tissue=Prostate Tumour;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-F1;Tissue=Prostate Tumour;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-F1;Tissue=Prostate Tumour;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-F1;Tissue=Prostate Tumour;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-F1;Tissue=Prostate Tumour;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.0;Sample=CPCG0574-F1;Tissue=Prostate Tumour;donor_id=CPCG0574;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-B1;Tissue=Blood;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-B1;Tissue=Blood;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-B1;Tissue=Blood;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-B1;Tissue=Blood;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-B1;Tissue=Blood;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-B1;Tissue=Blood;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-B1;Tissue=Blood;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-B1;Tissue=Blood;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-F1;Tissue=Prostate Tumour;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-F1;Tissue=Prostate Tumour;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-F1;Tissue=Prostate Tumour;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-F1;Tissue=Prostate Tumour;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-F1;Tissue=Prostate Tumour;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-F1;Tissue=Prostate Tumour;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-F1;Tissue=Prostate Tumour;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-F1;Tissue=Prostate Tumour;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-F1;Tissue=Prostate Tumour;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-F1;Tissue=Prostate Tumour;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-F1;Tissue=Prostate Tumour;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-F1;Tissue=Prostate Tumour;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-F1;Tissue=Prostate Tumour;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-F1;Tissue=Prostate Tumour;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-F1;Tissue=Prostate Tumour;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.8;Sample=CPCG0579-F1;Tissue=Prostate Tumour;donor_id=CPCG0579;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-B1;Tissue=Blood;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-B1;Tissue=Blood;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-B1;Tissue=Blood;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-B1;Tissue=Blood;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-B1;Tissue=Blood;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-B1;Tissue=Blood;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-B1;Tissue=Blood;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0493-B1;Tissue=Blood;donor_id=CPCG0493;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-B1;Tissue=Blood;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-B1;Tissue=Blood;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-B1;Tissue=Blood;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-B1;Tissue=Blood;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-B1;Tissue=Blood;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-B1;Tissue=Blood;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-B1;Tissue=Blood;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0509-B1;Tissue=Blood;donor_id=CPCG0509;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-B1;Tissue=Blood;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-B1;Tissue=Blood;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-B1;Tissue=Blood;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-B1;Tissue=Blood;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-B1;Tissue=Blood;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-B1;Tissue=Blood;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-B1;Tissue=Blood;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-B1;Tissue=Blood;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-F1;Tissue=Prostate Tumour;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-F1;Tissue=Prostate Tumour;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-F1;Tissue=Prostate Tumour;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-F1;Tissue=Prostate Tumour;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-F1;Tissue=Prostate Tumour;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-F1;Tissue=Prostate Tumour;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-F1;Tissue=Prostate Tumour;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-F1;Tissue=Prostate Tumour;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-F1;Tissue=Prostate Tumour;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-F1;Tissue=Prostate Tumour;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-F1;Tissue=Prostate Tumour;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-F1;Tissue=Prostate Tumour;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-F1;Tissue=Prostate Tumour;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-F1;Tissue=Prostate Tumour;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-F1;Tissue=Prostate Tumour;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.6;gender=male;phenotype=OBI_0000922;PreTreatment PSA=12.2;Sample=CPCG0589-F1;Tissue=Prostate Tumour;donor_id=CPCG0589;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-B1;Tissue=Blood;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-B1;Tissue=Blood;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-B1;Tissue=Blood;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-B1;Tissue=Blood;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-B1;Tissue=Blood;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-B1;Tissue=Blood;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-B1;Tissue=Blood;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-B1;Tissue=Blood;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-F1;Tissue=Prostate Tumour;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-F1;Tissue=Prostate Tumour;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-F1;Tissue=Prostate Tumour;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-F1;Tissue=Prostate Tumour;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-F1;Tissue=Prostate Tumour;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-F1;Tissue=Prostate Tumour;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-F1;Tissue=Prostate Tumour;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-F1;Tissue=Prostate Tumour;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-F1;Tissue=Prostate Tumour;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-F1;Tissue=Prostate Tumour;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-F1;Tissue=Prostate Tumour;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-F1;Tissue=Prostate Tumour;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-F1;Tissue=Prostate Tumour;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-F1;Tissue=Prostate Tumour;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-F1;Tissue=Prostate Tumour;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0592-F1;Tissue=Prostate Tumour;donor_id=CPCG0592;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-B1;Tissue=Blood;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-B1;Tissue=Blood;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-B1;Tissue=Blood;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-B1;Tissue=Blood;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-B1;Tissue=Blood;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-B1;Tissue=Blood;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-B1;Tissue=Blood;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-B1;Tissue=Blood;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-F1;Tissue=Prostate Tumour;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-F1;Tissue=Prostate Tumour;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-F1;Tissue=Prostate Tumour;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-F1;Tissue=Prostate Tumour;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-F1;Tissue=Prostate Tumour;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-F1;Tissue=Prostate Tumour;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-F1;Tissue=Prostate Tumour;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-F1;Tissue=Prostate Tumour;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-F1;Tissue=Prostate Tumour;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-F1;Tissue=Prostate Tumour;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-F1;Tissue=Prostate Tumour;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-F1;Tissue=Prostate Tumour;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-F1;Tissue=Prostate Tumour;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-F1;Tissue=Prostate Tumour;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-F1;Tissue=Prostate Tumour;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0594-F1;Tissue=Prostate Tumour;donor_id=CPCG0594;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-B1;Tissue=Blood;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-B1;Tissue=Blood;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-B1;Tissue=Blood;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-B1;Tissue=Blood;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-B1;Tissue=Blood;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-B1;Tissue=Blood;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-B1;Tissue=Blood;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-B1;Tissue=Blood;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-F1;Tissue=Prostate Tumour;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-F1;Tissue=Prostate Tumour;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-F1;Tissue=Prostate Tumour;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-F1;Tissue=Prostate Tumour;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-F1;Tissue=Prostate Tumour;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-F1;Tissue=Prostate Tumour;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-F1;Tissue=Prostate Tumour;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-F1;Tissue=Prostate Tumour;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-F1;Tissue=Prostate Tumour;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-F1;Tissue=Prostate Tumour;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-F1;Tissue=Prostate Tumour;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-F1;Tissue=Prostate Tumour;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-F1;Tissue=Prostate Tumour;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-F1;Tissue=Prostate Tumour;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-F1;Tissue=Prostate Tumour;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0602-F1;Tissue=Prostate Tumour;donor_id=CPCG0602;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-B1;Tissue=Blood;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-B1;Tissue=Blood;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-B1;Tissue=Blood;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-B1;Tissue=Blood;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-B1;Tissue=Blood;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-B1;Tissue=Blood;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-B1;Tissue=Blood;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-B1;Tissue=Blood;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.64;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.0;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.0;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.0;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.0;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.0;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.0;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.64;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.64;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.64;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.2;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.2;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.2;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.2;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.2;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.2;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=7.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=7.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=7.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=7.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=7.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=7.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.23;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.23;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.23;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.23;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.23;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.23;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.23;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.23;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.23;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.41;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.41;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.41;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.41;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=13.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=13.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-F1;Tissue=Prostate Tumour;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-F1;Tissue=Prostate Tumour;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-F1;Tissue=Prostate Tumour;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-F1;Tissue=Prostate Tumour;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-F1;Tissue=Prostate Tumour;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-F1;Tissue=Prostate Tumour;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-F1;Tissue=Prostate Tumour;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-F1;Tissue=Prostate Tumour;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-F1;Tissue=Prostate Tumour;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-F1;Tissue=Prostate Tumour;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-F1;Tissue=Prostate Tumour;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-F1;Tissue=Prostate Tumour;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-F1;Tissue=Prostate Tumour;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-F1;Tissue=Prostate Tumour;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-F1;Tissue=Prostate Tumour;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;phenotype=OBI_0000922;Sample=CPCG0603-F1;Tissue=Prostate Tumour;donor_id=CPCG0603;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-B1;Tissue=Blood;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-B1;Tissue=Blood;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-B1;Tissue=Blood;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-B1;Tissue=Blood;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-B1;Tissue=Blood;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-B1;Tissue=Blood;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-B1;Tissue=Blood;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-B1;Tissue=Blood;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-F1;Tissue=Prostate Tumour;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-F1;Tissue=Prostate Tumour;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-F1;Tissue=Prostate Tumour;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-F1;Tissue=Prostate Tumour;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-F1;Tissue=Prostate Tumour;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-F1;Tissue=Prostate Tumour;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-F1;Tissue=Prostate Tumour;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-F1;Tissue=Prostate Tumour;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-F1;Tissue=Prostate Tumour;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-F1;Tissue=Prostate Tumour;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-F1;Tissue=Prostate Tumour;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-F1;Tissue=Prostate Tumour;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-F1;Tissue=Prostate Tumour;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-F1;Tissue=Prostate Tumour;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-F1;Tissue=Prostate Tumour;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0607-F1;Tissue=Prostate Tumour;donor_id=CPCG0607;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.7;Sample=CPCG0008-F1;Tissue=Prostate Tumour;donor_id=CPCG0008;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.7;Sample=CPCG0008-F1;Tissue=Prostate Tumour;donor_id=CPCG0008;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.7;Sample=CPCG0008-F1;Tissue=Prostate Tumour;donor_id=CPCG0008;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.7;Sample=CPCG0008-F1;Tissue=Prostate Tumour;donor_id=CPCG0008;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.3;Sample=CPCG0036-B1;Tissue=Blood;donor_id=CPCG0036;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.3;Sample=CPCG0036-B1;Tissue=Blood;donor_id=CPCG0036;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0036-F1;Tissue=Prostate Tumour;donor_id=CPCG0036;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.6;Sample=CPCG0042-B1;Tissue=Blood;donor_id=CPCG0042;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0050-F1;Tissue=Prostate Tumour;donor_id=CPCG0050;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0050-F1;Tissue=Prostate Tumour;donor_id=CPCG0050;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0050-F1;Tissue=Prostate Tumour;donor_id=CPCG0050;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0050-F1;Tissue=Prostate Tumour;donor_id=CPCG0050;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0050-F1;Tissue=Prostate Tumour;donor_id=CPCG0050;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0050-F1;Tissue=Prostate Tumour;donor_id=CPCG0050;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=14.7;Sample=CPCG0071-F1;Tissue=Prostate Tumour;donor_id=CPCG0071;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=14.7;Sample=CPCG0071-F1;Tissue=Prostate Tumour;donor_id=CPCG0071;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=14.7;Sample=CPCG0071-F1;Tissue=Prostate Tumour;donor_id=CPCG0071;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=14.7;Sample=CPCG0071-F1;Tissue=Prostate Tumour;donor_id=CPCG0071;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=14.7;Sample=CPCG0071-F1;Tissue=Prostate Tumour;donor_id=CPCG0071;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=14.7;Sample=CPCG0071-F1;Tissue=Prostate Tumour;donor_id=CPCG0071;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.1;Sample=CPCG0126-F1;Tissue=Prostate Tumour;donor_id=CPCG0126;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.1;Sample=CPCG0126-F1;Tissue=Prostate Tumour;donor_id=CPCG0126;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.1;Sample=CPCG0126-F1;Tissue=Prostate Tumour;donor_id=CPCG0126;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.1;Sample=CPCG0126-F1;Tissue=Prostate Tumour;donor_id=CPCG0126;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.1;Sample=CPCG0126-F1;Tissue=Prostate Tumour;donor_id=CPCG0126;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.1;Sample=CPCG0126-F1;Tissue=Prostate Tumour;donor_id=CPCG0126;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.8;Sample=CPCG0435-F1;Tissue=Prostate Tumour;donor_id=CPCG0435;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.8;Sample=CPCG0435-F1;Tissue=Prostate Tumour;donor_id=CPCG0435;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.8;Sample=CPCG0435-F1;Tissue=Prostate Tumour;donor_id=CPCG0435;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.8;Sample=CPCG0435-F1;Tissue=Prostate Tumour;donor_id=CPCG0435;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.8;Sample=CPCG0435-F1;Tissue=Prostate Tumour;donor_id=CPCG0435;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.8;Sample=CPCG0435-F1;Tissue=Prostate Tumour;donor_id=CPCG0435;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.8;Sample=CPCG0435-F1;Tissue=Prostate Tumour;donor_id=CPCG0435;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.8;Sample=CPCG0435-F1;Tissue=Prostate Tumour;donor_id=CPCG0435;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.8;Sample=CPCG0435-B1;Tissue=Blood;donor_id=CPCG0435;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.8;Sample=CPCG0435-B1;Tissue=Blood;donor_id=CPCG0435;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.8;Sample=CPCG0435-B1;Tissue=Blood;donor_id=CPCG0435;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.8;Sample=CPCG0435-B1;Tissue=Blood;donor_id=CPCG0435;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.8;Sample=CPCG0435-B1;Tissue=Blood;donor_id=CPCG0435;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.8;Sample=CPCG0435-B1;Tissue=Blood;donor_id=CPCG0435;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.7;Sample=CPCG0240-B1;Tissue=Blood;donor_id=CPCG0240;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.7;Sample=CPCG0240-B1;Tissue=Blood;donor_id=CPCG0240;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.7;Sample=CPCG0240-B1;Tissue=Blood;donor_id=CPCG0240;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.7;Sample=CPCG0240-B1;Tissue=Blood;donor_id=CPCG0240;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.7;Sample=CPCG0240-B1;Tissue=Blood;donor_id=CPCG0240;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.7;Sample=CPCG0240-B1;Tissue=Blood;donor_id=CPCG0240;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.7;Sample=CPCG0240-B1;Tissue=Blood;donor_id=CPCG0240;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.7;Sample=CPCG0240-B1;Tissue=Blood;donor_id=CPCG0240;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.19999981;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.19999981;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.19999981;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.19999981;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.9;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=13.19999981;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.9;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=13.19999981;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.9;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=13.19999981;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.9;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=13.19999981;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.9;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=13.19999981;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.9;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=13.19999981;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.099999905;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.099999905;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.099999905;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.099999905;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.099999905;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0048-F1;Tissue=Prostate Tumour;donor_id=CPCG0048;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0048-F1;Tissue=Prostate Tumour;donor_id=CPCG0048;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0048-F1;Tissue=Prostate Tumour;donor_id=CPCG0048;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0048-F1;Tissue=Prostate Tumour;donor_id=CPCG0048;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0048-F1;Tissue=Prostate Tumour;donor_id=CPCG0048;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0048-F1;Tissue=Prostate Tumour;donor_id=CPCG0048;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0048-F1;Tissue=Prostate Tumour;donor_id=CPCG0048;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0048-F1;Tissue=Prostate Tumour;donor_id=CPCG0048;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0048-F1;Tissue=Prostate Tumour;donor_id=CPCG0048;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0048-F1;Tissue=Prostate Tumour;donor_id=CPCG0048;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;Gender=M;Gleason Score=3+3;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;Gender=M;Gleason Score=3+3;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;Gender=M;Gleason Score=3+3;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;Gender=M;Gleason Score=3+3;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;Gender=M;Gleason Score=3+3;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;Gender=M;Gleason Score=3+3;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=12.69999981;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=12.69999981;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=12.69999981;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=12.69999981;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=12.69999981;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=12.69999981;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=12.69999981;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=12.69999981;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=12.69999981;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=12.69999981;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=12.69999981;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=16.40999985;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=16.40999985;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=16.40999985;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=16.40999985;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=16.40999985;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=16.40999985;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=16.40999985;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=16.40999985;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=16.40999985;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=16.40999985;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=16.40999985;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=16.40999985;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.56;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.56;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.56;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.65;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.65;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.65;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.65;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.65;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.65;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.65;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.65;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.65;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.65;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.400000095;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.400000095;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.400000095;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.400000095;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.7;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=4.400000095;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.7;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=4.400000095;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.7;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=4.400000095;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.7;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=4.400000095;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.7;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=4.400000095;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.7;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=4.400000095;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.80000019;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.80000019;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.80000019;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.80000019;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.8;Sample=CPCG0154-F1;Tissue=Prostate Tumour;donor_id=CPCG0154;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.8;Sample=CPCG0154-F1;Tissue=Prostate Tumour;donor_id=CPCG0154;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.8;Sample=CPCG0154-F1;Tissue=Prostate Tumour;donor_id=CPCG0154;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.8;Sample=CPCG0154-F1;Tissue=Prostate Tumour;donor_id=CPCG0154;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.8;Sample=CPCG0154-F1;Tissue=Prostate Tumour;donor_id=CPCG0154;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.8;Sample=CPCG0154-F1;Tissue=Prostate Tumour;donor_id=CPCG0154;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.8;Sample=CPCG0154-F1;Tissue=Prostate Tumour;donor_id=CPCG0154;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.8;Sample=CPCG0154-F1;Tissue=Prostate Tumour;donor_id=CPCG0154;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.8;Sample=CPCG0154-F1;Tissue=Prostate Tumour;donor_id=CPCG0154;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.8;Sample=CPCG0154-F1;Tissue=Prostate Tumour;donor_id=CPCG0154;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.8;Sample=CPCG0154-F1;Tissue=Prostate Tumour;donor_id=CPCG0154;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.8;Sample=CPCG0154-F1;Tissue=Prostate Tumour;donor_id=CPCG0154;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.8;Sample=CPCG0154-F1;Tissue=Prostate Tumour;donor_id=CPCG0154;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.64;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.64;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.64;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.64;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=7.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=7.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=7.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=7.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=7.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=7.64;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.67;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.67;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.67;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.67;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.53;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.53;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.53;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.53;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.49;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.49;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.49;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.49;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.3;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.3;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.3;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.3;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=11.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=11.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=11.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=11.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=11.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=11.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=11.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=11.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=2.700000048;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=2.700000048;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=2.700000048;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=2.700000048;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=2.700000048;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=2.700000048;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=2.700000048;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=2.700000048;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=2.700000048;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=2.700000048;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.51;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.51;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.51;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.51;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.4;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.51;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.4;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.51;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.4;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.51;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.4;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.51;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.4;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.51;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.4;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.51;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.300000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.300000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.300000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9.300000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9.300000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9.300000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9.300000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9.300000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Gleason Score=3+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=6.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Gleason Score=3+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=6.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Gleason Score=3+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=6.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Gleason Score=3+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=6.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Gleason Score=3+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=6.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Gleason Score=3+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=6.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.15;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.15;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.15;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.63;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.63;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.63;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10.92;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10.92;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10.92;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=10.92;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=10.92;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=10.92;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=10.92;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=10.92;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=10.92;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.92;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=13.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=13.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=13.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=13.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.13;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.13;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.13;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.13;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.2;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.13;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.2;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.13;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.2;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.13;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.2;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.13;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.2;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.13;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.2;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.13;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.65;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.65;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.65;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.9;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=11.65;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.9;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=11.65;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.9;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=11.65;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.9;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=11.65;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.9;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=11.65;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.9;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=11.65;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.59;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.59;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.59;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.59;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;Gender=M;Gleason Score=3+3;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=13.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;Gender=M;Gleason Score=3+3;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=13.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;Gender=M;Gleason Score=3+3;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=13.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;Gender=M;Gleason Score=3+3;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=13.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;Gender=M;Gleason Score=3+3;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=13.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.4;Gender=M;Gleason Score=3+3;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=13.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.34;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.34;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.34;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.34;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=9.34;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=9.34;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=9.34;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=9.34;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=9.34;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=9.34;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=1.74;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=1.74;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=1.74;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=1.74;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=1.74;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=1.74;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=1.74;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=1.74;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=1.74;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=44.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=17.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=44.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=17.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=44.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=17.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=44.5;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=17.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=44.5;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=17.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=44.5;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=17.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=44.5;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=17.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=44.5;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=17.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=44.5;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=17.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=12.35;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=12.35;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=12.35;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.3;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=12.35;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.3;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=12.35;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.3;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=12.35;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.3;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=12.35;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.3;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=12.35;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.3;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=12.35;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.21;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.21;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=13.21;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.3;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=13.21;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.3;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=13.21;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.3;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=13.21;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.3;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=13.21;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.3;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=13.21;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=12.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=12.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=12.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=12.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=12.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=12.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=12.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=12.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=12.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.08;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.08;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.08;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.9;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=11.08;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.9;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=11.08;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.9;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=11.08;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.9;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=11.08;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.9;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=11.08;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.9;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=11.08;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.41;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.41;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.41;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.08;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.08;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.08;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=14.29;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=14.29;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=14.29;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.41;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.41;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.41;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.41;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.3;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.3;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.3;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.3;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.3;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.3;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.22;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.22;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.22;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.22;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.49;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.49;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.49;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=14;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=14;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=14;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.27;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.27;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.27;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.11;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.11;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.11;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.23;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.23;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.23;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.23;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.23;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.23;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.23;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=15;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=15;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=15;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.39;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.39;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.39;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.18;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.18;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.18;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.01;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.01;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.01;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=7.01;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=14.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=14.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=14.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.29;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.29;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.29;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.76;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.76;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.76;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.3;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.3;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.3;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=11.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.9;Gender=M;Gleason Score=3+4;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=11.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.9;Gender=M;Gleason Score=3+4;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=11.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.3;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.3;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10.55;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10.55;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10.55;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.36;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.36;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.89;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.89;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.89;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.89;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=43.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=43.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=43.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.5;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8.4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.5;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8.4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.5;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8.4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.5;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8.4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.5;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8.4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.5;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8.4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=16;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=16;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=16;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=16;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=16;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=16;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=16;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=16;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=16;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=16;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.099999905;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.099999905;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.099999905;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.099999905;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.099999905;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.099999905;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.099999905;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.4;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=5.099999905;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.4;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=5.099999905;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.4;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=5.099999905;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.4;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=5.099999905;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.4;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=5.099999905;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.4;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=5.099999905;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.4;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=5.099999905;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.4;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=5.099999905;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.799999952;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.799999952;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.799999952;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.799999952;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=3.799999952;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=3.799999952;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=3.799999952;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=3.799999952;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=3.799999952;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=3.799999952;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.299999952;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.299999952;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.299999952;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.299999952;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=3.299999952;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=3.299999952;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=3.299999952;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=3.299999952;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=3.299999952;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=3.299999952;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=17.79999924;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=17.79999924;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=17.79999924;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=17.79999924;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=17.79999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=17.79999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=17.79999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=17.79999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=17.79999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=17.79999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=17.79999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9.399999619;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9.399999619;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9.399999619;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9.399999619;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9.399999619;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9.399999619;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9.399999619;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9.399999619;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=7.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=7.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=7.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=7.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=7.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=7.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10.10000038;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10.10000038;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10.10000038;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10.10000038;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10.10000038;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10.10000038;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.199999809;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.199999809;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.199999809;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.199999809;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.199999809;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.800000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.800000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.800000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.800000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.7;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=8.800000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.7;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=8.800000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.7;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=8.800000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.7;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=8.800000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.7;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=8.800000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.7;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=8.800000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.199999809;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.199999809;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.199999809;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.199999809;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=29.89999962;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=29.89999962;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=29.89999962;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.4;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=29.89999962;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.4;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=29.89999962;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.4;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=29.89999962;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.4;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=29.89999962;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.4;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=29.89999962;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.4;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=29.89999962;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=30.29999924;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=30.29999924;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=30.29999924;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=30.29999924;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.800000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.800000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.800000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.800000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.800000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.0;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=6.800000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.0;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=6.800000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.0;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=6.800000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.0;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=6.800000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.0;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=6.800000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.0;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=6.800000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.0;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=6.800000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.300000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.300000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.300000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.300000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.300000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.300000191;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=6.300000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=6.300000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=6.300000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=6.300000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=6.300000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=6.300000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=1.600000024;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=1.600000024;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=1.600000024;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=1.600000024;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=1.600000024;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=1.600000024;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=1.600000024;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=1.600000024;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=1.600000024;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=1.600000024;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=1.600000024;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=20.39999962;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=20.39999962;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=20.39999962;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=20.39999962;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=4.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=4.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=4.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=4.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=4.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=4.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.699999809;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.699999809;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.699999809;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.699999809;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.64;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.23;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.32;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.32;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.9;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.32;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.9;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.32;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.9;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.32;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.9;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.32;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.9;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.32;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.9;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.32;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.9;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.32;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.3;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=13.21;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=6.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=6.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=6.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=6.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=6.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=6.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.49;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.27;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=2.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=2.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=2.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.5;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=2.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.5;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=2.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.5;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=2.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.5;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=2.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.5;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=2.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.5;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=2.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=19.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=19.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=19.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=19.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=19.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=19.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=19.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=19.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=19.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10.30000019;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10.30000019;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10.30000019;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=10.30000019;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=10.30000019;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=10.30000019;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=10.30000019;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=10.30000019;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=10.30000019;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10.10000038;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10.10000038;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10.10000038;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10.10000038;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10.10000038;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10.10000038;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10.10000038;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10.10000038;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10.10000038;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10.10000038;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.199999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.199999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.199999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.199999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.199999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.199999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.199999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.199999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=7.199999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=7.199999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=7.199999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=7.199999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=7.199999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=7.199999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=30.29999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=30.29999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=30.29999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=30.29999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=30.29999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=30.29999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=30.29999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=30.29999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=30.29999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.0;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=20.39999962;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.0;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=20.39999962;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.0;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=20.39999962;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.0;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=20.39999962;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.0;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=20.39999962;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.0;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=20.39999962;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=5.699999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=5.699999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=5.699999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=5.699999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=5.699999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=5.699999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=5.699999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.22;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.22;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.22;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.22;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.22;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.22;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.22;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=39.47;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=39.47;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=39.47;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=39.47;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.1;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.11;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.11;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.11;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.11;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.77;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.77;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.77;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.77;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.23;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.23;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.5;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.5;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.5;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.5;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.5;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.5;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=7.01;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=7.01;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=7.01;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=7.01;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=7.01;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=7.01;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.1;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.8;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.8;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.8;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.8;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.8;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.8;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.8;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.9;Gender=M;Gleason Score=3+4;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=11.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.9;Gender=M;Gleason Score=3+4;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=11.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.9;Gender=M;Gleason Score=3+4;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=11.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.9;Gender=M;Gleason Score=3+4;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=11.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=10.55;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=10.55;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=10.55;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=10.55;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=10.55;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=10.55;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;Gender=M;Gleason Score=4+3;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=3.36;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;Gender=M;Gleason Score=4+3;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=3.36;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;Gender=M;Gleason Score=4+3;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=3.36;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;Gender=M;Gleason Score=4+3;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=3.36;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;Gender=M;Gleason Score=4+3;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=3.36;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;Gender=M;Gleason Score=4+3;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=3.36;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.89;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.89;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.89;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.89;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.89;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.89;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=43.8;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=43.8;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=43.8;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=43.8;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=43.8;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=43.8;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.96;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.96;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.96;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.96;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.96;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.96;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.96;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.96;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.96;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.96;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=9.08;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=9.08;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=9.08;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=9.08;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=9.08;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=9.08;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=14.29;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=14.29;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=14.29;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=14.29;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=14.29;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=14.29;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.8;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=11.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.8;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=11.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.8;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=11.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.8;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=11.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.8;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=11.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.8;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=11.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.2;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.2;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.2;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.2;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.2;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.2;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=6.3;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.9;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.5;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.2;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=39.47;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.2;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=39.47;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.2;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=39.47;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.2;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=39.47;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.2;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=39.47;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.2;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=39.47;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=9.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=9.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=9.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=9.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=9.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=9.1;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.4;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.7;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.5;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=8.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=8.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=8.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=8.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=8.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.6;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=8.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=3.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.8;Gender=M;Gleason Score=3+4;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=5.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.8;Gender=M;Gleason Score=3+4;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=5.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.8;Gender=M;Gleason Score=3+4;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=5.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.8;Gender=M;Gleason Score=3+4;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=5.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.8;Gender=M;Gleason Score=3+4;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=5.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.8;Gender=M;Gleason Score=3+4;Pathology T=T2a;Phenotype=OBI_0000922;PreTreatment PSA=5.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=14;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=14;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=14;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=14;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=14;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=14;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.6;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.77;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.6;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.77;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.6;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.77;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.6;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.77;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.6;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.77;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.6;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.77;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.27;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.27;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.27;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.27;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.27;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.27;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.39;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.39;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.39;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.39;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.39;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.39;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.18;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.18;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.18;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.18;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.18;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.18;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.9;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.6;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.6;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.6;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.6;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.6;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.6;Gender=M;Gleason Score=3+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.1;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.1;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.1;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.1;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.1;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.1;Gender=M;Gleason Score=3+4;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=8.7;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=14.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=14.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=14.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=14.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=14.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=14.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.29;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.29;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.29;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.29;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.29;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.29;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.9;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.76;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.9;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.76;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.9;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.76;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.9;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.76;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.9;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.76;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.9;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=5.76;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.1;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.1;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.1;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.1;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=17.79999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=17.79999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.399999619;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.399999619;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.399999619;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=9.399999619;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=19.0;Sample=CPCG0002-F1;Tissue=Prostate Tumour;donor_id=CPCG0002;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=19.0;Sample=CPCG0002-F1;Tissue=Prostate Tumour;donor_id=CPCG0002;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=19.0;Sample=CPCG0002-F1;Tissue=Prostate Tumour;donor_id=CPCG0002;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=19.0;Sample=CPCG0002-F1;Tissue=Prostate Tumour;donor_id=CPCG0002;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=19.0;Sample=CPCG0002-F1;Tissue=Prostate Tumour;donor_id=CPCG0002;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=19.0;Sample=CPCG0002-F1;Tissue=Prostate Tumour;donor_id=CPCG0002;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.1;Sample=CPCG0004-B1;Tissue=Blood;donor_id=CPCG0004;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.1;Sample=CPCG0004-B1;Tissue=Blood;donor_id=CPCG0004;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.1;Sample=CPCG0004-B1;Tissue=Blood;donor_id=CPCG0004;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.1;Sample=CPCG0004-B1;Tissue=Blood;donor_id=CPCG0004;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.1;Sample=CPCG0004-B1;Tissue=Blood;donor_id=CPCG0004;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.1;Sample=CPCG0004-B1;Tissue=Blood;donor_id=CPCG0004;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.5;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=14.1;Sample=CPCG0004-F1;Tissue=Prostate Tumour;donor_id=CPCG0004;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.5;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=14.1;Sample=CPCG0004-F1;Tissue=Prostate Tumour;donor_id=CPCG0004;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.5;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=14.1;Sample=CPCG0004-F1;Tissue=Prostate Tumour;donor_id=CPCG0004;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.5;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=14.1;Sample=CPCG0004-F1;Tissue=Prostate Tumour;donor_id=CPCG0004;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.5;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=14.1;Sample=CPCG0004-F1;Tissue=Prostate Tumour;donor_id=CPCG0004;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.5;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=14.1;Sample=CPCG0004-F1;Tissue=Prostate Tumour;donor_id=CPCG0004;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.5;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=14.1;Sample=CPCG0004-F1;Tissue=Prostate Tumour;donor_id=CPCG0004;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.5;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=14.1;Sample=CPCG0004-F1;Tissue=Prostate Tumour;donor_id=CPCG0004;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.4;Sample=CPCG0005-B1;Tissue=Blood;donor_id=CPCG0005;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.4;Sample=CPCG0005-B1;Tissue=Blood;donor_id=CPCG0005;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.4;Sample=CPCG0005-B1;Tissue=Blood;donor_id=CPCG0005;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.4;Sample=CPCG0005-B1;Tissue=Blood;donor_id=CPCG0005;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.4;Sample=CPCG0005-B1;Tissue=Blood;donor_id=CPCG0005;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0005-F1;Tissue=Prostate Tumour;donor_id=CPCG0005;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0005-F1;Tissue=Prostate Tumour;donor_id=CPCG0005;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0005-F1;Tissue=Prostate Tumour;donor_id=CPCG0005;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0005-F1;Tissue=Prostate Tumour;donor_id=CPCG0005;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0005-F1;Tissue=Prostate Tumour;donor_id=CPCG0005;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0005-F1;Tissue=Prostate Tumour;donor_id=CPCG0005;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.4;Sample=CPCG0007-B1;Tissue=Blood;donor_id=CPCG0007;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.4;Sample=CPCG0007-B1;Tissue=Blood;donor_id=CPCG0007;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.4;Sample=CPCG0007-B1;Tissue=Blood;donor_id=CPCG0007;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.4;Sample=CPCG0007-B1;Tissue=Blood;donor_id=CPCG0007;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.4;Sample=CPCG0007-B1;Tissue=Blood;donor_id=CPCG0007;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.4;Sample=CPCG0007-B1;Tissue=Blood;donor_id=CPCG0007;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.4;Sample=CPCG0007-B1;Tissue=Blood;donor_id=CPCG0007;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.4;Sample=CPCG0007-F1;Tissue=Prostate Tumour;donor_id=CPCG0007;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.4;Sample=CPCG0007-F1;Tissue=Prostate Tumour;donor_id=CPCG0007;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.4;Sample=CPCG0007-F1;Tissue=Prostate Tumour;donor_id=CPCG0007;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.4;Sample=CPCG0007-F1;Tissue=Prostate Tumour;donor_id=CPCG0007;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.4;Sample=CPCG0007-F1;Tissue=Prostate Tumour;donor_id=CPCG0007;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.4;Sample=CPCG0007-F1;Tissue=Prostate Tumour;donor_id=CPCG0007;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.7;Sample=CPCG0008-B1;Tissue=Blood;donor_id=CPCG0008;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.7;Sample=CPCG0008-B1;Tissue=Blood;donor_id=CPCG0008;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.7;Sample=CPCG0008-B1;Tissue=Blood;donor_id=CPCG0008;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.7;Sample=CPCG0008-B1;Tissue=Blood;donor_id=CPCG0008;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.7;Sample=CPCG0008-B1;Tissue=Blood;donor_id=CPCG0008;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.7;Sample=CPCG0008-B1;Tissue=Blood;donor_id=CPCG0008;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.3;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.3;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.3;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.3;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.3;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.3;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=8;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.6;Sample=CPCG0015-B1;Tissue=Blood;donor_id=CPCG0015;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.6;Sample=CPCG0015-B1;Tissue=Blood;donor_id=CPCG0015;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.6;Sample=CPCG0015-B1;Tissue=Blood;donor_id=CPCG0015;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.6;Sample=CPCG0015-B1;Tissue=Blood;donor_id=CPCG0015;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0015-F1;Tissue=Prostate Tumour;donor_id=CPCG0015;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0015-F1;Tissue=Prostate Tumour;donor_id=CPCG0015;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0015-F1;Tissue=Prostate Tumour;donor_id=CPCG0015;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0015-F1;Tissue=Prostate Tumour;donor_id=CPCG0015;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0015-F1;Tissue=Prostate Tumour;donor_id=CPCG0015;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0015-F1;Tissue=Prostate Tumour;donor_id=CPCG0015;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.3;Sample=CPCG0019-B1;Tissue=Blood;donor_id=CPCG0019;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.3;Sample=CPCG0019-B1;Tissue=Blood;donor_id=CPCG0019;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.3;Sample=CPCG0019-B1;Tissue=Blood;donor_id=CPCG0019;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.3;Sample=CPCG0019-B1;Tissue=Blood;donor_id=CPCG0019;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.4;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=7.3;Sample=CPCG0019-F1;Tissue=Prostate Tumour;donor_id=CPCG0019;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.4;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=7.3;Sample=CPCG0019-F1;Tissue=Prostate Tumour;donor_id=CPCG0019;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.4;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=7.3;Sample=CPCG0019-F1;Tissue=Prostate Tumour;donor_id=CPCG0019;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.4;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=7.3;Sample=CPCG0019-F1;Tissue=Prostate Tumour;donor_id=CPCG0019;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.4;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=7.3;Sample=CPCG0019-F1;Tissue=Prostate Tumour;donor_id=CPCG0019;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.4;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=7.3;Sample=CPCG0019-F1;Tissue=Prostate Tumour;donor_id=CPCG0019;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=12.6;Sample=CPCG0022-B1;Tissue=Blood;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=12.6;Sample=CPCG0022-B1;Tissue=Blood;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=12.6;Sample=CPCG0022-B1;Tissue=Blood;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=12.6;Sample=CPCG0022-B1;Tissue=Blood;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=12.6;Sample=CPCG0022-B1;Tissue=Blood;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=12.6;Sample=CPCG0022-B1;Tissue=Blood;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=12.6;Sample=CPCG0022-B1;Tissue=Blood;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=12.6;Sample=CPCG0022-B1;Tissue=Blood;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.6;Sample=CPCG0022-F1;Tissue=Prostate Tumour;donor_id=CPCG0022;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.0;Sample=CPCG0027-B1;Tissue=Blood;donor_id=CPCG0027;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.0;Sample=CPCG0027-B1;Tissue=Blood;donor_id=CPCG0027;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.0;Sample=CPCG0027-B1;Tissue=Blood;donor_id=CPCG0027;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.0;Sample=CPCG0027-B1;Tissue=Blood;donor_id=CPCG0027;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0027-F1;Tissue=Prostate Tumour;donor_id=CPCG0027;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0027-F1;Tissue=Prostate Tumour;donor_id=CPCG0027;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0027-F1;Tissue=Prostate Tumour;donor_id=CPCG0027;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0027-F1;Tissue=Prostate Tumour;donor_id=CPCG0027;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0027-F1;Tissue=Prostate Tumour;donor_id=CPCG0027;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0027-F1;Tissue=Prostate Tumour;donor_id=CPCG0027;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.0;Sample=CPCG0030-B1;Tissue=Blood;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.0;Sample=CPCG0030-B1;Tissue=Blood;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.0;Sample=CPCG0030-B1;Tissue=Blood;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.0;Sample=CPCG0030-B1;Tissue=Blood;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.0;Sample=CPCG0030-B1;Tissue=Blood;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0030-F1;Tissue=Prostate Tumour;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0030-F1;Tissue=Prostate Tumour;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0030-F1;Tissue=Prostate Tumour;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0030-F1;Tissue=Prostate Tumour;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0030-F1;Tissue=Prostate Tumour;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0030-F1;Tissue=Prostate Tumour;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0030-F1;Tissue=Prostate Tumour;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0030-F1;Tissue=Prostate Tumour;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0030-F1;Tissue=Prostate Tumour;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0030-F1;Tissue=Prostate Tumour;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0030-F1;Tissue=Prostate Tumour;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0030-F1;Tissue=Prostate Tumour;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.3;Sample=CPCG0036-B1;Tissue=Blood;donor_id=CPCG0036;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.3;Sample=CPCG0036-B1;Tissue=Blood;donor_id=CPCG0036;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.3;Sample=CPCG0036-B1;Tissue=Blood;donor_id=CPCG0036;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.3;Sample=CPCG0036-B1;Tissue=Blood;donor_id=CPCG0036;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0036-F1;Tissue=Prostate Tumour;donor_id=CPCG0036;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0036-F1;Tissue=Prostate Tumour;donor_id=CPCG0036;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0036-F1;Tissue=Prostate Tumour;donor_id=CPCG0036;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0036-F1;Tissue=Prostate Tumour;donor_id=CPCG0036;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0036-F1;Tissue=Prostate Tumour;donor_id=CPCG0036;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0036-F1;Tissue=Prostate Tumour;donor_id=CPCG0036;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.6;Sample=CPCG0042-B1;Tissue=Blood;donor_id=CPCG0042;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.6;Sample=CPCG0042-B1;Tissue=Blood;donor_id=CPCG0042;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.6;Sample=CPCG0042-B1;Tissue=Blood;donor_id=CPCG0042;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.6;Sample=CPCG0042-B1;Tissue=Blood;donor_id=CPCG0042;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.5;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0042-F1;Tissue=Prostate Tumour;donor_id=CPCG0042;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.5;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0042-F1;Tissue=Prostate Tumour;donor_id=CPCG0042;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.5;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0042-F1;Tissue=Prostate Tumour;donor_id=CPCG0042;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.5;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0042-F1;Tissue=Prostate Tumour;donor_id=CPCG0042;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.5;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0042-F1;Tissue=Prostate Tumour;donor_id=CPCG0042;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.5;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0042-F1;Tissue=Prostate Tumour;donor_id=CPCG0042;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0043-F1;Tissue=Prostate Tumour;donor_id=CPCG0043;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0043-F1;Tissue=Prostate Tumour;donor_id=CPCG0043;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0043-F1;Tissue=Prostate Tumour;donor_id=CPCG0043;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0043-F1;Tissue=Prostate Tumour;donor_id=CPCG0043;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0043-F1;Tissue=Prostate Tumour;donor_id=CPCG0043;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0043-F1;Tissue=Prostate Tumour;donor_id=CPCG0043;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.7;Sample=CPCG0050-B1;Tissue=Blood;donor_id=CPCG0050;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.7;Sample=CPCG0050-B1;Tissue=Blood;donor_id=CPCG0050;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.7;Sample=CPCG0050-B1;Tissue=Blood;donor_id=CPCG0050;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.7;Sample=CPCG0050-B1;Tissue=Blood;donor_id=CPCG0050;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.7;Sample=CPCG0050-B1;Tissue=Blood;donor_id=CPCG0050;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.4;Sample=CPCG0059-B1;Tissue=Blood;donor_id=CPCG0059;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.4;Sample=CPCG0059-B1;Tissue=Blood;donor_id=CPCG0059;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.4;Sample=CPCG0059-B1;Tissue=Blood;donor_id=CPCG0059;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.4;Sample=CPCG0059-F1;Tissue=Prostate Tumour;donor_id=CPCG0059;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.4;Sample=CPCG0059-F1;Tissue=Prostate Tumour;donor_id=CPCG0059;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.4;Sample=CPCG0059-F1;Tissue=Prostate Tumour;donor_id=CPCG0059;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.4;Sample=CPCG0059-F1;Tissue=Prostate Tumour;donor_id=CPCG0059;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.4;Sample=CPCG0059-F1;Tissue=Prostate Tumour;donor_id=CPCG0059;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.4;Sample=CPCG0059-F1;Tissue=Prostate Tumour;donor_id=CPCG0059;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.0;Sample=CPCG0067-B1;Tissue=Blood;donor_id=CPCG0067;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.0;Sample=CPCG0067-B1;Tissue=Blood;donor_id=CPCG0067;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.0;Sample=CPCG0067-B1;Tissue=Blood;donor_id=CPCG0067;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.0;Sample=CPCG0067-B1;Tissue=Blood;donor_id=CPCG0067;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.0;Sample=CPCG0067-B1;Tissue=Blood;donor_id=CPCG0067;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0067-F1;Tissue=Prostate Tumour;donor_id=CPCG0067;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0067-F1;Tissue=Prostate Tumour;donor_id=CPCG0067;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0067-F1;Tissue=Prostate Tumour;donor_id=CPCG0067;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0067-F1;Tissue=Prostate Tumour;donor_id=CPCG0067;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0067-F1;Tissue=Prostate Tumour;donor_id=CPCG0067;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0067-F1;Tissue=Prostate Tumour;donor_id=CPCG0067;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0068-F1;Tissue=Prostate Tumour;donor_id=CPCG0068;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0068-F1;Tissue=Prostate Tumour;donor_id=CPCG0068;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0068-F1;Tissue=Prostate Tumour;donor_id=CPCG0068;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0068-F1;Tissue=Prostate Tumour;donor_id=CPCG0068;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0068-F1;Tissue=Prostate Tumour;donor_id=CPCG0068;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0068-F1;Tissue=Prostate Tumour;donor_id=CPCG0068;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0068-F1;Tissue=Prostate Tumour;donor_id=CPCG0068;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0068-F1;Tissue=Prostate Tumour;donor_id=CPCG0068;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0069-B1;Tissue=Blood;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0069-B1;Tissue=Blood;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0069-B1;Tissue=Blood;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0069-B1;Tissue=Blood;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0069-B1;Tissue=Blood;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0069-B1;Tissue=Blood;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0069-B1;Tissue=Blood;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0069-B1;Tissue=Blood;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0069-B1;Tissue=Blood;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0069-B1;Tissue=Blood;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.3;Sample=CPCG0069-F1;Tissue=Prostate Tumour;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.3;Sample=CPCG0069-F1;Tissue=Prostate Tumour;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.3;Sample=CPCG0069-F1;Tissue=Prostate Tumour;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.3;Sample=CPCG0069-F1;Tissue=Prostate Tumour;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.3;Sample=CPCG0069-F1;Tissue=Prostate Tumour;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.3;Sample=CPCG0069-F1;Tissue=Prostate Tumour;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.3;Sample=CPCG0069-F1;Tissue=Prostate Tumour;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.3;Sample=CPCG0069-F1;Tissue=Prostate Tumour;donor_id=CPCG0069;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.9;Sample=CPCG0070-B1;Tissue=Blood;donor_id=CPCG0070;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.9;Sample=CPCG0070-B1;Tissue=Blood;donor_id=CPCG0070;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.9;Sample=CPCG0070-B1;Tissue=Blood;donor_id=CPCG0070;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.9;Sample=CPCG0070-B1;Tissue=Blood;donor_id=CPCG0070;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0070-F1;Tissue=Prostate Tumour;donor_id=CPCG0070;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0070-F1;Tissue=Prostate Tumour;donor_id=CPCG0070;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0070-F1;Tissue=Prostate Tumour;donor_id=CPCG0070;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0070-F1;Tissue=Prostate Tumour;donor_id=CPCG0070;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0070-F1;Tissue=Prostate Tumour;donor_id=CPCG0070;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0070-F1;Tissue=Prostate Tumour;donor_id=CPCG0070;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0070-F1;Tissue=Prostate Tumour;donor_id=CPCG0070;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0070-F1;Tissue=Prostate Tumour;donor_id=CPCG0070;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.9;Sample=CPCG0070-F1;Tissue=Prostate Tumour;donor_id=CPCG0070;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.7;Sample=CPCG0071-B1;Tissue=Blood;donor_id=CPCG0071;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.7;Sample=CPCG0071-B1;Tissue=Blood;donor_id=CPCG0071;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.7;Sample=CPCG0071-B1;Tissue=Blood;donor_id=CPCG0071;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.7;Sample=CPCG0071-B1;Tissue=Blood;donor_id=CPCG0071;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.7;Sample=CPCG0071-B1;Tissue=Blood;donor_id=CPCG0071;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.7;Sample=CPCG0071-B1;Tissue=Blood;donor_id=CPCG0071;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=14.7;Sample=CPCG0071-F1;Tissue=Prostate Tumour;donor_id=CPCG0071;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.3;Sample=CPCG0072-B1;Tissue=Blood;donor_id=CPCG0072;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.3;Sample=CPCG0072-B1;Tissue=Blood;donor_id=CPCG0072;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.3;Sample=CPCG0072-B1;Tissue=Blood;donor_id=CPCG0072;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.3;Sample=CPCG0072-B1;Tissue=Blood;donor_id=CPCG0072;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=9.3;Sample=CPCG0072-F1;Tissue=Prostate Tumour;donor_id=CPCG0072;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=9.3;Sample=CPCG0072-F1;Tissue=Prostate Tumour;donor_id=CPCG0072;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=9.3;Sample=CPCG0072-F1;Tissue=Prostate Tumour;donor_id=CPCG0072;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=9.3;Sample=CPCG0072-F1;Tissue=Prostate Tumour;donor_id=CPCG0072;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=9.3;Sample=CPCG0072-F1;Tissue=Prostate Tumour;donor_id=CPCG0072;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=9.3;Sample=CPCG0072-F1;Tissue=Prostate Tumour;donor_id=CPCG0072;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=9.3;Sample=CPCG0072-F1;Tissue=Prostate Tumour;donor_id=CPCG0072;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=9.3;Sample=CPCG0072-F1;Tissue=Prostate Tumour;donor_id=CPCG0072;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=9.3;Sample=CPCG0072-F1;Tissue=Prostate Tumour;donor_id=CPCG0072;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=9.3;Sample=CPCG0072-F1;Tissue=Prostate Tumour;donor_id=CPCG0072;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.3;Sample=CPCG0074-B1;Tissue=Blood;donor_id=CPCG0074;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.3;Sample=CPCG0074-B1;Tissue=Blood;donor_id=CPCG0074;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.3;Sample=CPCG0074-B1;Tissue=Blood;donor_id=CPCG0074;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0074-F1;Tissue=Prostate Tumour;donor_id=CPCG0074;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0074-F1;Tissue=Prostate Tumour;donor_id=CPCG0074;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0074-F1;Tissue=Prostate Tumour;donor_id=CPCG0074;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0074-F1;Tissue=Prostate Tumour;donor_id=CPCG0074;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0074-F1;Tissue=Prostate Tumour;donor_id=CPCG0074;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0074-F1;Tissue=Prostate Tumour;donor_id=CPCG0074;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.1;Sample=CPCG0075-B1;Tissue=Blood;donor_id=CPCG0075;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.1;Sample=CPCG0075-B1;Tissue=Blood;donor_id=CPCG0075;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.1;Sample=CPCG0075-B1;Tissue=Blood;donor_id=CPCG0075;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.1;Sample=CPCG0075-B1;Tissue=Blood;donor_id=CPCG0075;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.1;Sample=CPCG0075-B1;Tissue=Blood;donor_id=CPCG0075;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.1;Sample=CPCG0075-B1;Tissue=Blood;donor_id=CPCG0075;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.1;Sample=CPCG0075-F1;Tissue=Prostate Tumour;donor_id=CPCG0075;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.1;Sample=CPCG0075-F1;Tissue=Prostate Tumour;donor_id=CPCG0075;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.1;Sample=CPCG0075-F1;Tissue=Prostate Tumour;donor_id=CPCG0075;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.1;Sample=CPCG0075-F1;Tissue=Prostate Tumour;donor_id=CPCG0075;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.1;Sample=CPCG0075-F1;Tissue=Prostate Tumour;donor_id=CPCG0075;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.1;Sample=CPCG0075-F1;Tissue=Prostate Tumour;donor_id=CPCG0075;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=12.7;Sample=CPCG0076-B1;Tissue=Blood;donor_id=CPCG0076;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=12.7;Sample=CPCG0076-B1;Tissue=Blood;donor_id=CPCG0076;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=12.7;Sample=CPCG0076-B1;Tissue=Blood;donor_id=CPCG0076;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.7;Sample=CPCG0076-F1;Tissue=Prostate Tumour;donor_id=CPCG0076;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.7;Sample=CPCG0076-F1;Tissue=Prostate Tumour;donor_id=CPCG0076;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.7;Sample=CPCG0076-F1;Tissue=Prostate Tumour;donor_id=CPCG0076;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.7;Sample=CPCG0076-F1;Tissue=Prostate Tumour;donor_id=CPCG0076;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.7;Sample=CPCG0076-F1;Tissue=Prostate Tumour;donor_id=CPCG0076;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=12.7;Sample=CPCG0076-F1;Tissue=Prostate Tumour;donor_id=CPCG0076;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=17.79999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=17.79999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=17.79999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=17.79999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=17.79999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=17.79999924;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.8;Sample=CPCG0082-B1;Tissue=Blood;donor_id=CPCG0082;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.8;Sample=CPCG0082-B1;Tissue=Blood;donor_id=CPCG0082;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.8;Sample=CPCG0082-B1;Tissue=Blood;donor_id=CPCG0082;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.8;Sample=CPCG0082-B1;Tissue=Blood;donor_id=CPCG0082;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0082-F1;Tissue=Prostate Tumour;donor_id=CPCG0082;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0082-F1;Tissue=Prostate Tumour;donor_id=CPCG0082;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0082-F1;Tissue=Prostate Tumour;donor_id=CPCG0082;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0082-F1;Tissue=Prostate Tumour;donor_id=CPCG0082;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0082-F1;Tissue=Prostate Tumour;donor_id=CPCG0082;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0082-F1;Tissue=Prostate Tumour;donor_id=CPCG0082;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.0;Sample=CPCG0084-B1;Tissue=Blood;donor_id=CPCG0084;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.0;Sample=CPCG0084-B1;Tissue=Blood;donor_id=CPCG0084;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.0;Sample=CPCG0084-B1;Tissue=Blood;donor_id=CPCG0084;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.0;Sample=CPCG0084-F1;Tissue=Prostate Tumour;donor_id=CPCG0084;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.0;Sample=CPCG0084-F1;Tissue=Prostate Tumour;donor_id=CPCG0084;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.0;Sample=CPCG0084-F1;Tissue=Prostate Tumour;donor_id=CPCG0084;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.0;Sample=CPCG0084-F1;Tissue=Prostate Tumour;donor_id=CPCG0084;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.0;Sample=CPCG0084-F1;Tissue=Prostate Tumour;donor_id=CPCG0084;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.0;Sample=CPCG0084-F1;Tissue=Prostate Tumour;donor_id=CPCG0084;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0089-B1;Tissue=Blood;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0089-B1;Tissue=Blood;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0089-B1;Tissue=Blood;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0089-B1;Tissue=Blood;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0089-B1;Tissue=Blood;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0089-B1;Tissue=Blood;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0089-B1;Tissue=Blood;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0089-B1;Tissue=Blood;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0089-B1;Tissue=Blood;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0089-B1;Tissue=Blood;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0089-B1;Tissue=Blood;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0089-F1;Tissue=Prostate Tumour;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0089-F1;Tissue=Prostate Tumour;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0089-F1;Tissue=Prostate Tumour;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0089-F1;Tissue=Prostate Tumour;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0089-F1;Tissue=Prostate Tumour;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0089-F1;Tissue=Prostate Tumour;donor_id=CPCG0089;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0090-B1;Tissue=Blood;donor_id=CPCG0090;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0090-B1;Tissue=Blood;donor_id=CPCG0090;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0090-B1;Tissue=Blood;donor_id=CPCG0090;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0090-B1;Tissue=Blood;donor_id=CPCG0090;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0090-B1;Tissue=Blood;donor_id=CPCG0090;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0090-F1;Tissue=Prostate Tumour;donor_id=CPCG0090;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0090-F1;Tissue=Prostate Tumour;donor_id=CPCG0090;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0090-F1;Tissue=Prostate Tumour;donor_id=CPCG0090;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0090-F1;Tissue=Prostate Tumour;donor_id=CPCG0090;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0090-F1;Tissue=Prostate Tumour;donor_id=CPCG0090;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0090-F1;Tissue=Prostate Tumour;donor_id=CPCG0090;ENA-CHECKLIST=ERC000026;
Age at Treatment=82.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.4;Sample=CPCG0091-B1;Tissue=Blood;donor_id=CPCG0091;ENA-CHECKLIST=ERC000026;
Age at Treatment=82.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.4;Sample=CPCG0091-B1;Tissue=Blood;donor_id=CPCG0091;ENA-CHECKLIST=ERC000026;
Age at Treatment=82.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.4;Sample=CPCG0091-B1;Tissue=Blood;donor_id=CPCG0091;ENA-CHECKLIST=ERC000026;
Age at Treatment=82.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.4;Sample=CPCG0091-F1;Tissue=Prostate Tumour;donor_id=CPCG0091;ENA-CHECKLIST=ERC000026;
Age at Treatment=82.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.4;Sample=CPCG0091-F1;Tissue=Prostate Tumour;donor_id=CPCG0091;ENA-CHECKLIST=ERC000026;
Age at Treatment=82.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.4;Sample=CPCG0091-F1;Tissue=Prostate Tumour;donor_id=CPCG0091;ENA-CHECKLIST=ERC000026;
Age at Treatment=82.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.4;Sample=CPCG0091-F1;Tissue=Prostate Tumour;donor_id=CPCG0091;ENA-CHECKLIST=ERC000026;
Age at Treatment=82.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.4;Sample=CPCG0091-F1;Tissue=Prostate Tumour;donor_id=CPCG0091;ENA-CHECKLIST=ERC000026;
Age at Treatment=82.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.4;Sample=CPCG0091-F1;Tissue=Prostate Tumour;donor_id=CPCG0091;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.5;Sample=CPCG0092-B1;Tissue=Blood;donor_id=CPCG0092;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.5;Sample=CPCG0092-B1;Tissue=Blood;donor_id=CPCG0092;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.5;Sample=CPCG0092-B1;Tissue=Blood;donor_id=CPCG0092;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=11.5;Sample=CPCG0092-F1;Tissue=Prostate Tumour;donor_id=CPCG0092;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=11.5;Sample=CPCG0092-F1;Tissue=Prostate Tumour;donor_id=CPCG0092;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=11.5;Sample=CPCG0092-F1;Tissue=Prostate Tumour;donor_id=CPCG0092;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=11.5;Sample=CPCG0092-F1;Tissue=Prostate Tumour;donor_id=CPCG0092;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=11.5;Sample=CPCG0092-F1;Tissue=Prostate Tumour;donor_id=CPCG0092;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=11.5;Sample=CPCG0092-F1;Tissue=Prostate Tumour;donor_id=CPCG0092;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.8;Sample=CPCG0093-B1;Tissue=Blood;donor_id=CPCG0093;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.8;Sample=CPCG0093-B1;Tissue=Blood;donor_id=CPCG0093;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.8;Sample=CPCG0093-B1;Tissue=Blood;donor_id=CPCG0093;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.1;Sample=CPCG0096-B1;Tissue=Blood;donor_id=CPCG0096;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.1;Sample=CPCG0096-B1;Tissue=Blood;donor_id=CPCG0096;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.1;Sample=CPCG0096-B1;Tissue=Blood;donor_id=CPCG0096;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.1;Sample=CPCG0096-F1;Tissue=Prostate Tumour;donor_id=CPCG0096;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.1;Sample=CPCG0096-F1;Tissue=Prostate Tumour;donor_id=CPCG0096;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.1;Sample=CPCG0096-F1;Tissue=Prostate Tumour;donor_id=CPCG0096;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.1;Sample=CPCG0096-F1;Tissue=Prostate Tumour;donor_id=CPCG0096;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.1;Sample=CPCG0096-F1;Tissue=Prostate Tumour;donor_id=CPCG0096;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.1;Sample=CPCG0096-F1;Tissue=Prostate Tumour;donor_id=CPCG0096;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.7;Sample=CPCG0097-B1;Tissue=Blood;donor_id=CPCG0097;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.7;Sample=CPCG0097-B1;Tissue=Blood;donor_id=CPCG0097;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.7;Sample=CPCG0097-B1;Tissue=Blood;donor_id=CPCG0097;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.7;Sample=CPCG0097-B1;Tissue=Blood;donor_id=CPCG0097;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.7;Sample=CPCG0097-B1;Tissue=Blood;donor_id=CPCG0097;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.7;Sample=CPCG0097-F1;Tissue=Prostate Tumour;donor_id=CPCG0097;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.7;Sample=CPCG0097-F1;Tissue=Prostate Tumour;donor_id=CPCG0097;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.7;Sample=CPCG0097-F1;Tissue=Prostate Tumour;donor_id=CPCG0097;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.7;Sample=CPCG0097-F1;Tissue=Prostate Tumour;donor_id=CPCG0097;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.7;Sample=CPCG0097-F1;Tissue=Prostate Tumour;donor_id=CPCG0097;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.7;Sample=CPCG0097-F1;Tissue=Prostate Tumour;donor_id=CPCG0097;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=80.7;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.56;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.56;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.56;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.56;Tissue=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0100;gender=male;Germline BRCA Status=WT;Gleason Score=4+5;IDC-P Status=Positive (20-40%);phenotype=Prostate Cancer;Sample=CPCG0100-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0100;gender=male;Germline BRCA Status=WT;Gleason Score=4+5;IDC-P Status=Positive (20-40%);phenotype=Prostate Cancer;Sample=CPCG0100-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0100;gender=male;Germline BRCA Status=WT;Gleason Score=4+5;IDC-P Status=Positive (20-40%);phenotype=Prostate Cancer;Sample=CPCG0100-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0100;gender=male;Germline BRCA Status=WT;Gleason Score=4+5;IDC-P Status=Positive (20-40%);phenotype=Prostate Cancer;Sample=CPCG0100-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0100;gender=male;Germline BRCA Status=WT;Gleason Score=4+5;IDC-P Status=Positive (20-40%);phenotype=Prostate Cancer;Sample=CPCG0100-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0100;gender=male;Germline BRCA Status=WT;Gleason Score=4+5;IDC-P Status=Positive (20-40%);phenotype=Prostate Cancer;Sample=CPCG0100-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;phenotype=Prostate Cancer;Sample=CPCG0103-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;phenotype=Prostate Cancer;Sample=CPCG0103-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;phenotype=Prostate Cancer;Sample=CPCG0103-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;phenotype=Prostate Cancer;Sample=CPCG0103-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;Gleason Score=3+4;IDC-P Status=Positive (15%);phenotype=Prostate Cancer;Sample=CPCG0103-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;Gleason Score=3+4;IDC-P Status=Positive (15%);phenotype=Prostate Cancer;Sample=CPCG0103-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;Gleason Score=3+4;IDC-P Status=Positive (15%);phenotype=Prostate Cancer;Sample=CPCG0103-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;Gleason Score=3+4;IDC-P Status=Positive (15%);phenotype=Prostate Cancer;Sample=CPCG0103-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;Gleason Score=3+4;IDC-P Status=Positive (15%);phenotype=Prostate Cancer;Sample=CPCG0103-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;Gleason Score=3+4;IDC-P Status=Positive (15%);phenotype=Prostate Cancer;Sample=CPCG0103-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.1;Sample=CPCG0107-F1;Tissue=Prostate Tumour;donor_id=CPCG0107;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.1;Sample=CPCG0107-F1;Tissue=Prostate Tumour;donor_id=CPCG0107;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.1;Sample=CPCG0107-F1;Tissue=Prostate Tumour;donor_id=CPCG0107;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.1;Sample=CPCG0107-F1;Tissue=Prostate Tumour;donor_id=CPCG0107;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.1;Sample=CPCG0107-F1;Tissue=Prostate Tumour;donor_id=CPCG0107;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.1;Sample=CPCG0107-F1;Tissue=Prostate Tumour;donor_id=CPCG0107;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.5;Sample=CPCG0119-B1;Tissue=Blood;donor_id=CPCG0119;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.5;Sample=CPCG0119-B1;Tissue=Blood;donor_id=CPCG0119;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.5;Sample=CPCG0119-B1;Tissue=Blood;donor_id=CPCG0119;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.5;Sample=CPCG0119-F1;Tissue=Prostate Tumour;donor_id=CPCG0119;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.5;Sample=CPCG0119-F1;Tissue=Prostate Tumour;donor_id=CPCG0119;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.5;Sample=CPCG0119-F1;Tissue=Prostate Tumour;donor_id=CPCG0119;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.5;Sample=CPCG0119-F1;Tissue=Prostate Tumour;donor_id=CPCG0119;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.5;Sample=CPCG0119-F1;Tissue=Prostate Tumour;donor_id=CPCG0119;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.5;Sample=CPCG0119-F1;Tissue=Prostate Tumour;donor_id=CPCG0119;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.8;Sample=CPCG0120-B1;Tissue=Blood;donor_id=CPCG0120;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.8;Sample=CPCG0120-B1;Tissue=Blood;donor_id=CPCG0120;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.8;Sample=CPCG0120-B1;Tissue=Blood;donor_id=CPCG0120;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.8;Sample=CPCG0120-B1;Tissue=Blood;donor_id=CPCG0120;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.8;Sample=CPCG0120-B1;Tissue=Blood;donor_id=CPCG0120;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.8;Sample=CPCG0120-B1;Tissue=Blood;donor_id=CPCG0120;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.8;Sample=CPCG0120-B1;Tissue=Blood;donor_id=CPCG0120;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.8;Sample=CPCG0120-B1;Tissue=Blood;donor_id=CPCG0120;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.8;Sample=CPCG0120-B1;Tissue=Blood;donor_id=CPCG0120;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=14.8;Sample=CPCG0120-F1;Tissue=Prostate Tumour;donor_id=CPCG0120;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=14.8;Sample=CPCG0120-F1;Tissue=Prostate Tumour;donor_id=CPCG0120;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=14.8;Sample=CPCG0120-F1;Tissue=Prostate Tumour;donor_id=CPCG0120;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=14.8;Sample=CPCG0120-F1;Tissue=Prostate Tumour;donor_id=CPCG0120;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=14.8;Sample=CPCG0120-F1;Tissue=Prostate Tumour;donor_id=CPCG0120;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=14.8;Sample=CPCG0120-F1;Tissue=Prostate Tumour;donor_id=CPCG0120;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.4;Sample=CPCG0122-B1;Tissue=Blood;donor_id=CPCG0122;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.4;Sample=CPCG0122-B1;Tissue=Blood;donor_id=CPCG0122;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.4;Sample=CPCG0122-B1;Tissue=Blood;donor_id=CPCG0122;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.4;Sample=CPCG0122-B1;Tissue=Blood;donor_id=CPCG0122;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.4;Sample=CPCG0122-B1;Tissue=Blood;donor_id=CPCG0122;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0122-F1;Tissue=Prostate Tumour;donor_id=CPCG0122;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0122-F1;Tissue=Prostate Tumour;donor_id=CPCG0122;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0122-F1;Tissue=Prostate Tumour;donor_id=CPCG0122;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0122-F1;Tissue=Prostate Tumour;donor_id=CPCG0122;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0122-F1;Tissue=Prostate Tumour;donor_id=CPCG0122;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0122-F1;Tissue=Prostate Tumour;donor_id=CPCG0122;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0122-F1;Tissue=Prostate Tumour;donor_id=CPCG0122;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0122-F1;Tissue=Prostate Tumour;donor_id=CPCG0122;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0122-F1;Tissue=Prostate Tumour;donor_id=CPCG0122;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.199999809;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.199999809;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=7.199999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;Gender=M;Gleason Score=4+3;Phenotype=OBI_0000922;PreTreatment PSA=7.199999809;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.2;Sample=CPCG0125-F1;Tissue=Prostate Tumour;donor_id=CPCG0125;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.2;Sample=CPCG0125-F1;Tissue=Prostate Tumour;donor_id=CPCG0125;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.2;Sample=CPCG0125-F1;Tissue=Prostate Tumour;donor_id=CPCG0125;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.2;Sample=CPCG0125-F1;Tissue=Prostate Tumour;donor_id=CPCG0125;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.2;Sample=CPCG0125-F1;Tissue=Prostate Tumour;donor_id=CPCG0125;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=7.2;Sample=CPCG0125-F1;Tissue=Prostate Tumour;donor_id=CPCG0125;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.1;Sample=CPCG0126-B1;Tissue=Blood;donor_id=CPCG0126;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.1;Sample=CPCG0126-B1;Tissue=Blood;donor_id=CPCG0126;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.1;Sample=CPCG0126-B1;Tissue=Blood;donor_id=CPCG0126;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=30.29999924;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=16.7;Sample=CPCG0129-F1;Tissue=Prostate Tumour;donor_id=CPCG0129;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=16.7;Sample=CPCG0129-F1;Tissue=Prostate Tumour;donor_id=CPCG0129;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=16.7;Sample=CPCG0129-F1;Tissue=Prostate Tumour;donor_id=CPCG0129;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=16.7;Sample=CPCG0129-F1;Tissue=Prostate Tumour;donor_id=CPCG0129;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=16.7;Sample=CPCG0129-F1;Tissue=Prostate Tumour;donor_id=CPCG0129;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=16.7;Sample=CPCG0129-F1;Tissue=Prostate Tumour;donor_id=CPCG0129;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=16.7;Sample=CPCG0129-F1;Tissue=Prostate Tumour;donor_id=CPCG0129;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=16.7;Sample=CPCG0129-F1;Tissue=Prostate Tumour;donor_id=CPCG0129;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=18.7;Sample=CPCG0130-F1;Tissue=Prostate Tumour;donor_id=CPCG0130;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=18.7;Sample=CPCG0130-F1;Tissue=Prostate Tumour;donor_id=CPCG0130;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=18.7;Sample=CPCG0130-F1;Tissue=Prostate Tumour;donor_id=CPCG0130;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=18.7;Sample=CPCG0130-F1;Tissue=Prostate Tumour;donor_id=CPCG0130;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=18.7;Sample=CPCG0130-F1;Tissue=Prostate Tumour;donor_id=CPCG0130;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=18.7;Sample=CPCG0130-F1;Tissue=Prostate Tumour;donor_id=CPCG0130;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=18.7;Sample=CPCG0130-F1;Tissue=Prostate Tumour;donor_id=CPCG0130;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=18.7;Sample=CPCG0130-F1;Tissue=Prostate Tumour;donor_id=CPCG0130;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0131-F1;Tissue=Prostate Tumour;donor_id=CPCG0131;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0131-F1;Tissue=Prostate Tumour;donor_id=CPCG0131;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0131-F1;Tissue=Prostate Tumour;donor_id=CPCG0131;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0131-F1;Tissue=Prostate Tumour;donor_id=CPCG0131;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0131-F1;Tissue=Prostate Tumour;donor_id=CPCG0131;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0131-F1;Tissue=Prostate Tumour;donor_id=CPCG0131;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0131-F1;Tissue=Prostate Tumour;donor_id=CPCG0131;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0131-F1;Tissue=Prostate Tumour;donor_id=CPCG0131;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.4;Sample=CPCG0132-F1;Tissue=Prostate Tumour;donor_id=CPCG0132;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.4;Sample=CPCG0132-F1;Tissue=Prostate Tumour;donor_id=CPCG0132;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.4;Sample=CPCG0132-F1;Tissue=Prostate Tumour;donor_id=CPCG0132;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.4;Sample=CPCG0132-F1;Tissue=Prostate Tumour;donor_id=CPCG0132;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.4;Sample=CPCG0132-F1;Tissue=Prostate Tumour;donor_id=CPCG0132;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.4;Sample=CPCG0132-F1;Tissue=Prostate Tumour;donor_id=CPCG0132;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=10;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=10;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.67;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.67;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.67;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.0;Sample=CPCG0187-B1;Tissue=Blood;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.0;Sample=CPCG0187-B1;Tissue=Blood;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.0;Sample=CPCG0187-B1;Tissue=Blood;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.0;Sample=CPCG0187-B1;Tissue=Blood;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0187-F1;Tissue=Prostate Tumour;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0187-F1;Tissue=Prostate Tumour;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0187-F1;Tissue=Prostate Tumour;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0187-F1;Tissue=Prostate Tumour;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0187-F1;Tissue=Prostate Tumour;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0187-F1;Tissue=Prostate Tumour;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0187-F1;Tissue=Prostate Tumour;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0187-F1;Tissue=Prostate Tumour;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0187-F1;Tissue=Prostate Tumour;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.2;Sample=CPCG0188-B1;Tissue=Blood;donor_id=CPCG0188;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.2;Sample=CPCG0188-B1;Tissue=Blood;donor_id=CPCG0188;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.2;Sample=CPCG0188-B1;Tissue=Blood;donor_id=CPCG0188;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.2;Sample=CPCG0188-B1;Tissue=Blood;donor_id=CPCG0188;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=7.2;Sample=CPCG0188-F1;Tissue=Prostate Tumour;donor_id=CPCG0188;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=7.2;Sample=CPCG0188-F1;Tissue=Prostate Tumour;donor_id=CPCG0188;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=7.2;Sample=CPCG0188-F1;Tissue=Prostate Tumour;donor_id=CPCG0188;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=7.2;Sample=CPCG0188-F1;Tissue=Prostate Tumour;donor_id=CPCG0188;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=7.2;Sample=CPCG0188-F1;Tissue=Prostate Tumour;donor_id=CPCG0188;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=7.2;Sample=CPCG0188-F1;Tissue=Prostate Tumour;donor_id=CPCG0188;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=7.2;Sample=CPCG0188-F1;Tissue=Prostate Tumour;donor_id=CPCG0188;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.7;Sample=CPCG0194-B1;Tissue=Blood;donor_id=CPCG0194;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.7;Sample=CPCG0194-B1;Tissue=Blood;donor_id=CPCG0194;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.7;Sample=CPCG0194-F1;Tissue=Prostate Tumour;donor_id=CPCG0194;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.7;Sample=CPCG0194-F1;Tissue=Prostate Tumour;donor_id=CPCG0194;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.7;Sample=CPCG0194-F1;Tissue=Prostate Tumour;donor_id=CPCG0194;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.7;Sample=CPCG0194-F1;Tissue=Prostate Tumour;donor_id=CPCG0194;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.7;Sample=CPCG0194-F1;Tissue=Prostate Tumour;donor_id=CPCG0194;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.7;Sample=CPCG0194-F1;Tissue=Prostate Tumour;donor_id=CPCG0194;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.2;Sample=CPCG0198-B1;Tissue=Blood;donor_id=CPCG0198;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.2;Sample=CPCG0198-B1;Tissue=Blood;donor_id=CPCG0198;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.2;Sample=CPCG0198-B1;Tissue=Blood;donor_id=CPCG0198;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.2;Sample=CPCG0198-B1;Tissue=Blood;donor_id=CPCG0198;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.53;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.53;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.53;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.51;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.2;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=9.300000191;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.5;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.3;Sample=CPCG0219-B1;Tissue=Blood;donor_id=CPCG0219;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.3;Sample=CPCG0219-B1;Tissue=Blood;donor_id=CPCG0219;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.3;Sample=CPCG0219-B1;Tissue=Blood;donor_id=CPCG0219;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0219-F1;Tissue=Prostate Tumour;donor_id=CPCG0219;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0219-F1;Tissue=Prostate Tumour;donor_id=CPCG0219;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0219-F1;Tissue=Prostate Tumour;donor_id=CPCG0219;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0219-F1;Tissue=Prostate Tumour;donor_id=CPCG0219;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0219-F1;Tissue=Prostate Tumour;donor_id=CPCG0219;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0219-F1;Tissue=Prostate Tumour;donor_id=CPCG0219;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=33.0;Sample=CPCG0220-F1;Tissue=Prostate Tumour;donor_id=CPCG0220;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=33.0;Sample=CPCG0220-F1;Tissue=Prostate Tumour;donor_id=CPCG0220;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=33.0;Sample=CPCG0220-F1;Tissue=Prostate Tumour;donor_id=CPCG0220;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=33.0;Sample=CPCG0220-F1;Tissue=Prostate Tumour;donor_id=CPCG0220;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=33.0;Sample=CPCG0220-F1;Tissue=Prostate Tumour;donor_id=CPCG0220;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=33.0;Sample=CPCG0220-F1;Tissue=Prostate Tumour;donor_id=CPCG0220;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.8;Sample=CPCG0221-F1;Tissue=Prostate Tumour;donor_id=CPCG0221;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.8;Sample=CPCG0221-F1;Tissue=Prostate Tumour;donor_id=CPCG0221;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.8;Sample=CPCG0221-F1;Tissue=Prostate Tumour;donor_id=CPCG0221;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.8;Sample=CPCG0221-F1;Tissue=Prostate Tumour;donor_id=CPCG0221;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.8;Sample=CPCG0221-F1;Tissue=Prostate Tumour;donor_id=CPCG0221;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.8;Sample=CPCG0221-F1;Tissue=Prostate Tumour;donor_id=CPCG0221;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.3;Sample=CPCG0222-F1;Tissue=Prostate Tumour;donor_id=CPCG0222;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.3;Sample=CPCG0222-F1;Tissue=Prostate Tumour;donor_id=CPCG0222;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.3;Sample=CPCG0222-F1;Tissue=Prostate Tumour;donor_id=CPCG0222;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.3;Sample=CPCG0222-F1;Tissue=Prostate Tumour;donor_id=CPCG0222;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.3;Sample=CPCG0222-F1;Tissue=Prostate Tumour;donor_id=CPCG0222;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.3;Sample=CPCG0222-F1;Tissue=Prostate Tumour;donor_id=CPCG0222;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0223-F1;Tissue=Prostate Tumour;donor_id=CPCG0223;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0223-F1;Tissue=Prostate Tumour;donor_id=CPCG0223;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0223-F1;Tissue=Prostate Tumour;donor_id=CPCG0223;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0223-F1;Tissue=Prostate Tumour;donor_id=CPCG0223;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0223-F1;Tissue=Prostate Tumour;donor_id=CPCG0223;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0223-F1;Tissue=Prostate Tumour;donor_id=CPCG0223;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0225-F1;Tissue=Prostate Tumour;donor_id=CPCG0225;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0225-F1;Tissue=Prostate Tumour;donor_id=CPCG0225;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0225-F1;Tissue=Prostate Tumour;donor_id=CPCG0225;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0225-F1;Tissue=Prostate Tumour;donor_id=CPCG0225;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0225-F1;Tissue=Prostate Tumour;donor_id=CPCG0225;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0225-F1;Tissue=Prostate Tumour;donor_id=CPCG0225;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0226-F1;Tissue=Prostate Tumour;donor_id=CPCG0226;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0226-F1;Tissue=Prostate Tumour;donor_id=CPCG0226;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0226-F1;Tissue=Prostate Tumour;donor_id=CPCG0226;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0226-F1;Tissue=Prostate Tumour;donor_id=CPCG0226;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0226-F1;Tissue=Prostate Tumour;donor_id=CPCG0226;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0226-F1;Tissue=Prostate Tumour;donor_id=CPCG0226;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0227-F1;Tissue=Prostate Tumour;donor_id=CPCG0227;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0227-F1;Tissue=Prostate Tumour;donor_id=CPCG0227;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0227-F1;Tissue=Prostate Tumour;donor_id=CPCG0227;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0227-F1;Tissue=Prostate Tumour;donor_id=CPCG0227;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0227-F1;Tissue=Prostate Tumour;donor_id=CPCG0227;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0227-F1;Tissue=Prostate Tumour;donor_id=CPCG0227;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.5;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=8.1;Sample=CPCG0228-F1;Tissue=Prostate Tumour;donor_id=CPCG0228;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.5;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=8.1;Sample=CPCG0228-F1;Tissue=Prostate Tumour;donor_id=CPCG0228;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.5;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=8.1;Sample=CPCG0228-F1;Tissue=Prostate Tumour;donor_id=CPCG0228;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.5;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=8.1;Sample=CPCG0228-F1;Tissue=Prostate Tumour;donor_id=CPCG0228;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.5;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=8.1;Sample=CPCG0228-F1;Tissue=Prostate Tumour;donor_id=CPCG0228;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.5;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=8.1;Sample=CPCG0228-F1;Tissue=Prostate Tumour;donor_id=CPCG0228;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.9;Sample=CPCG0229-F1;Tissue=Prostate Tumour;donor_id=CPCG0229;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.9;Sample=CPCG0229-F1;Tissue=Prostate Tumour;donor_id=CPCG0229;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.9;Sample=CPCG0229-F1;Tissue=Prostate Tumour;donor_id=CPCG0229;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.9;Sample=CPCG0229-F1;Tissue=Prostate Tumour;donor_id=CPCG0229;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.9;Sample=CPCG0229-F1;Tissue=Prostate Tumour;donor_id=CPCG0229;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.9;Sample=CPCG0229-F1;Tissue=Prostate Tumour;donor_id=CPCG0229;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.0;Sample=CPCG0235-B1;Tissue=Blood;donor_id=CPCG0235;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.0;Sample=CPCG0235-B1;Tissue=Blood;donor_id=CPCG0235;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.0;Sample=CPCG0235-B1;Tissue=Blood;donor_id=CPCG0235;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.0;Sample=CPCG0235-B1;Tissue=Blood;donor_id=CPCG0235;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.0;Sample=CPCG0235-B1;Tissue=Blood;donor_id=CPCG0235;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0235-F1;Tissue=Prostate Tumour;donor_id=CPCG0235;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0235-F1;Tissue=Prostate Tumour;donor_id=CPCG0235;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0235-F1;Tissue=Prostate Tumour;donor_id=CPCG0235;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0235-F1;Tissue=Prostate Tumour;donor_id=CPCG0235;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0235-F1;Tissue=Prostate Tumour;donor_id=CPCG0235;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.2;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0235-F1;Tissue=Prostate Tumour;donor_id=CPCG0235;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.7;Sample=CPCG0237-B1;Tissue=Blood;donor_id=CPCG0237;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.7;Sample=CPCG0237-B1;Tissue=Blood;donor_id=CPCG0237;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.7;Sample=CPCG0237-B1;Tissue=Blood;donor_id=CPCG0237;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0237-F1;Tissue=Prostate Tumour;donor_id=CPCG0237;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0237-F1;Tissue=Prostate Tumour;donor_id=CPCG0237;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0237-F1;Tissue=Prostate Tumour;donor_id=CPCG0237;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0237-F1;Tissue=Prostate Tumour;donor_id=CPCG0237;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0237-F1;Tissue=Prostate Tumour;donor_id=CPCG0237;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0237-F1;Tissue=Prostate Tumour;donor_id=CPCG0237;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0237-F1;Tissue=Prostate Tumour;donor_id=CPCG0237;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0237-F1;Tissue=Prostate Tumour;donor_id=CPCG0237;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0237-F1;Tissue=Prostate Tumour;donor_id=CPCG0237;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0237-F1;Tissue=Prostate Tumour;donor_id=CPCG0237;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0237-F1;Tissue=Prostate Tumour;donor_id=CPCG0237;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=2.7;Sample=CPCG0240-F1;Tissue=Prostate Tumour;donor_id=CPCG0240;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=2.7;Sample=CPCG0240-F1;Tissue=Prostate Tumour;donor_id=CPCG0240;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=2.7;Sample=CPCG0240-F1;Tissue=Prostate Tumour;donor_id=CPCG0240;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=2.7;Sample=CPCG0240-F1;Tissue=Prostate Tumour;donor_id=CPCG0240;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=2.7;Sample=CPCG0240-F1;Tissue=Prostate Tumour;donor_id=CPCG0240;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=2.7;Sample=CPCG0240-F1;Tissue=Prostate Tumour;donor_id=CPCG0240;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.6;Sample=CPCG0243-B1;Tissue=Blood;donor_id=CPCG0243;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.6;Sample=CPCG0243-B1;Tissue=Blood;donor_id=CPCG0243;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.6;Sample=CPCG0243-B1;Tissue=Blood;donor_id=CPCG0243;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.6;Sample=CPCG0243-F1;Tissue=Prostate Tumour;donor_id=CPCG0243;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.6;Sample=CPCG0243-F1;Tissue=Prostate Tumour;donor_id=CPCG0243;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.6;Sample=CPCG0243-F1;Tissue=Prostate Tumour;donor_id=CPCG0243;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.6;Sample=CPCG0243-F1;Tissue=Prostate Tumour;donor_id=CPCG0243;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.6;Sample=CPCG0243-F1;Tissue=Prostate Tumour;donor_id=CPCG0243;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=13.6;Sample=CPCG0243-F1;Tissue=Prostate Tumour;donor_id=CPCG0243;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.0;Sample=CPCG0257-B1;Tissue=Blood;donor_id=CPCG0257;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.0;Sample=CPCG0257-B1;Tissue=Blood;donor_id=CPCG0257;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.0;Sample=CPCG0257-B1;Tissue=Blood;donor_id=CPCG0257;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0257-F1;Tissue=Prostate Tumour;donor_id=CPCG0257;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0257-F1;Tissue=Prostate Tumour;donor_id=CPCG0257;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0257-F1;Tissue=Prostate Tumour;donor_id=CPCG0257;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0257-F1;Tissue=Prostate Tumour;donor_id=CPCG0257;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0257-F1;Tissue=Prostate Tumour;donor_id=CPCG0257;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0257-F1;Tissue=Prostate Tumour;donor_id=CPCG0257;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;Gender=M;Gleason Score=4+3;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.59;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0271-F1;Tissue=Prostate Tumour;donor_id=CPCG0271;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0271-F1;Tissue=Prostate Tumour;donor_id=CPCG0271;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0271-F1;Tissue=Prostate Tumour;donor_id=CPCG0271;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0271-F1;Tissue=Prostate Tumour;donor_id=CPCG0271;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0271-F1;Tissue=Prostate Tumour;donor_id=CPCG0271;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0271-F1;Tissue=Prostate Tumour;donor_id=CPCG0271;ENA-CHECKLIST=ERC000026;
Age at Treatment=81.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.1;Sample=CPCG0274-B1;Tissue=Blood;donor_id=CPCG0274;ENA-CHECKLIST=ERC000026;
Age at Treatment=81.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.1;Sample=CPCG0274-B1;Tissue=Blood;donor_id=CPCG0274;ENA-CHECKLIST=ERC000026;
Age at Treatment=81.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.1;Sample=CPCG0274-B1;Tissue=Blood;donor_id=CPCG0274;ENA-CHECKLIST=ERC000026;
Age at Treatment=81.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.1;Sample=CPCG0274-F1;Tissue=Prostate Tumour;donor_id=CPCG0274;ENA-CHECKLIST=ERC000026;
Age at Treatment=81.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.1;Sample=CPCG0274-F1;Tissue=Prostate Tumour;donor_id=CPCG0274;ENA-CHECKLIST=ERC000026;
Age at Treatment=81.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.1;Sample=CPCG0274-F1;Tissue=Prostate Tumour;donor_id=CPCG0274;ENA-CHECKLIST=ERC000026;
Age at Treatment=81.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.1;Sample=CPCG0274-F1;Tissue=Prostate Tumour;donor_id=CPCG0274;ENA-CHECKLIST=ERC000026;
Age at Treatment=81.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.1;Sample=CPCG0274-F1;Tissue=Prostate Tumour;donor_id=CPCG0274;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.92;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=7.92;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.92;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.92;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.92;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.92;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.92;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.92;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.64;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=81.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=2.1;Sample=CPCG0274-F1;Tissue=Prostate Tumour;donor_id=CPCG0274;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0277-F1;Tissue=Prostate Tumour;donor_id=CPCG0277;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0277-F1;Tissue=Prostate Tumour;donor_id=CPCG0277;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0277-F1;Tissue=Prostate Tumour;donor_id=CPCG0277;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0277-F1;Tissue=Prostate Tumour;donor_id=CPCG0277;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0277-F1;Tissue=Prostate Tumour;donor_id=CPCG0277;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0277-F1;Tissue=Prostate Tumour;donor_id=CPCG0277;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0278-F1;Tissue=Prostate Tumour;donor_id=CPCG0278;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0278-F1;Tissue=Prostate Tumour;donor_id=CPCG0278;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0278-F1;Tissue=Prostate Tumour;donor_id=CPCG0278;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0278-F1;Tissue=Prostate Tumour;donor_id=CPCG0278;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0278-F1;Tissue=Prostate Tumour;donor_id=CPCG0278;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.4;Sample=CPCG0278-F1;Tissue=Prostate Tumour;donor_id=CPCG0278;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0279-F1;Tissue=Prostate Tumour;donor_id=CPCG0279;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0279-F1;Tissue=Prostate Tumour;donor_id=CPCG0279;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0279-F1;Tissue=Prostate Tumour;donor_id=CPCG0279;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0279-F1;Tissue=Prostate Tumour;donor_id=CPCG0279;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0279-F1;Tissue=Prostate Tumour;donor_id=CPCG0279;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=14.0;Sample=CPCG0279-F1;Tissue=Prostate Tumour;donor_id=CPCG0279;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0280-F1;Tissue=Prostate Tumour;donor_id=CPCG0280;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0280-F1;Tissue=Prostate Tumour;donor_id=CPCG0280;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0280-F1;Tissue=Prostate Tumour;donor_id=CPCG0280;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0280-F1;Tissue=Prostate Tumour;donor_id=CPCG0280;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0280-F1;Tissue=Prostate Tumour;donor_id=CPCG0280;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0280-F1;Tissue=Prostate Tumour;donor_id=CPCG0280;ENA-CHECKLIST=ERC000026;
Age at Treatment=82.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.5;Sample=CPCG0281-F1;Tissue=Prostate Tumour;donor_id=CPCG0281;ENA-CHECKLIST=ERC000026;
Age at Treatment=82.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.5;Sample=CPCG0281-F1;Tissue=Prostate Tumour;donor_id=CPCG0281;ENA-CHECKLIST=ERC000026;
Age at Treatment=82.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.5;Sample=CPCG0281-F1;Tissue=Prostate Tumour;donor_id=CPCG0281;ENA-CHECKLIST=ERC000026;
Age at Treatment=82.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.5;Sample=CPCG0281-F1;Tissue=Prostate Tumour;donor_id=CPCG0281;ENA-CHECKLIST=ERC000026;
Age at Treatment=82.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.5;Sample=CPCG0281-F1;Tissue=Prostate Tumour;donor_id=CPCG0281;ENA-CHECKLIST=ERC000026;
Age at Treatment=82.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.5;Sample=CPCG0281-F1;Tissue=Prostate Tumour;donor_id=CPCG0281;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.9;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0282-F1;Tissue=Prostate Tumour;donor_id=CPCG0282;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.9;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0282-F1;Tissue=Prostate Tumour;donor_id=CPCG0282;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.9;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0282-F1;Tissue=Prostate Tumour;donor_id=CPCG0282;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.9;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0282-F1;Tissue=Prostate Tumour;donor_id=CPCG0282;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.9;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0282-F1;Tissue=Prostate Tumour;donor_id=CPCG0282;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.9;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0282-F1;Tissue=Prostate Tumour;donor_id=CPCG0282;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.7;Sample=CPCG0283-F1;Tissue=Prostate Tumour;donor_id=CPCG0283;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.7;Sample=CPCG0283-F1;Tissue=Prostate Tumour;donor_id=CPCG0283;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.7;Sample=CPCG0283-F1;Tissue=Prostate Tumour;donor_id=CPCG0283;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.7;Sample=CPCG0283-F1;Tissue=Prostate Tumour;donor_id=CPCG0283;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.7;Sample=CPCG0283-F1;Tissue=Prostate Tumour;donor_id=CPCG0283;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.7;Sample=CPCG0283-F1;Tissue=Prostate Tumour;donor_id=CPCG0283;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=9.4;Sample=CPCG0285-F1;Tissue=Prostate Tumour;donor_id=CPCG0285;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=9.4;Sample=CPCG0285-F1;Tissue=Prostate Tumour;donor_id=CPCG0285;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=9.4;Sample=CPCG0285-F1;Tissue=Prostate Tumour;donor_id=CPCG0285;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=9.4;Sample=CPCG0285-F1;Tissue=Prostate Tumour;donor_id=CPCG0285;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=9.4;Sample=CPCG0285-F1;Tissue=Prostate Tumour;donor_id=CPCG0285;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=9.4;Sample=CPCG0285-F1;Tissue=Prostate Tumour;donor_id=CPCG0285;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.0;Sample=CPCG0286-F1;Tissue=Prostate Tumour;donor_id=CPCG0286;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.0;Sample=CPCG0286-F1;Tissue=Prostate Tumour;donor_id=CPCG0286;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.0;Sample=CPCG0286-F1;Tissue=Prostate Tumour;donor_id=CPCG0286;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.0;Sample=CPCG0286-F1;Tissue=Prostate Tumour;donor_id=CPCG0286;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.0;Sample=CPCG0286-F1;Tissue=Prostate Tumour;donor_id=CPCG0286;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.0;Sample=CPCG0286-F1;Tissue=Prostate Tumour;donor_id=CPCG0286;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.5;Sample=CPCG0287-F1;Tissue=Prostate Tumour;donor_id=CPCG0287;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.5;Sample=CPCG0287-F1;Tissue=Prostate Tumour;donor_id=CPCG0287;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.5;Sample=CPCG0287-F1;Tissue=Prostate Tumour;donor_id=CPCG0287;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.5;Sample=CPCG0287-F1;Tissue=Prostate Tumour;donor_id=CPCG0287;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.5;Sample=CPCG0287-F1;Tissue=Prostate Tumour;donor_id=CPCG0287;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=8.5;Sample=CPCG0287-F1;Tissue=Prostate Tumour;donor_id=CPCG0287;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=12.9;Sample=CPCG0288-F1;Tissue=Prostate Tumour;donor_id=CPCG0288;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=12.9;Sample=CPCG0288-F1;Tissue=Prostate Tumour;donor_id=CPCG0288;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=12.9;Sample=CPCG0288-F1;Tissue=Prostate Tumour;donor_id=CPCG0288;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=12.9;Sample=CPCG0288-F1;Tissue=Prostate Tumour;donor_id=CPCG0288;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=12.9;Sample=CPCG0288-F1;Tissue=Prostate Tumour;donor_id=CPCG0288;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=12.9;Sample=CPCG0288-F1;Tissue=Prostate Tumour;donor_id=CPCG0288;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.4;Sample=CPCG0289-F1;Tissue=Prostate Tumour;donor_id=CPCG0289;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.4;Sample=CPCG0289-F1;Tissue=Prostate Tumour;donor_id=CPCG0289;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.4;Sample=CPCG0289-F1;Tissue=Prostate Tumour;donor_id=CPCG0289;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.4;Sample=CPCG0289-F1;Tissue=Prostate Tumour;donor_id=CPCG0289;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.4;Sample=CPCG0289-F1;Tissue=Prostate Tumour;donor_id=CPCG0289;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.4;Sample=CPCG0289-F1;Tissue=Prostate Tumour;donor_id=CPCG0289;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0290-F1;Tissue=Prostate Tumour;donor_id=CPCG0290;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0290-F1;Tissue=Prostate Tumour;donor_id=CPCG0290;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0290-F1;Tissue=Prostate Tumour;donor_id=CPCG0290;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0290-F1;Tissue=Prostate Tumour;donor_id=CPCG0290;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0290-F1;Tissue=Prostate Tumour;donor_id=CPCG0290;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0290-F1;Tissue=Prostate Tumour;donor_id=CPCG0290;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0290-F1;Tissue=Prostate Tumour;donor_id=CPCG0290;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0291-F1;Tissue=Prostate Tumour;donor_id=CPCG0291;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0291-F1;Tissue=Prostate Tumour;donor_id=CPCG0291;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0291-F1;Tissue=Prostate Tumour;donor_id=CPCG0291;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0291-F1;Tissue=Prostate Tumour;donor_id=CPCG0291;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0291-F1;Tissue=Prostate Tumour;donor_id=CPCG0291;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0291-F1;Tissue=Prostate Tumour;donor_id=CPCG0291;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0292-F1;Tissue=Prostate Tumour;donor_id=CPCG0292;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0292-F1;Tissue=Prostate Tumour;donor_id=CPCG0292;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0292-F1;Tissue=Prostate Tumour;donor_id=CPCG0292;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0292-F1;Tissue=Prostate Tumour;donor_id=CPCG0292;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0292-F1;Tissue=Prostate Tumour;donor_id=CPCG0292;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0292-F1;Tissue=Prostate Tumour;donor_id=CPCG0292;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.1;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0293-F1;Tissue=Prostate Tumour;donor_id=CPCG0293;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.1;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0293-F1;Tissue=Prostate Tumour;donor_id=CPCG0293;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.1;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0293-F1;Tissue=Prostate Tumour;donor_id=CPCG0293;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.1;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0293-F1;Tissue=Prostate Tumour;donor_id=CPCG0293;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.1;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0293-F1;Tissue=Prostate Tumour;donor_id=CPCG0293;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.1;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0293-F1;Tissue=Prostate Tumour;donor_id=CPCG0293;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.1;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0293-F1;Tissue=Prostate Tumour;donor_id=CPCG0293;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0300-F1;Tissue=Prostate Tumour;donor_id=CPCG0300;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0300-F1;Tissue=Prostate Tumour;donor_id=CPCG0300;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0300-F1;Tissue=Prostate Tumour;donor_id=CPCG0300;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0300-F1;Tissue=Prostate Tumour;donor_id=CPCG0300;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0300-F1;Tissue=Prostate Tumour;donor_id=CPCG0300;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.4;Sample=CPCG0300-F1;Tissue=Prostate Tumour;donor_id=CPCG0300;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0301-F1;Tissue=Prostate Tumour;donor_id=CPCG0301;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0301-F1;Tissue=Prostate Tumour;donor_id=CPCG0301;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0301-F1;Tissue=Prostate Tumour;donor_id=CPCG0301;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0301-F1;Tissue=Prostate Tumour;donor_id=CPCG0301;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0301-F1;Tissue=Prostate Tumour;donor_id=CPCG0301;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0301-F1;Tissue=Prostate Tumour;donor_id=CPCG0301;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0302-F1;Tissue=Prostate Tumour;donor_id=CPCG0302;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0302-F1;Tissue=Prostate Tumour;donor_id=CPCG0302;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0302-F1;Tissue=Prostate Tumour;donor_id=CPCG0302;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0302-F1;Tissue=Prostate Tumour;donor_id=CPCG0302;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0302-F1;Tissue=Prostate Tumour;donor_id=CPCG0302;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0302-F1;Tissue=Prostate Tumour;donor_id=CPCG0302;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=22.0;Sample=CPCG0303-F1;Tissue=Prostate Tumour;donor_id=CPCG0303;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=22.0;Sample=CPCG0303-F1;Tissue=Prostate Tumour;donor_id=CPCG0303;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=22.0;Sample=CPCG0303-F1;Tissue=Prostate Tumour;donor_id=CPCG0303;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=22.0;Sample=CPCG0303-F1;Tissue=Prostate Tumour;donor_id=CPCG0303;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=22.0;Sample=CPCG0303-F1;Tissue=Prostate Tumour;donor_id=CPCG0303;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=22.0;Sample=CPCG0303-F1;Tissue=Prostate Tumour;donor_id=CPCG0303;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.9;Sample=CPCG0304-F1;Tissue=Prostate Tumour;donor_id=CPCG0304;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.9;Sample=CPCG0304-F1;Tissue=Prostate Tumour;donor_id=CPCG0304;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.9;Sample=CPCG0304-F1;Tissue=Prostate Tumour;donor_id=CPCG0304;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.9;Sample=CPCG0304-F1;Tissue=Prostate Tumour;donor_id=CPCG0304;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.9;Sample=CPCG0304-F1;Tissue=Prostate Tumour;donor_id=CPCG0304;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.9;Sample=CPCG0304-F1;Tissue=Prostate Tumour;donor_id=CPCG0304;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0305-F1;Tissue=Prostate Tumour;donor_id=CPCG0305;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0305-F1;Tissue=Prostate Tumour;donor_id=CPCG0305;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0305-F1;Tissue=Prostate Tumour;donor_id=CPCG0305;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0305-F1;Tissue=Prostate Tumour;donor_id=CPCG0305;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0305-F1;Tissue=Prostate Tumour;donor_id=CPCG0305;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0305-F1;Tissue=Prostate Tumour;donor_id=CPCG0305;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0306-F1;Tissue=Prostate Tumour;donor_id=CPCG0306;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0306-F1;Tissue=Prostate Tumour;donor_id=CPCG0306;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0306-F1;Tissue=Prostate Tumour;donor_id=CPCG0306;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0306-F1;Tissue=Prostate Tumour;donor_id=CPCG0306;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0306-F1;Tissue=Prostate Tumour;donor_id=CPCG0306;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=3.8;Sample=CPCG0306-F1;Tissue=Prostate Tumour;donor_id=CPCG0306;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.8;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=10.6;Sample=CPCG0307-F1;Tissue=Prostate Tumour;donor_id=CPCG0307;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.8;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=10.6;Sample=CPCG0307-F1;Tissue=Prostate Tumour;donor_id=CPCG0307;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.8;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=10.6;Sample=CPCG0307-F1;Tissue=Prostate Tumour;donor_id=CPCG0307;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.8;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=10.6;Sample=CPCG0307-F1;Tissue=Prostate Tumour;donor_id=CPCG0307;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.8;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=10.6;Sample=CPCG0307-F1;Tissue=Prostate Tumour;donor_id=CPCG0307;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.8;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=10.6;Sample=CPCG0307-F1;Tissue=Prostate Tumour;donor_id=CPCG0307;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.5;Sample=CPCG0308-F1;Tissue=Prostate Tumour;donor_id=CPCG0308;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.5;Sample=CPCG0308-F1;Tissue=Prostate Tumour;donor_id=CPCG0308;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.5;Sample=CPCG0308-F1;Tissue=Prostate Tumour;donor_id=CPCG0308;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.5;Sample=CPCG0308-F1;Tissue=Prostate Tumour;donor_id=CPCG0308;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.5;Sample=CPCG0308-F1;Tissue=Prostate Tumour;donor_id=CPCG0308;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.5;Sample=CPCG0308-F1;Tissue=Prostate Tumour;donor_id=CPCG0308;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0309-F1;Tissue=Prostate Tumour;donor_id=CPCG0309;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0309-F1;Tissue=Prostate Tumour;donor_id=CPCG0309;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0309-F1;Tissue=Prostate Tumour;donor_id=CPCG0309;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0309-F1;Tissue=Prostate Tumour;donor_id=CPCG0309;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0309-F1;Tissue=Prostate Tumour;donor_id=CPCG0309;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.0;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0309-F1;Tissue=Prostate Tumour;donor_id=CPCG0309;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0310-F1;Tissue=Prostate Tumour;donor_id=CPCG0310;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0310-F1;Tissue=Prostate Tumour;donor_id=CPCG0310;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0310-F1;Tissue=Prostate Tumour;donor_id=CPCG0310;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0310-F1;Tissue=Prostate Tumour;donor_id=CPCG0310;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0310-F1;Tissue=Prostate Tumour;donor_id=CPCG0310;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=10.1;Sample=CPCG0310-F1;Tissue=Prostate Tumour;donor_id=CPCG0310;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.2;Sample=CPCG0311-F1;Tissue=Prostate Tumour;donor_id=CPCG0311;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.2;Sample=CPCG0311-F1;Tissue=Prostate Tumour;donor_id=CPCG0311;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.2;Sample=CPCG0311-F1;Tissue=Prostate Tumour;donor_id=CPCG0311;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.2;Sample=CPCG0311-F1;Tissue=Prostate Tumour;donor_id=CPCG0311;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.2;Sample=CPCG0311-F1;Tissue=Prostate Tumour;donor_id=CPCG0311;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.2;Sample=CPCG0311-F1;Tissue=Prostate Tumour;donor_id=CPCG0311;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=13.1;Sample=CPCG0312-F1;Tissue=Prostate Tumour;donor_id=CPCG0312;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=13.1;Sample=CPCG0312-F1;Tissue=Prostate Tumour;donor_id=CPCG0312;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=13.1;Sample=CPCG0312-F1;Tissue=Prostate Tumour;donor_id=CPCG0312;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=13.1;Sample=CPCG0312-F1;Tissue=Prostate Tumour;donor_id=CPCG0312;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=13.1;Sample=CPCG0312-F1;Tissue=Prostate Tumour;donor_id=CPCG0312;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=13.1;Sample=CPCG0312-F1;Tissue=Prostate Tumour;donor_id=CPCG0312;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=13.1;Sample=CPCG0312-F1;Tissue=Prostate Tumour;donor_id=CPCG0312;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0313-F1;Tissue=Prostate Tumour;donor_id=CPCG0313;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0313-F1;Tissue=Prostate Tumour;donor_id=CPCG0313;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0313-F1;Tissue=Prostate Tumour;donor_id=CPCG0313;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0313-F1;Tissue=Prostate Tumour;donor_id=CPCG0313;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0313-F1;Tissue=Prostate Tumour;donor_id=CPCG0313;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0313-F1;Tissue=Prostate Tumour;donor_id=CPCG0313;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=5.8;Sample=CPCG0313-F1;Tissue=Prostate Tumour;donor_id=CPCG0313;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0314-F1;Tissue=Prostate Tumour;donor_id=CPCG0314;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0314-F1;Tissue=Prostate Tumour;donor_id=CPCG0314;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0314-F1;Tissue=Prostate Tumour;donor_id=CPCG0314;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0314-F1;Tissue=Prostate Tumour;donor_id=CPCG0314;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0314-F1;Tissue=Prostate Tumour;donor_id=CPCG0314;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.0;Sample=CPCG0314-F1;Tissue=Prostate Tumour;donor_id=CPCG0314;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.5;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0315-F1;Tissue=Prostate Tumour;donor_id=CPCG0315;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.5;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0315-F1;Tissue=Prostate Tumour;donor_id=CPCG0315;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.5;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0315-F1;Tissue=Prostate Tumour;donor_id=CPCG0315;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.5;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0315-F1;Tissue=Prostate Tumour;donor_id=CPCG0315;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.5;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0315-F1;Tissue=Prostate Tumour;donor_id=CPCG0315;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.5;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=8.6;Sample=CPCG0315-F1;Tissue=Prostate Tumour;donor_id=CPCG0315;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0316-F1;Tissue=Prostate Tumour;donor_id=CPCG0316;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0316-F1;Tissue=Prostate Tumour;donor_id=CPCG0316;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0316-F1;Tissue=Prostate Tumour;donor_id=CPCG0316;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0316-F1;Tissue=Prostate Tumour;donor_id=CPCG0316;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0316-F1;Tissue=Prostate Tumour;donor_id=CPCG0316;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.0;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=7.7;Sample=CPCG0316-F1;Tissue=Prostate Tumour;donor_id=CPCG0316;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0317-F1;Tissue=Prostate Tumour;donor_id=CPCG0317;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0317-F1;Tissue=Prostate Tumour;donor_id=CPCG0317;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0317-F1;Tissue=Prostate Tumour;donor_id=CPCG0317;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0317-F1;Tissue=Prostate Tumour;donor_id=CPCG0317;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0317-F1;Tissue=Prostate Tumour;donor_id=CPCG0317;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=13.0;Sample=CPCG0317-F1;Tissue=Prostate Tumour;donor_id=CPCG0317;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0318-F1;Tissue=Prostate Tumour;donor_id=CPCG0318;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0318-F1;Tissue=Prostate Tumour;donor_id=CPCG0318;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0318-F1;Tissue=Prostate Tumour;donor_id=CPCG0318;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0318-F1;Tissue=Prostate Tumour;donor_id=CPCG0318;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0318-F1;Tissue=Prostate Tumour;donor_id=CPCG0318;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.4;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.3;Sample=CPCG0318-F1;Tissue=Prostate Tumour;donor_id=CPCG0318;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0319-F1;Tissue=Prostate Tumour;donor_id=CPCG0319;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0319-F1;Tissue=Prostate Tumour;donor_id=CPCG0319;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0319-F1;Tissue=Prostate Tumour;donor_id=CPCG0319;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0319-F1;Tissue=Prostate Tumour;donor_id=CPCG0319;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0319-F1;Tissue=Prostate Tumour;donor_id=CPCG0319;ENA-CHECKLIST=ERC000026;
Age at Treatment=79.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0319-F1;Tissue=Prostate Tumour;donor_id=CPCG0319;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.6;Sample=CPCG0320-F1;Tissue=Prostate Tumour;donor_id=CPCG0320;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.6;Sample=CPCG0320-F1;Tissue=Prostate Tumour;donor_id=CPCG0320;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.6;Sample=CPCG0320-F1;Tissue=Prostate Tumour;donor_id=CPCG0320;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.6;Sample=CPCG0320-F1;Tissue=Prostate Tumour;donor_id=CPCG0320;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.6;Sample=CPCG0320-F1;Tissue=Prostate Tumour;donor_id=CPCG0320;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.6;Sample=CPCG0320-F1;Tissue=Prostate Tumour;donor_id=CPCG0320;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.2;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.6;Sample=CPCG0320-F1;Tissue=Prostate Tumour;donor_id=CPCG0320;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0321-F1;Tissue=Prostate Tumour;donor_id=CPCG0321;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0321-F1;Tissue=Prostate Tumour;donor_id=CPCG0321;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0321-F1;Tissue=Prostate Tumour;donor_id=CPCG0321;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0321-F1;Tissue=Prostate Tumour;donor_id=CPCG0321;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0321-F1;Tissue=Prostate Tumour;donor_id=CPCG0321;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0321-F1;Tissue=Prostate Tumour;donor_id=CPCG0321;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.8;Sample=CPCG0321-F1;Tissue=Prostate Tumour;donor_id=CPCG0321;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0322-F1;Tissue=Prostate Tumour;donor_id=CPCG0322;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0322-F1;Tissue=Prostate Tumour;donor_id=CPCG0322;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0322-F1;Tissue=Prostate Tumour;donor_id=CPCG0322;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0322-F1;Tissue=Prostate Tumour;donor_id=CPCG0322;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0322-F1;Tissue=Prostate Tumour;donor_id=CPCG0322;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0322-F1;Tissue=Prostate Tumour;donor_id=CPCG0322;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.6;Sample=CPCG0323-F1;Tissue=Prostate Tumour;donor_id=CPCG0323;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.6;Sample=CPCG0323-F1;Tissue=Prostate Tumour;donor_id=CPCG0323;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.6;Sample=CPCG0323-F1;Tissue=Prostate Tumour;donor_id=CPCG0323;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.6;Sample=CPCG0323-F1;Tissue=Prostate Tumour;donor_id=CPCG0323;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.6;Sample=CPCG0323-F1;Tissue=Prostate Tumour;donor_id=CPCG0323;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.6;Sample=CPCG0323-F1;Tissue=Prostate Tumour;donor_id=CPCG0323;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=0.7;Sample=CPCG0326-F1;Tissue=Prostate Tumour;donor_id=CPCG0326;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=0.7;Sample=CPCG0326-F1;Tissue=Prostate Tumour;donor_id=CPCG0326;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=0.7;Sample=CPCG0326-F1;Tissue=Prostate Tumour;donor_id=CPCG0326;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=0.7;Sample=CPCG0326-F1;Tissue=Prostate Tumour;donor_id=CPCG0326;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=0.7;Sample=CPCG0326-F1;Tissue=Prostate Tumour;donor_id=CPCG0326;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=0.7;Sample=CPCG0326-F1;Tissue=Prostate Tumour;donor_id=CPCG0326;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0327-F1;Tissue=Prostate Tumour;donor_id=CPCG0327;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0327-F1;Tissue=Prostate Tumour;donor_id=CPCG0327;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0327-F1;Tissue=Prostate Tumour;donor_id=CPCG0327;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0327-F1;Tissue=Prostate Tumour;donor_id=CPCG0327;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0327-F1;Tissue=Prostate Tumour;donor_id=CPCG0327;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0327-F1;Tissue=Prostate Tumour;donor_id=CPCG0327;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.1;Sample=CPCG0327-F1;Tissue=Prostate Tumour;donor_id=CPCG0327;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=15.5;Sample=CPCG0328-F1;Tissue=Prostate Tumour;donor_id=CPCG0328;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=15.5;Sample=CPCG0328-F1;Tissue=Prostate Tumour;donor_id=CPCG0328;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=15.5;Sample=CPCG0328-F1;Tissue=Prostate Tumour;donor_id=CPCG0328;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=15.5;Sample=CPCG0328-F1;Tissue=Prostate Tumour;donor_id=CPCG0328;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=15.5;Sample=CPCG0328-F1;Tissue=Prostate Tumour;donor_id=CPCG0328;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=15.5;Sample=CPCG0328-F1;Tissue=Prostate Tumour;donor_id=CPCG0328;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.4;Sample=CPCG0329-F1;Tissue=Prostate Tumour;donor_id=CPCG0329;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.4;Sample=CPCG0329-F1;Tissue=Prostate Tumour;donor_id=CPCG0329;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.4;Sample=CPCG0329-F1;Tissue=Prostate Tumour;donor_id=CPCG0329;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.4;Sample=CPCG0329-F1;Tissue=Prostate Tumour;donor_id=CPCG0329;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.4;Sample=CPCG0329-F1;Tissue=Prostate Tumour;donor_id=CPCG0329;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.4;Sample=CPCG0329-F1;Tissue=Prostate Tumour;donor_id=CPCG0329;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.4;Sample=CPCG0329-F1;Tissue=Prostate Tumour;donor_id=CPCG0329;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0330-F1;Tissue=Prostate Tumour;donor_id=CPCG0330;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0330-F1;Tissue=Prostate Tumour;donor_id=CPCG0330;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0330-F1;Tissue=Prostate Tumour;donor_id=CPCG0330;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0330-F1;Tissue=Prostate Tumour;donor_id=CPCG0330;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0330-F1;Tissue=Prostate Tumour;donor_id=CPCG0330;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0330-F1;Tissue=Prostate Tumour;donor_id=CPCG0330;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.8;Sample=CPCG0333-B1;Tissue=Blood;donor_id=CPCG0333;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.8;Sample=CPCG0333-B1;Tissue=Blood;donor_id=CPCG0333;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.8;Sample=CPCG0333-B1;Tissue=Blood;donor_id=CPCG0333;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.8;Sample=CPCG0333-B1;Tissue=Blood;donor_id=CPCG0333;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=9.8;Sample=CPCG0333-F1;Tissue=Prostate Tumour;donor_id=CPCG0333;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=9.8;Sample=CPCG0333-F1;Tissue=Prostate Tumour;donor_id=CPCG0333;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=9.8;Sample=CPCG0333-F1;Tissue=Prostate Tumour;donor_id=CPCG0333;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=9.8;Sample=CPCG0333-F1;Tissue=Prostate Tumour;donor_id=CPCG0333;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=9.8;Sample=CPCG0333-F1;Tissue=Prostate Tumour;donor_id=CPCG0333;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=9.8;Sample=CPCG0333-F1;Tissue=Prostate Tumour;donor_id=CPCG0333;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.1;Sample=CPCG0335-B1;Tissue=Blood;donor_id=CPCG0335;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.1;Sample=CPCG0335-B1;Tissue=Blood;donor_id=CPCG0335;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=14.1;Sample=CPCG0335-B1;Tissue=Blood;donor_id=CPCG0335;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=14.1;Sample=CPCG0335-F1;Tissue=Prostate Tumour;donor_id=CPCG0335;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=14.1;Sample=CPCG0335-F1;Tissue=Prostate Tumour;donor_id=CPCG0335;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=14.1;Sample=CPCG0335-F1;Tissue=Prostate Tumour;donor_id=CPCG0335;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=14.1;Sample=CPCG0335-F1;Tissue=Prostate Tumour;donor_id=CPCG0335;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=14.1;Sample=CPCG0335-F1;Tissue=Prostate Tumour;donor_id=CPCG0335;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=14.1;Sample=CPCG0335-F1;Tissue=Prostate Tumour;donor_id=CPCG0335;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=14.1;Sample=CPCG0335-F1;Tissue=Prostate Tumour;donor_id=CPCG0335;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=14.1;Sample=CPCG0335-F1;Tissue=Prostate Tumour;donor_id=CPCG0335;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=OBI_0000922;Sample=CPCG0338-B1;Tissue=Blood;donor_id=CPCG0338;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=OBI_0000922;Sample=CPCG0338-B1;Tissue=Blood;donor_id=CPCG0338;ENA-CHECKLIST=ERC000026;
gender=male;phenotype=OBI_0000922;Sample=CPCG0338-B1;Tissue=Blood;donor_id=CPCG0338;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.7;Sample=CPCG0347-F1;Tissue=Prostate Tumour;donor_id=CPCG0347;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.7;Sample=CPCG0347-F1;Tissue=Prostate Tumour;donor_id=CPCG0347;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.7;Sample=CPCG0347-F1;Tissue=Prostate Tumour;donor_id=CPCG0347;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.7;Sample=CPCG0347-F1;Tissue=Prostate Tumour;donor_id=CPCG0347;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.7;Sample=CPCG0347-F1;Tissue=Prostate Tumour;donor_id=CPCG0347;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.7;Sample=CPCG0347-F1;Tissue=Prostate Tumour;donor_id=CPCG0347;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.1;Sample=CPCG0349-B1;Tissue=Blood;donor_id=CPCG0349;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.1;Sample=CPCG0349-B1;Tissue=Blood;donor_id=CPCG0349;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.1;Sample=CPCG0349-B1;Tissue=Blood;donor_id=CPCG0349;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.1;Sample=CPCG0349-B1;Tissue=Blood;donor_id=CPCG0349;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=7.1;Sample=CPCG0349-F1;Tissue=Prostate Tumour;donor_id=CPCG0349;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=7.1;Sample=CPCG0349-F1;Tissue=Prostate Tumour;donor_id=CPCG0349;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=7.1;Sample=CPCG0349-F1;Tissue=Prostate Tumour;donor_id=CPCG0349;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=7.1;Sample=CPCG0349-F1;Tissue=Prostate Tumour;donor_id=CPCG0349;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=7.1;Sample=CPCG0349-F1;Tissue=Prostate Tumour;donor_id=CPCG0349;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=7.1;Sample=CPCG0349-F1;Tissue=Prostate Tumour;donor_id=CPCG0349;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.1;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.6;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.2;Gender=M;Gleason Score=3+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.11;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.2;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.9;Sample=CPCG0377-B1;Tissue=Blood;donor_id=CPCG0377;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.9;Sample=CPCG0377-B1;Tissue=Blood;donor_id=CPCG0377;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.9;Sample=CPCG0377-B1;Tissue=Blood;donor_id=CPCG0377;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0377-F1;Tissue=Prostate Tumour;donor_id=CPCG0377;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0377-F1;Tissue=Prostate Tumour;donor_id=CPCG0377;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0377-F1;Tissue=Prostate Tumour;donor_id=CPCG0377;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0377-F1;Tissue=Prostate Tumour;donor_id=CPCG0377;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0377-F1;Tissue=Prostate Tumour;donor_id=CPCG0377;ENA-CHECKLIST=ERC000026;
Age at Treatment=76.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0377-F1;Tissue=Prostate Tumour;donor_id=CPCG0377;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.8;Sample=CPCG0382-B1;Tissue=Blood;donor_id=CPCG0382;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.8;Sample=CPCG0382-B1;Tissue=Blood;donor_id=CPCG0382;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.8;Sample=CPCG0382-B1;Tissue=Blood;donor_id=CPCG0382;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.8;Sample=CPCG0382-F1;Tissue=Prostate Tumour;donor_id=CPCG0382;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.8;Sample=CPCG0382-F1;Tissue=Prostate Tumour;donor_id=CPCG0382;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.8;Sample=CPCG0382-F1;Tissue=Prostate Tumour;donor_id=CPCG0382;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.8;Sample=CPCG0382-F1;Tissue=Prostate Tumour;donor_id=CPCG0382;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.8;Sample=CPCG0382-F1;Tissue=Prostate Tumour;donor_id=CPCG0382;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.1;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=6.8;Sample=CPCG0382-F1;Tissue=Prostate Tumour;donor_id=CPCG0382;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.1;Gender=M;Gleason Score=4+3;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=4.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.3;Sample=CPCG0389-B1;Tissue=Blood;donor_id=CPCG0389;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.3;Sample=CPCG0389-B1;Tissue=Blood;donor_id=CPCG0389;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.3;Sample=CPCG0389-B1;Tissue=Blood;donor_id=CPCG0389;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.2;Sample=CPCG0390-B1;Tissue=Blood;donor_id=CPCG0390;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.2;Sample=CPCG0390-B1;Tissue=Blood;donor_id=CPCG0390;ENA-CHECKLIST=ERC000026;
Age at Treatment=74.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.2;Sample=CPCG0390-B1;Tissue=Blood;donor_id=CPCG0390;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.3;Sample=CPCG0393-B1;Tissue=Blood;donor_id=CPCG0393;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.3;Sample=CPCG0393-B1;Tissue=Blood;donor_id=CPCG0393;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=7.3;Sample=CPCG0393-B1;Tissue=Blood;donor_id=CPCG0393;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=2.5;Sample=CPCG0394-F1;Tissue=Prostate Tumour;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=2.5;Sample=CPCG0394-F1;Tissue=Prostate Tumour;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=2.5;Sample=CPCG0394-F1;Tissue=Prostate Tumour;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=2.5;Sample=CPCG0394-F1;Tissue=Prostate Tumour;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=2.5;Sample=CPCG0394-F1;Tissue=Prostate Tumour;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=2.5;Sample=CPCG0394-F1;Tissue=Prostate Tumour;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=2.5;Sample=CPCG0394-F1;Tissue=Prostate Tumour;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=2.5;Sample=CPCG0394-F1;Tissue=Prostate Tumour;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=2.5;Sample=CPCG0394-F1;Tissue=Prostate Tumour;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0395-F1;Tissue=Prostate Tumour;donor_id=CPCG0395;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0395-F1;Tissue=Prostate Tumour;donor_id=CPCG0395;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0395-F1;Tissue=Prostate Tumour;donor_id=CPCG0395;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0395-F1;Tissue=Prostate Tumour;donor_id=CPCG0395;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0395-F1;Tissue=Prostate Tumour;donor_id=CPCG0395;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.2;Sample=CPCG0395-F1;Tissue=Prostate Tumour;donor_id=CPCG0395;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0396-F1;Tissue=Prostate Tumour;donor_id=CPCG0396;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0396-F1;Tissue=Prostate Tumour;donor_id=CPCG0396;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0396-F1;Tissue=Prostate Tumour;donor_id=CPCG0396;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0396-F1;Tissue=Prostate Tumour;donor_id=CPCG0396;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0396-F1;Tissue=Prostate Tumour;donor_id=CPCG0396;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0396-F1;Tissue=Prostate Tumour;donor_id=CPCG0396;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=18.0;Sample=CPCG0396-F1;Tissue=Prostate Tumour;donor_id=CPCG0396;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0397-F1;Tissue=Prostate Tumour;donor_id=CPCG0397;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0397-F1;Tissue=Prostate Tumour;donor_id=CPCG0397;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0397-F1;Tissue=Prostate Tumour;donor_id=CPCG0397;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0397-F1;Tissue=Prostate Tumour;donor_id=CPCG0397;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0397-F1;Tissue=Prostate Tumour;donor_id=CPCG0397;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.2;Sample=CPCG0397-F1;Tissue=Prostate Tumour;donor_id=CPCG0397;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0398-F1;Tissue=Prostate Tumour;donor_id=CPCG0398;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0398-F1;Tissue=Prostate Tumour;donor_id=CPCG0398;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0398-F1;Tissue=Prostate Tumour;donor_id=CPCG0398;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0398-F1;Tissue=Prostate Tumour;donor_id=CPCG0398;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0398-F1;Tissue=Prostate Tumour;donor_id=CPCG0398;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0398-F1;Tissue=Prostate Tumour;donor_id=CPCG0398;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.3;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0402-F1;Tissue=Prostate Tumour;donor_id=CPCG0402;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.3;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0402-F1;Tissue=Prostate Tumour;donor_id=CPCG0402;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.3;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0402-F1;Tissue=Prostate Tumour;donor_id=CPCG0402;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.3;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0402-F1;Tissue=Prostate Tumour;donor_id=CPCG0402;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.3;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0402-F1;Tissue=Prostate Tumour;donor_id=CPCG0402;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.3;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0402-F1;Tissue=Prostate Tumour;donor_id=CPCG0402;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.3;gender=male;Gleason Score=4+5;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0402-F1;Tissue=Prostate Tumour;donor_id=CPCG0402;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0406-F1;Tissue=Prostate Tumour;donor_id=CPCG0406;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0406-F1;Tissue=Prostate Tumour;donor_id=CPCG0406;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0406-F1;Tissue=Prostate Tumour;donor_id=CPCG0406;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0406-F1;Tissue=Prostate Tumour;donor_id=CPCG0406;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0406-F1;Tissue=Prostate Tumour;donor_id=CPCG0406;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0406-F1;Tissue=Prostate Tumour;donor_id=CPCG0406;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.5;Sample=CPCG0408-B1;Tissue=Blood;donor_id=CPCG0408;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.5;Sample=CPCG0408-B1;Tissue=Blood;donor_id=CPCG0408;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.5;Sample=CPCG0408-B1;Tissue=Blood;donor_id=CPCG0408;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=3.5;Sample=CPCG0408-F1;Tissue=Prostate Tumour;donor_id=CPCG0408;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=3.5;Sample=CPCG0408-F1;Tissue=Prostate Tumour;donor_id=CPCG0408;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=3.5;Sample=CPCG0408-F1;Tissue=Prostate Tumour;donor_id=CPCG0408;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=3.5;Sample=CPCG0408-F1;Tissue=Prostate Tumour;donor_id=CPCG0408;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=3.5;Sample=CPCG0408-F1;Tissue=Prostate Tumour;donor_id=CPCG0408;ENA-CHECKLIST=ERC000026;
Age at Treatment=67.9;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=3.5;Sample=CPCG0408-F1;Tissue=Prostate Tumour;donor_id=CPCG0408;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.1;Gender=M;Gleason Score=3+4;Pathology T=T2c;Phenotype=OBI_0000922;PreTreatment PSA=6.89;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0415-F1;Tissue=Prostate Tumour;donor_id=CPCG0415;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0415-F1;Tissue=Prostate Tumour;donor_id=CPCG0415;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0415-F1;Tissue=Prostate Tumour;donor_id=CPCG0415;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0415-F1;Tissue=Prostate Tumour;donor_id=CPCG0415;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0415-F1;Tissue=Prostate Tumour;donor_id=CPCG0415;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0415-F1;Tissue=Prostate Tumour;donor_id=CPCG0415;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.5;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.5;Sample=CPCG0415-F1;Tissue=Prostate Tumour;donor_id=CPCG0415;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0416-F1;Tissue=Prostate Tumour;donor_id=CPCG0416;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0416-F1;Tissue=Prostate Tumour;donor_id=CPCG0416;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0416-F1;Tissue=Prostate Tumour;donor_id=CPCG0416;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0416-F1;Tissue=Prostate Tumour;donor_id=CPCG0416;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0416-F1;Tissue=Prostate Tumour;donor_id=CPCG0416;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.3;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0416-F1;Tissue=Prostate Tumour;donor_id=CPCG0416;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.3;Sample=CPCG0418-F1;Tissue=Prostate Tumour;donor_id=CPCG0418;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.3;Sample=CPCG0418-F1;Tissue=Prostate Tumour;donor_id=CPCG0418;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.3;Sample=CPCG0418-F1;Tissue=Prostate Tumour;donor_id=CPCG0418;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.3;Sample=CPCG0418-F1;Tissue=Prostate Tumour;donor_id=CPCG0418;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.3;Sample=CPCG0418-F1;Tissue=Prostate Tumour;donor_id=CPCG0418;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.3;Sample=CPCG0418-F1;Tissue=Prostate Tumour;donor_id=CPCG0418;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0423-F1;Tissue=Prostate Tumour;donor_id=CPCG0423;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0423-F1;Tissue=Prostate Tumour;donor_id=CPCG0423;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0423-F1;Tissue=Prostate Tumour;donor_id=CPCG0423;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0423-F1;Tissue=Prostate Tumour;donor_id=CPCG0423;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0423-F1;Tissue=Prostate Tumour;donor_id=CPCG0423;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.4;Sample=CPCG0423-F1;Tissue=Prostate Tumour;donor_id=CPCG0423;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.0;Sample=CPCG0428-F1;Tissue=Prostate Tumour;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.0;Sample=CPCG0428-F1;Tissue=Prostate Tumour;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.0;Sample=CPCG0428-F1;Tissue=Prostate Tumour;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.0;Sample=CPCG0428-F1;Tissue=Prostate Tumour;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.0;Sample=CPCG0428-F1;Tissue=Prostate Tumour;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.0;Sample=CPCG0428-F1;Tissue=Prostate Tumour;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.0;Sample=CPCG0428-F1;Tissue=Prostate Tumour;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.0;Sample=CPCG0428-F1;Tissue=Prostate Tumour;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=7.0;Sample=CPCG0428-F1;Tissue=Prostate Tumour;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0434-F1;Tissue=Prostate Tumour;donor_id=CPCG0434;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0434-F1;Tissue=Prostate Tumour;donor_id=CPCG0434;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0434-F1;Tissue=Prostate Tumour;donor_id=CPCG0434;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0434-F1;Tissue=Prostate Tumour;donor_id=CPCG0434;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0434-F1;Tissue=Prostate Tumour;donor_id=CPCG0434;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=8.3;Sample=CPCG0434-F1;Tissue=Prostate Tumour;donor_id=CPCG0434;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.2;Sample=CPCG0439-F1;Tissue=Prostate Tumour;donor_id=CPCG0439;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.2;Sample=CPCG0439-F1;Tissue=Prostate Tumour;donor_id=CPCG0439;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.2;Sample=CPCG0439-F1;Tissue=Prostate Tumour;donor_id=CPCG0439;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.2;Sample=CPCG0439-F1;Tissue=Prostate Tumour;donor_id=CPCG0439;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.2;Sample=CPCG0439-F1;Tissue=Prostate Tumour;donor_id=CPCG0439;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.2;Sample=CPCG0439-F1;Tissue=Prostate Tumour;donor_id=CPCG0439;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.6;Sample=CPCG0445-F1;Tissue=Prostate Tumour;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.6;Sample=CPCG0445-F1;Tissue=Prostate Tumour;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.6;Sample=CPCG0445-F1;Tissue=Prostate Tumour;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.6;Sample=CPCG0445-F1;Tissue=Prostate Tumour;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.6;Sample=CPCG0445-F1;Tissue=Prostate Tumour;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.6;Sample=CPCG0445-F1;Tissue=Prostate Tumour;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.6;Sample=CPCG0445-F1;Tissue=Prostate Tumour;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.6;Sample=CPCG0445-F1;Tissue=Prostate Tumour;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=3.6;Sample=CPCG0445-F1;Tissue=Prostate Tumour;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=47.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0448-F1;Tissue=Prostate Tumour;donor_id=CPCG0448;ENA-CHECKLIST=ERC000026;
Age at Treatment=47.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0448-F1;Tissue=Prostate Tumour;donor_id=CPCG0448;ENA-CHECKLIST=ERC000026;
Age at Treatment=47.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0448-F1;Tissue=Prostate Tumour;donor_id=CPCG0448;ENA-CHECKLIST=ERC000026;
Age at Treatment=47.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0448-F1;Tissue=Prostate Tumour;donor_id=CPCG0448;ENA-CHECKLIST=ERC000026;
Age at Treatment=47.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0448-F1;Tissue=Prostate Tumour;donor_id=CPCG0448;ENA-CHECKLIST=ERC000026;
Age at Treatment=47.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0448-F1;Tissue=Prostate Tumour;donor_id=CPCG0448;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;phenotype=Prostate Cancer;Sample=CPCG0450-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;phenotype=Prostate Cancer;Sample=CPCG0450-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;phenotype=Prostate Cancer;Sample=CPCG0450-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;phenotype=Prostate Cancer;Sample=CPCG0450-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;phenotype=Prostate Cancer;Sample=CPCG0450-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;phenotype=Prostate Cancer;Sample=CPCG0450-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;phenotype=Prostate Cancer;Sample=CPCG0450-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;phenotype=Prostate Cancer;Sample=CPCG0450-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;phenotype=Prostate Cancer;Sample=CPCG0450-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;phenotype=Prostate Cancer;Sample=CPCG0450-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;phenotype=Prostate Cancer;Sample=CPCG0450-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;phenotype=Prostate Cancer;Sample=CPCG0450-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0450-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0450-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0450-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0450-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0450-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0450-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0450;gender=male;Germline BRCA Status=MT;IDC-P Status=Negative;phenotype=Prostate Cancer;Sample=CPCG0450-F1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Gross Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0451-F1;Tissue=Prostate Tumour;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0451-F1;Tissue=Prostate Tumour;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0451-F1;Tissue=Prostate Tumour;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0451-F1;Tissue=Prostate Tumour;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0451-F1;Tissue=Prostate Tumour;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.9;Sample=CPCG0451-F1;Tissue=Prostate Tumour;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0452-F1;Tissue=Prostate Tumour;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0452-F1;Tissue=Prostate Tumour;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0452-F1;Tissue=Prostate Tumour;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0452-F1;Tissue=Prostate Tumour;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0452-F1;Tissue=Prostate Tumour;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0452-F1;Tissue=Prostate Tumour;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0452-F1;Tissue=Prostate Tumour;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.1;Sample=CPCG0452-F1;Tissue=Prostate Tumour;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0453-F1;Tissue=Prostate Tumour;donor_id=CPCG0453;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0453-F1;Tissue=Prostate Tumour;donor_id=CPCG0453;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0453-F1;Tissue=Prostate Tumour;donor_id=CPCG0453;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0453-F1;Tissue=Prostate Tumour;donor_id=CPCG0453;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0453-F1;Tissue=Prostate Tumour;donor_id=CPCG0453;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0453-F1;Tissue=Prostate Tumour;donor_id=CPCG0453;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.2;Sample=CPCG0454-F1;Tissue=Prostate Tumour;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.2;Sample=CPCG0454-F1;Tissue=Prostate Tumour;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.2;Sample=CPCG0454-F1;Tissue=Prostate Tumour;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.2;Sample=CPCG0454-F1;Tissue=Prostate Tumour;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.2;Sample=CPCG0454-F1;Tissue=Prostate Tumour;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.2;Sample=CPCG0454-F1;Tissue=Prostate Tumour;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0455-F1;Tissue=Prostate Tumour;donor_id=CPCG0455;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0455-F1;Tissue=Prostate Tumour;donor_id=CPCG0455;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0455-F1;Tissue=Prostate Tumour;donor_id=CPCG0455;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0455-F1;Tissue=Prostate Tumour;donor_id=CPCG0455;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0455-F1;Tissue=Prostate Tumour;donor_id=CPCG0455;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0455-F1;Tissue=Prostate Tumour;donor_id=CPCG0455;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0455-F1;Tissue=Prostate Tumour;donor_id=CPCG0455;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0456-F1;Tissue=Prostate Tumour;donor_id=CPCG0456;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0456-F1;Tissue=Prostate Tumour;donor_id=CPCG0456;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0456-F1;Tissue=Prostate Tumour;donor_id=CPCG0456;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0456-F1;Tissue=Prostate Tumour;donor_id=CPCG0456;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0456-F1;Tissue=Prostate Tumour;donor_id=CPCG0456;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.8;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=6.0;Sample=CPCG0456-F1;Tissue=Prostate Tumour;donor_id=CPCG0456;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0457-F1;Tissue=Prostate Tumour;donor_id=CPCG0457;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0457-F1;Tissue=Prostate Tumour;donor_id=CPCG0457;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0457-F1;Tissue=Prostate Tumour;donor_id=CPCG0457;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0457-F1;Tissue=Prostate Tumour;donor_id=CPCG0457;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0457-F1;Tissue=Prostate Tumour;donor_id=CPCG0457;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.8;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=4.9;Sample=CPCG0457-F1;Tissue=Prostate Tumour;donor_id=CPCG0457;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=9.4;Sample=CPCG0459-F1;Tissue=Prostate Tumour;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=9.4;Sample=CPCG0459-F1;Tissue=Prostate Tumour;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=9.4;Sample=CPCG0459-F1;Tissue=Prostate Tumour;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=9.4;Sample=CPCG0459-F1;Tissue=Prostate Tumour;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=9.4;Sample=CPCG0459-F1;Tissue=Prostate Tumour;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=9.4;Sample=CPCG0459-F1;Tissue=Prostate Tumour;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=9.4;Sample=CPCG0459-F1;Tissue=Prostate Tumour;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=9.4;Sample=CPCG0459-F1;Tissue=Prostate Tumour;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=9.4;Sample=CPCG0459-F1;Tissue=Prostate Tumour;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=11.7;Sample=CPCG0462-F1;Tissue=Prostate Tumour;donor_id=CPCG0462;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=11.7;Sample=CPCG0462-F1;Tissue=Prostate Tumour;donor_id=CPCG0462;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=11.7;Sample=CPCG0462-F1;Tissue=Prostate Tumour;donor_id=CPCG0462;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=11.7;Sample=CPCG0462-F1;Tissue=Prostate Tumour;donor_id=CPCG0462;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=11.7;Sample=CPCG0462-F1;Tissue=Prostate Tumour;donor_id=CPCG0462;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=11.7;Sample=CPCG0462-F1;Tissue=Prostate Tumour;donor_id=CPCG0462;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0463-F1;Tissue=Prostate Tumour;donor_id=CPCG0463;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0463-F1;Tissue=Prostate Tumour;donor_id=CPCG0463;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0463-F1;Tissue=Prostate Tumour;donor_id=CPCG0463;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0463-F1;Tissue=Prostate Tumour;donor_id=CPCG0463;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0463-F1;Tissue=Prostate Tumour;donor_id=CPCG0463;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0463-F1;Tissue=Prostate Tumour;donor_id=CPCG0463;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0463-F1;Tissue=Prostate Tumour;donor_id=CPCG0463;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=11.2;Sample=CPCG0463-F1;Tissue=Prostate Tumour;donor_id=CPCG0463;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0464-F1;Tissue=Prostate Tumour;donor_id=CPCG0464;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0464-F1;Tissue=Prostate Tumour;donor_id=CPCG0464;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0464-F1;Tissue=Prostate Tumour;donor_id=CPCG0464;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0464-F1;Tissue=Prostate Tumour;donor_id=CPCG0464;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0464-F1;Tissue=Prostate Tumour;donor_id=CPCG0464;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.5;Sample=CPCG0464-F1;Tissue=Prostate Tumour;donor_id=CPCG0464;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.1;Sample=CPCG0465-F1;Tissue=Prostate Tumour;donor_id=CPCG0465;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.1;Sample=CPCG0465-F1;Tissue=Prostate Tumour;donor_id=CPCG0465;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.1;Sample=CPCG0465-F1;Tissue=Prostate Tumour;donor_id=CPCG0465;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.1;Sample=CPCG0465-F1;Tissue=Prostate Tumour;donor_id=CPCG0465;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.1;Sample=CPCG0465-F1;Tissue=Prostate Tumour;donor_id=CPCG0465;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.1;Sample=CPCG0465-F1;Tissue=Prostate Tumour;donor_id=CPCG0465;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.1;Sample=CPCG0465-F1;Tissue=Prostate Tumour;donor_id=CPCG0465;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.9;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=4.1;Sample=CPCG0465-F1;Tissue=Prostate Tumour;donor_id=CPCG0465;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0466-F1;Tissue=Prostate Tumour;donor_id=CPCG0466;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0466-F1;Tissue=Prostate Tumour;donor_id=CPCG0466;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0466-F1;Tissue=Prostate Tumour;donor_id=CPCG0466;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0466-F1;Tissue=Prostate Tumour;donor_id=CPCG0466;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0466-F1;Tissue=Prostate Tumour;donor_id=CPCG0466;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0466-F1;Tissue=Prostate Tumour;donor_id=CPCG0466;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.7;Sample=CPCG0467-F1;Tissue=Prostate Tumour;donor_id=CPCG0467;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.7;Sample=CPCG0467-F1;Tissue=Prostate Tumour;donor_id=CPCG0467;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.7;Sample=CPCG0467-F1;Tissue=Prostate Tumour;donor_id=CPCG0467;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.7;Sample=CPCG0467-F1;Tissue=Prostate Tumour;donor_id=CPCG0467;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.7;Sample=CPCG0467-F1;Tissue=Prostate Tumour;donor_id=CPCG0467;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=6.7;Sample=CPCG0467-F1;Tissue=Prostate Tumour;donor_id=CPCG0467;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.1;Sample=CPCG0470-F1;Tissue=Prostate Tumour;donor_id=CPCG0470;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.1;Sample=CPCG0470-F1;Tissue=Prostate Tumour;donor_id=CPCG0470;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.1;Sample=CPCG0470-F1;Tissue=Prostate Tumour;donor_id=CPCG0470;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.1;Sample=CPCG0470-F1;Tissue=Prostate Tumour;donor_id=CPCG0470;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.1;Sample=CPCG0470-F1;Tissue=Prostate Tumour;donor_id=CPCG0470;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=3.1;Sample=CPCG0470-F1;Tissue=Prostate Tumour;donor_id=CPCG0470;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0471-F1;Tissue=Prostate Tumour;donor_id=CPCG0471;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0471-F1;Tissue=Prostate Tumour;donor_id=CPCG0471;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0471-F1;Tissue=Prostate Tumour;donor_id=CPCG0471;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0471-F1;Tissue=Prostate Tumour;donor_id=CPCG0471;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0471-F1;Tissue=Prostate Tumour;donor_id=CPCG0471;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=7.6;Sample=CPCG0471-F1;Tissue=Prostate Tumour;donor_id=CPCG0471;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0472-F1;Tissue=Prostate Tumour;donor_id=CPCG0472;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0472-F1;Tissue=Prostate Tumour;donor_id=CPCG0472;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0472-F1;Tissue=Prostate Tumour;donor_id=CPCG0472;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0472-F1;Tissue=Prostate Tumour;donor_id=CPCG0472;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0472-F1;Tissue=Prostate Tumour;donor_id=CPCG0472;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.7;Sample=CPCG0472-F1;Tissue=Prostate Tumour;donor_id=CPCG0472;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-F1;Tissue=Prostate Tumour;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-F1;Tissue=Prostate Tumour;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-F1;Tissue=Prostate Tumour;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-F1;Tissue=Prostate Tumour;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-F1;Tissue=Prostate Tumour;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-F1;Tissue=Prostate Tumour;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0482-F1;Tissue=Prostate Tumour;donor_id=CPCG0482;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0482-F1;Tissue=Prostate Tumour;donor_id=CPCG0482;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0482-F1;Tissue=Prostate Tumour;donor_id=CPCG0482;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0482-F1;Tissue=Prostate Tumour;donor_id=CPCG0482;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0482-F1;Tissue=Prostate Tumour;donor_id=CPCG0482;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0482-F1;Tissue=Prostate Tumour;donor_id=CPCG0482;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.3;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0482-F1;Tissue=Prostate Tumour;donor_id=CPCG0482;ENA-CHECKLIST=ERC000026;
Age at Treatment=42.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0483-F1;Tissue=Prostate Tumour;donor_id=CPCG0483;ENA-CHECKLIST=ERC000026;
Age at Treatment=42.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0483-F1;Tissue=Prostate Tumour;donor_id=CPCG0483;ENA-CHECKLIST=ERC000026;
Age at Treatment=42.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0483-F1;Tissue=Prostate Tumour;donor_id=CPCG0483;ENA-CHECKLIST=ERC000026;
Age at Treatment=42.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0483-F1;Tissue=Prostate Tumour;donor_id=CPCG0483;ENA-CHECKLIST=ERC000026;
Age at Treatment=42.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0483-F1;Tissue=Prostate Tumour;donor_id=CPCG0483;ENA-CHECKLIST=ERC000026;
Age at Treatment=42.1;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0483-F1;Tissue=Prostate Tumour;donor_id=CPCG0483;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0487-F1;Tissue=Prostate Tumour;donor_id=CPCG0487;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0487-F1;Tissue=Prostate Tumour;donor_id=CPCG0487;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0487-F1;Tissue=Prostate Tumour;donor_id=CPCG0487;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0487-F1;Tissue=Prostate Tumour;donor_id=CPCG0487;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0487-F1;Tissue=Prostate Tumour;donor_id=CPCG0487;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.1;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=5.3;Sample=CPCG0487-F1;Tissue=Prostate Tumour;donor_id=CPCG0487;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.67;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.67;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.67;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.67;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.53;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.53;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.53;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.53;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.49;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.49;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.49;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.49;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.15;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.15;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.15;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.63;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.63;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.63;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=2.700000048;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;Gender=M;Gleason Score=3+4;Phenotype=OBI_0000922;PreTreatment PSA=2.700000048;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.7;Sample=CPCG0204-B1;Tissue=Blood;donor_id=CPCG0204;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.7;Sample=CPCG0204-B1;Tissue=Blood;donor_id=CPCG0204;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.7;Sample=CPCG0204-B1;Tissue=Blood;donor_id=CPCG0204;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.7;Sample=CPCG0204-B1;Tissue=Blood;donor_id=CPCG0204;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.7;Sample=CPCG0204-B1;Tissue=Blood;donor_id=CPCG0204;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.7;Sample=CPCG0204-F1;Tissue=Prostate Tumour;donor_id=CPCG0204;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.7;Sample=CPCG0204-F1;Tissue=Prostate Tumour;donor_id=CPCG0204;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.7;Sample=CPCG0204-F1;Tissue=Prostate Tumour;donor_id=CPCG0204;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.7;Sample=CPCG0204-F1;Tissue=Prostate Tumour;donor_id=CPCG0204;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.7;Sample=CPCG0204-F1;Tissue=Prostate Tumour;donor_id=CPCG0204;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.7;Sample=CPCG0204-F1;Tissue=Prostate Tumour;donor_id=CPCG0204;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.7;Sample=CPCG0204-F1;Tissue=Prostate Tumour;donor_id=CPCG0204;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.7;Sample=CPCG0204-F1;Tissue=Prostate Tumour;donor_id=CPCG0204;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.7;Sample=CPCG0204-F1;Tissue=Prostate Tumour;donor_id=CPCG0204;ENA-CHECKLIST=ERC000026;
Age at Treatment=75.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=9.7;Sample=CPCG0204-F1;Tissue=Prostate Tumour;donor_id=CPCG0204;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0294-F1;Tissue=Prostate Tumour;donor_id=CPCG0294;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0294-F1;Tissue=Prostate Tumour;donor_id=CPCG0294;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0294-F1;Tissue=Prostate Tumour;donor_id=CPCG0294;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0294-F1;Tissue=Prostate Tumour;donor_id=CPCG0294;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0294-F1;Tissue=Prostate Tumour;donor_id=CPCG0294;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0294-F1;Tissue=Prostate Tumour;donor_id=CPCG0294;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.7;gender=male;Gleason Score=3+3;phenotype=OBI_0000922;PreTreatment PSA=5.7;Sample=CPCG0294-F1;Tissue=Prostate Tumour;donor_id=CPCG0294;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=12.4;Sample=CPCG0295-F1;Tissue=Prostate Tumour;donor_id=CPCG0295;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=12.4;Sample=CPCG0295-F1;Tissue=Prostate Tumour;donor_id=CPCG0295;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=12.4;Sample=CPCG0295-F1;Tissue=Prostate Tumour;donor_id=CPCG0295;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=12.4;Sample=CPCG0295-F1;Tissue=Prostate Tumour;donor_id=CPCG0295;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=12.4;Sample=CPCG0295-F1;Tissue=Prostate Tumour;donor_id=CPCG0295;ENA-CHECKLIST=ERC000026;
Age at Treatment=77.0;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=12.4;Sample=CPCG0295-F1;Tissue=Prostate Tumour;donor_id=CPCG0295;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.5;Sample=CPCG0296-F1;Tissue=Prostate Tumour;donor_id=CPCG0296;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.5;Sample=CPCG0296-F1;Tissue=Prostate Tumour;donor_id=CPCG0296;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.5;Sample=CPCG0296-F1;Tissue=Prostate Tumour;donor_id=CPCG0296;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.5;Sample=CPCG0296-F1;Tissue=Prostate Tumour;donor_id=CPCG0296;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.5;Sample=CPCG0296-F1;Tissue=Prostate Tumour;donor_id=CPCG0296;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.5;Sample=CPCG0296-F1;Tissue=Prostate Tumour;donor_id=CPCG0296;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.5;Sample=CPCG0296-F1;Tissue=Prostate Tumour;donor_id=CPCG0296;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.6;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=10.5;Sample=CPCG0296-F1;Tissue=Prostate Tumour;donor_id=CPCG0296;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=2.2;Sample=CPCG0297-F1;Tissue=Prostate Tumour;donor_id=CPCG0297;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=2.2;Sample=CPCG0297-F1;Tissue=Prostate Tumour;donor_id=CPCG0297;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=2.2;Sample=CPCG0297-F1;Tissue=Prostate Tumour;donor_id=CPCG0297;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=2.2;Sample=CPCG0297-F1;Tissue=Prostate Tumour;donor_id=CPCG0297;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=2.2;Sample=CPCG0297-F1;Tissue=Prostate Tumour;donor_id=CPCG0297;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.7;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=2.2;Sample=CPCG0297-F1;Tissue=Prostate Tumour;donor_id=CPCG0297;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.2;Sample=CPCG0298-F1;Tissue=Prostate Tumour;donor_id=CPCG0298;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.2;Sample=CPCG0298-F1;Tissue=Prostate Tumour;donor_id=CPCG0298;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.2;Sample=CPCG0298-F1;Tissue=Prostate Tumour;donor_id=CPCG0298;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.2;Sample=CPCG0298-F1;Tissue=Prostate Tumour;donor_id=CPCG0298;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.2;Sample=CPCG0298-F1;Tissue=Prostate Tumour;donor_id=CPCG0298;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.6;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.2;Sample=CPCG0298-F1;Tissue=Prostate Tumour;donor_id=CPCG0298;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=17.3;Sample=CPCG0299-F1;Tissue=Prostate Tumour;donor_id=CPCG0299;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=17.3;Sample=CPCG0299-F1;Tissue=Prostate Tumour;donor_id=CPCG0299;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=17.3;Sample=CPCG0299-F1;Tissue=Prostate Tumour;donor_id=CPCG0299;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=17.3;Sample=CPCG0299-F1;Tissue=Prostate Tumour;donor_id=CPCG0299;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=17.3;Sample=CPCG0299-F1;Tissue=Prostate Tumour;donor_id=CPCG0299;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=17.3;Sample=CPCG0299-F1;Tissue=Prostate Tumour;donor_id=CPCG0299;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.4;gender=male;Gleason Score=4+4;phenotype=OBI_0000922;PreTreatment PSA=17.3;Sample=CPCG0299-F1;Tissue=Prostate Tumour;donor_id=CPCG0299;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=53.7;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=7.41;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.5;Sample=CPCG0394-B1;Tissue=Blood;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.5;Sample=CPCG0394-B1;Tissue=Blood;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.5;Sample=CPCG0394-B1;Tissue=Blood;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.5;Sample=CPCG0394-B1;Tissue=Blood;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.5;Sample=CPCG0394-B1;Tissue=Blood;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.5;Sample=CPCG0394-B1;Tissue=Blood;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.5;Sample=CPCG0394-B1;Tissue=Blood;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=50.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=2.5;Sample=CPCG0394-B1;Tissue=Blood;donor_id=CPCG0394;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.2;Sample=CPCG0395-B1;Tissue=Blood;donor_id=CPCG0395;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.2;Sample=CPCG0395-B1;Tissue=Blood;donor_id=CPCG0395;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.2;Sample=CPCG0395-B1;Tissue=Blood;donor_id=CPCG0395;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.2;Sample=CPCG0395-B1;Tissue=Blood;donor_id=CPCG0395;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.2;Sample=CPCG0395-B1;Tissue=Blood;donor_id=CPCG0395;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.2;Sample=CPCG0395-B1;Tissue=Blood;donor_id=CPCG0395;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.2;Sample=CPCG0395-B1;Tissue=Blood;donor_id=CPCG0395;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.2;Sample=CPCG0395-B1;Tissue=Blood;donor_id=CPCG0395;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=18.0;Sample=CPCG0396-B1;Tissue=Blood;donor_id=CPCG0396;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=18.0;Sample=CPCG0396-B1;Tissue=Blood;donor_id=CPCG0396;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=18.0;Sample=CPCG0396-B1;Tissue=Blood;donor_id=CPCG0396;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=18.0;Sample=CPCG0396-B1;Tissue=Blood;donor_id=CPCG0396;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=18.0;Sample=CPCG0396-B1;Tissue=Blood;donor_id=CPCG0396;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=18.0;Sample=CPCG0396-B1;Tissue=Blood;donor_id=CPCG0396;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=18.0;Sample=CPCG0396-B1;Tissue=Blood;donor_id=CPCG0396;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=18.0;Sample=CPCG0396-B1;Tissue=Blood;donor_id=CPCG0396;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.2;Sample=CPCG0397-B1;Tissue=Blood;donor_id=CPCG0397;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.2;Sample=CPCG0397-B1;Tissue=Blood;donor_id=CPCG0397;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.2;Sample=CPCG0397-B1;Tissue=Blood;donor_id=CPCG0397;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.2;Sample=CPCG0397-B1;Tissue=Blood;donor_id=CPCG0397;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.2;Sample=CPCG0397-B1;Tissue=Blood;donor_id=CPCG0397;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.2;Sample=CPCG0397-B1;Tissue=Blood;donor_id=CPCG0397;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.2;Sample=CPCG0397-B1;Tissue=Blood;donor_id=CPCG0397;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.2;Sample=CPCG0397-B1;Tissue=Blood;donor_id=CPCG0397;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.4;Sample=CPCG0398-B1;Tissue=Blood;donor_id=CPCG0398;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.4;Sample=CPCG0398-B1;Tissue=Blood;donor_id=CPCG0398;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.4;Sample=CPCG0398-B1;Tissue=Blood;donor_id=CPCG0398;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.4;Sample=CPCG0398-B1;Tissue=Blood;donor_id=CPCG0398;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.4;Sample=CPCG0398-B1;Tissue=Blood;donor_id=CPCG0398;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.4;Sample=CPCG0398-B1;Tissue=Blood;donor_id=CPCG0398;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.4;Sample=CPCG0398-B1;Tissue=Blood;donor_id=CPCG0398;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.4;Sample=CPCG0398-B1;Tissue=Blood;donor_id=CPCG0398;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.5;Sample=CPCG0402-B1;Tissue=Blood;donor_id=CPCG0402;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.5;Sample=CPCG0402-B1;Tissue=Blood;donor_id=CPCG0402;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.5;Sample=CPCG0402-B1;Tissue=Blood;donor_id=CPCG0402;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.5;Sample=CPCG0402-B1;Tissue=Blood;donor_id=CPCG0402;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.5;Sample=CPCG0402-B1;Tissue=Blood;donor_id=CPCG0402;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.5;Sample=CPCG0402-B1;Tissue=Blood;donor_id=CPCG0402;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.5;Sample=CPCG0402-B1;Tissue=Blood;donor_id=CPCG0402;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.5;Sample=CPCG0402-B1;Tissue=Blood;donor_id=CPCG0402;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=3.6;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0406-B1;Tissue=Blood;donor_id=CPCG0406;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0406-B1;Tissue=Blood;donor_id=CPCG0406;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0406-B1;Tissue=Blood;donor_id=CPCG0406;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0406-B1;Tissue=Blood;donor_id=CPCG0406;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0406-B1;Tissue=Blood;donor_id=CPCG0406;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0406-B1;Tissue=Blood;donor_id=CPCG0406;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0406-B1;Tissue=Blood;donor_id=CPCG0406;ENA-CHECKLIST=ERC000026;
Age at Treatment=55.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0406-B1;Tissue=Blood;donor_id=CPCG0406;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.5;Sample=CPCG0415-B1;Tissue=Blood;donor_id=CPCG0415;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.5;Sample=CPCG0415-B1;Tissue=Blood;donor_id=CPCG0415;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.5;Sample=CPCG0415-B1;Tissue=Blood;donor_id=CPCG0415;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.5;Sample=CPCG0415-B1;Tissue=Blood;donor_id=CPCG0415;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.5;Sample=CPCG0415-B1;Tissue=Blood;donor_id=CPCG0415;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.5;Sample=CPCG0415-B1;Tissue=Blood;donor_id=CPCG0415;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.5;Sample=CPCG0415-B1;Tissue=Blood;donor_id=CPCG0415;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.5;Sample=CPCG0415-B1;Tissue=Blood;donor_id=CPCG0415;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0416-B1;Tissue=Blood;donor_id=CPCG0416;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0416-B1;Tissue=Blood;donor_id=CPCG0416;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0416-B1;Tissue=Blood;donor_id=CPCG0416;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0416-B1;Tissue=Blood;donor_id=CPCG0416;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0416-B1;Tissue=Blood;donor_id=CPCG0416;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0416-B1;Tissue=Blood;donor_id=CPCG0416;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0416-B1;Tissue=Blood;donor_id=CPCG0416;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.8;Sample=CPCG0416-B1;Tissue=Blood;donor_id=CPCG0416;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0418-B1;Tissue=Blood;donor_id=CPCG0418;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0418-B1;Tissue=Blood;donor_id=CPCG0418;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0418-B1;Tissue=Blood;donor_id=CPCG0418;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0418-B1;Tissue=Blood;donor_id=CPCG0418;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0418-B1;Tissue=Blood;donor_id=CPCG0418;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0418-B1;Tissue=Blood;donor_id=CPCG0418;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0418-B1;Tissue=Blood;donor_id=CPCG0418;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.3;Sample=CPCG0418-B1;Tissue=Blood;donor_id=CPCG0418;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.4;Sample=CPCG0423-B1;Tissue=Blood;donor_id=CPCG0423;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.4;Sample=CPCG0423-B1;Tissue=Blood;donor_id=CPCG0423;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.4;Sample=CPCG0423-B1;Tissue=Blood;donor_id=CPCG0423;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.4;Sample=CPCG0423-B1;Tissue=Blood;donor_id=CPCG0423;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.4;Sample=CPCG0423-B1;Tissue=Blood;donor_id=CPCG0423;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.4;Sample=CPCG0423-B1;Tissue=Blood;donor_id=CPCG0423;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.4;Sample=CPCG0423-B1;Tissue=Blood;donor_id=CPCG0423;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.4;Sample=CPCG0423-B1;Tissue=Blood;donor_id=CPCG0423;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-B1;Tissue=Blood;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-B1;Tissue=Blood;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-B1;Tissue=Blood;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-B1;Tissue=Blood;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-B1;Tissue=Blood;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-B1;Tissue=Blood;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-B1;Tissue=Blood;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-B1;Tissue=Blood;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-F1;Tissue=Prostate Tumour;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-F1;Tissue=Prostate Tumour;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-F1;Tissue=Prostate Tumour;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-F1;Tissue=Prostate Tumour;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-F1;Tissue=Prostate Tumour;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-F1;Tissue=Prostate Tumour;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-F1;Tissue=Prostate Tumour;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-F1;Tissue=Prostate Tumour;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-F1;Tissue=Prostate Tumour;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-F1;Tissue=Prostate Tumour;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-F1;Tissue=Prostate Tumour;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-F1;Tissue=Prostate Tumour;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-F1;Tissue=Prostate Tumour;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-F1;Tissue=Prostate Tumour;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-F1;Tissue=Prostate Tumour;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.4;gender=male;phenotype=OBI_0000922;PreTreatment PSA=10.0;Sample=CPCG0424-F1;Tissue=Prostate Tumour;donor_id=CPCG0424;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-B1;Tissue=Blood;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-B1;Tissue=Blood;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-B1;Tissue=Blood;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-B1;Tissue=Blood;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-B1;Tissue=Blood;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-B1;Tissue=Blood;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-B1;Tissue=Blood;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-B1;Tissue=Blood;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-F1;Tissue=Prostate Tumour;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-F1;Tissue=Prostate Tumour;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-F1;Tissue=Prostate Tumour;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-F1;Tissue=Prostate Tumour;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-F1;Tissue=Prostate Tumour;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-F1;Tissue=Prostate Tumour;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-F1;Tissue=Prostate Tumour;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-F1;Tissue=Prostate Tumour;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-F1;Tissue=Prostate Tumour;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-F1;Tissue=Prostate Tumour;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-F1;Tissue=Prostate Tumour;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-F1;Tissue=Prostate Tumour;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-F1;Tissue=Prostate Tumour;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-F1;Tissue=Prostate Tumour;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-F1;Tissue=Prostate Tumour;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.8;Sample=CPCG0426-F1;Tissue=Prostate Tumour;donor_id=CPCG0426;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.0;Sample=CPCG0428-B1;Tissue=Blood;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.0;Sample=CPCG0428-B1;Tissue=Blood;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.0;Sample=CPCG0428-B1;Tissue=Blood;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.0;Sample=CPCG0428-B1;Tissue=Blood;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.0;Sample=CPCG0428-B1;Tissue=Blood;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.0;Sample=CPCG0428-B1;Tissue=Blood;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.0;Sample=CPCG0428-B1;Tissue=Blood;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.0;Sample=CPCG0428-B1;Tissue=Blood;donor_id=CPCG0428;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-B1;Tissue=Blood;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-B1;Tissue=Blood;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-B1;Tissue=Blood;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-B1;Tissue=Blood;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-B1;Tissue=Blood;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-B1;Tissue=Blood;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-B1;Tissue=Blood;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-B1;Tissue=Blood;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-F1;Tissue=Prostate Tumour;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-F1;Tissue=Prostate Tumour;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-F1;Tissue=Prostate Tumour;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-F1;Tissue=Prostate Tumour;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-F1;Tissue=Prostate Tumour;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-F1;Tissue=Prostate Tumour;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-F1;Tissue=Prostate Tumour;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-F1;Tissue=Prostate Tumour;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-F1;Tissue=Prostate Tumour;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-F1;Tissue=Prostate Tumour;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-F1;Tissue=Prostate Tumour;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-F1;Tissue=Prostate Tumour;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-F1;Tissue=Prostate Tumour;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-F1;Tissue=Prostate Tumour;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-F1;Tissue=Prostate Tumour;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=13.3;Sample=CPCG0432-F1;Tissue=Prostate Tumour;donor_id=CPCG0432;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-B1;Tissue=Blood;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-B1;Tissue=Blood;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-B1;Tissue=Blood;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-B1;Tissue=Blood;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-B1;Tissue=Blood;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-B1;Tissue=Blood;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-B1;Tissue=Blood;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-B1;Tissue=Blood;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.7;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.6;Sample=CPCG0433-F1;Tissue=Prostate Tumour;donor_id=CPCG0433;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.3;Sample=CPCG0434-B1;Tissue=Blood;donor_id=CPCG0434;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.3;Sample=CPCG0434-B1;Tissue=Blood;donor_id=CPCG0434;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.3;Sample=CPCG0434-B1;Tissue=Blood;donor_id=CPCG0434;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.3;Sample=CPCG0434-B1;Tissue=Blood;donor_id=CPCG0434;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.3;Sample=CPCG0434-B1;Tissue=Blood;donor_id=CPCG0434;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.3;Sample=CPCG0434-B1;Tissue=Blood;donor_id=CPCG0434;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.3;Sample=CPCG0434-B1;Tissue=Blood;donor_id=CPCG0434;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.3;Sample=CPCG0434-B1;Tissue=Blood;donor_id=CPCG0434;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-B1;Tissue=Blood;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-B1;Tissue=Blood;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-B1;Tissue=Blood;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-B1;Tissue=Blood;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-B1;Tissue=Blood;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-B1;Tissue=Blood;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-B1;Tissue=Blood;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-B1;Tissue=Blood;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-F1;Tissue=Prostate Tumour;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-F1;Tissue=Prostate Tumour;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-F1;Tissue=Prostate Tumour;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-F1;Tissue=Prostate Tumour;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-F1;Tissue=Prostate Tumour;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-F1;Tissue=Prostate Tumour;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-F1;Tissue=Prostate Tumour;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-F1;Tissue=Prostate Tumour;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-F1;Tissue=Prostate Tumour;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-F1;Tissue=Prostate Tumour;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-F1;Tissue=Prostate Tumour;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-F1;Tissue=Prostate Tumour;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-F1;Tissue=Prostate Tumour;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-F1;Tissue=Prostate Tumour;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-F1;Tissue=Prostate Tumour;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=68.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.9;Sample=CPCG0437-F1;Tissue=Prostate Tumour;donor_id=CPCG0437;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.2;Sample=CPCG0439-B1;Tissue=Blood;donor_id=CPCG0439;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.2;Sample=CPCG0439-B1;Tissue=Blood;donor_id=CPCG0439;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.2;Sample=CPCG0439-B1;Tissue=Blood;donor_id=CPCG0439;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.2;Sample=CPCG0439-B1;Tissue=Blood;donor_id=CPCG0439;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.2;Sample=CPCG0439-B1;Tissue=Blood;donor_id=CPCG0439;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.2;Sample=CPCG0439-B1;Tissue=Blood;donor_id=CPCG0439;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.2;Sample=CPCG0439-B1;Tissue=Blood;donor_id=CPCG0439;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.2;Sample=CPCG0439-B1;Tissue=Blood;donor_id=CPCG0439;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.6;Sample=CPCG0445-B1;Tissue=Blood;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.6;Sample=CPCG0445-B1;Tissue=Blood;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.6;Sample=CPCG0445-B1;Tissue=Blood;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.6;Sample=CPCG0445-B1;Tissue=Blood;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.6;Sample=CPCG0445-B1;Tissue=Blood;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.6;Sample=CPCG0445-B1;Tissue=Blood;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.6;Sample=CPCG0445-B1;Tissue=Blood;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.6;Sample=CPCG0445-B1;Tissue=Blood;donor_id=CPCG0445;ENA-CHECKLIST=ERC000026;
Age at Treatment=47.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0448-B1;Tissue=Blood;donor_id=CPCG0448;ENA-CHECKLIST=ERC000026;
Age at Treatment=47.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0448-B1;Tissue=Blood;donor_id=CPCG0448;ENA-CHECKLIST=ERC000026;
Age at Treatment=47.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0448-B1;Tissue=Blood;donor_id=CPCG0448;ENA-CHECKLIST=ERC000026;
Age at Treatment=47.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0448-B1;Tissue=Blood;donor_id=CPCG0448;ENA-CHECKLIST=ERC000026;
Age at Treatment=47.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0448-B1;Tissue=Blood;donor_id=CPCG0448;ENA-CHECKLIST=ERC000026;
Age at Treatment=47.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0448-B1;Tissue=Blood;donor_id=CPCG0448;ENA-CHECKLIST=ERC000026;
Age at Treatment=47.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0448-B1;Tissue=Blood;donor_id=CPCG0448;ENA-CHECKLIST=ERC000026;
Age at Treatment=47.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0448-B1;Tissue=Blood;donor_id=CPCG0448;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.9;Sample=CPCG0451-B1;Tissue=Blood;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.9;Sample=CPCG0451-B1;Tissue=Blood;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.9;Sample=CPCG0451-B1;Tissue=Blood;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.9;Sample=CPCG0451-B1;Tissue=Blood;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.9;Sample=CPCG0451-B1;Tissue=Blood;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.9;Sample=CPCG0451-B1;Tissue=Blood;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.9;Sample=CPCG0451-B1;Tissue=Blood;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.9;Sample=CPCG0451-B1;Tissue=Blood;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.1;Sample=CPCG0452-B1;Tissue=Blood;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.1;Sample=CPCG0452-B1;Tissue=Blood;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.1;Sample=CPCG0452-B1;Tissue=Blood;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.1;Sample=CPCG0452-B1;Tissue=Blood;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.1;Sample=CPCG0452-B1;Tissue=Blood;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.1;Sample=CPCG0452-B1;Tissue=Blood;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.1;Sample=CPCG0452-B1;Tissue=Blood;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.1;Sample=CPCG0452-B1;Tissue=Blood;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.0;Sample=CPCG0453-B1;Tissue=Blood;donor_id=CPCG0453;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.0;Sample=CPCG0453-B1;Tissue=Blood;donor_id=CPCG0453;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.0;Sample=CPCG0453-B1;Tissue=Blood;donor_id=CPCG0453;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.0;Sample=CPCG0453-B1;Tissue=Blood;donor_id=CPCG0453;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.0;Sample=CPCG0453-B1;Tissue=Blood;donor_id=CPCG0453;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.0;Sample=CPCG0453-B1;Tissue=Blood;donor_id=CPCG0453;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.0;Sample=CPCG0453-B1;Tissue=Blood;donor_id=CPCG0453;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.0;Sample=CPCG0453-B1;Tissue=Blood;donor_id=CPCG0453;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.2;Sample=CPCG0454-B1;Tissue=Blood;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.2;Sample=CPCG0454-B1;Tissue=Blood;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.2;Sample=CPCG0454-B1;Tissue=Blood;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.2;Sample=CPCG0454-B1;Tissue=Blood;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.2;Sample=CPCG0454-B1;Tissue=Blood;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.2;Sample=CPCG0454-B1;Tissue=Blood;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.2;Sample=CPCG0454-B1;Tissue=Blood;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.2;Sample=CPCG0454-B1;Tissue=Blood;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.9;Sample=CPCG0455-B1;Tissue=Blood;donor_id=CPCG0455;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.9;Sample=CPCG0455-B1;Tissue=Blood;donor_id=CPCG0455;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.9;Sample=CPCG0455-B1;Tissue=Blood;donor_id=CPCG0455;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.9;Sample=CPCG0455-B1;Tissue=Blood;donor_id=CPCG0455;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.9;Sample=CPCG0455-B1;Tissue=Blood;donor_id=CPCG0455;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.9;Sample=CPCG0455-B1;Tissue=Blood;donor_id=CPCG0455;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.9;Sample=CPCG0455-B1;Tissue=Blood;donor_id=CPCG0455;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.9;Sample=CPCG0455-B1;Tissue=Blood;donor_id=CPCG0455;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.0;Sample=CPCG0456-B1;Tissue=Blood;donor_id=CPCG0456;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.0;Sample=CPCG0456-B1;Tissue=Blood;donor_id=CPCG0456;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.0;Sample=CPCG0456-B1;Tissue=Blood;donor_id=CPCG0456;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.0;Sample=CPCG0456-B1;Tissue=Blood;donor_id=CPCG0456;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.0;Sample=CPCG0456-B1;Tissue=Blood;donor_id=CPCG0456;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.0;Sample=CPCG0456-B1;Tissue=Blood;donor_id=CPCG0456;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.0;Sample=CPCG0456-B1;Tissue=Blood;donor_id=CPCG0456;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.0;Sample=CPCG0456-B1;Tissue=Blood;donor_id=CPCG0456;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.9;Sample=CPCG0457-B1;Tissue=Blood;donor_id=CPCG0457;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.9;Sample=CPCG0457-B1;Tissue=Blood;donor_id=CPCG0457;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.9;Sample=CPCG0457-B1;Tissue=Blood;donor_id=CPCG0457;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.9;Sample=CPCG0457-B1;Tissue=Blood;donor_id=CPCG0457;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.9;Sample=CPCG0457-B1;Tissue=Blood;donor_id=CPCG0457;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.9;Sample=CPCG0457-B1;Tissue=Blood;donor_id=CPCG0457;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.9;Sample=CPCG0457-B1;Tissue=Blood;donor_id=CPCG0457;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.9;Sample=CPCG0457-B1;Tissue=Blood;donor_id=CPCG0457;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-B1;Tissue=Blood;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-B1;Tissue=Blood;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-B1;Tissue=Blood;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-B1;Tissue=Blood;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-B1;Tissue=Blood;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-B1;Tissue=Blood;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-B1;Tissue=Blood;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-B1;Tissue=Blood;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-F1;Tissue=Prostate Tumour;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-F1;Tissue=Prostate Tumour;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-F1;Tissue=Prostate Tumour;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-F1;Tissue=Prostate Tumour;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-F1;Tissue=Prostate Tumour;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-F1;Tissue=Prostate Tumour;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-F1;Tissue=Prostate Tumour;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-F1;Tissue=Prostate Tumour;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-F1;Tissue=Prostate Tumour;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-F1;Tissue=Prostate Tumour;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-F1;Tissue=Prostate Tumour;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-F1;Tissue=Prostate Tumour;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-F1;Tissue=Prostate Tumour;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-F1;Tissue=Prostate Tumour;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-F1;Tissue=Prostate Tumour;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.0;gender=male;Gleason Score=4+3;phenotype=OBI_0000922;PreTreatment PSA=15.6;Sample=CPCG0458-F1;Tissue=Prostate Tumour;donor_id=CPCG0458;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.4;Sample=CPCG0459-B1;Tissue=Blood;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.4;Sample=CPCG0459-B1;Tissue=Blood;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.4;Sample=CPCG0459-B1;Tissue=Blood;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.4;Sample=CPCG0459-B1;Tissue=Blood;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.4;Sample=CPCG0459-B1;Tissue=Blood;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.4;Sample=CPCG0459-B1;Tissue=Blood;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.4;Sample=CPCG0459-B1;Tissue=Blood;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.4;Sample=CPCG0459-B1;Tissue=Blood;donor_id=CPCG0459;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.7;Sample=CPCG0462-B1;Tissue=Blood;donor_id=CPCG0462;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.7;Sample=CPCG0462-B1;Tissue=Blood;donor_id=CPCG0462;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.7;Sample=CPCG0462-B1;Tissue=Blood;donor_id=CPCG0462;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.7;Sample=CPCG0462-B1;Tissue=Blood;donor_id=CPCG0462;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.7;Sample=CPCG0462-B1;Tissue=Blood;donor_id=CPCG0462;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.7;Sample=CPCG0462-B1;Tissue=Blood;donor_id=CPCG0462;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.7;Sample=CPCG0462-B1;Tissue=Blood;donor_id=CPCG0462;ENA-CHECKLIST=ERC000026;
Age at Treatment=63.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.7;Sample=CPCG0462-B1;Tissue=Blood;donor_id=CPCG0462;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0463-B1;Tissue=Blood;donor_id=CPCG0463;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0463-B1;Tissue=Blood;donor_id=CPCG0463;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0463-B1;Tissue=Blood;donor_id=CPCG0463;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0463-B1;Tissue=Blood;donor_id=CPCG0463;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0463-B1;Tissue=Blood;donor_id=CPCG0463;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0463-B1;Tissue=Blood;donor_id=CPCG0463;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0463-B1;Tissue=Blood;donor_id=CPCG0463;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.2;gender=male;phenotype=OBI_0000747;PreTreatment PSA=11.2;Sample=CPCG0463-B1;Tissue=Blood;donor_id=CPCG0463;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.5;Sample=CPCG0464-B1;Tissue=Blood;donor_id=CPCG0464;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.5;Sample=CPCG0464-B1;Tissue=Blood;donor_id=CPCG0464;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.5;Sample=CPCG0464-B1;Tissue=Blood;donor_id=CPCG0464;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.5;Sample=CPCG0464-B1;Tissue=Blood;donor_id=CPCG0464;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.5;Sample=CPCG0464-B1;Tissue=Blood;donor_id=CPCG0464;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.5;Sample=CPCG0464-B1;Tissue=Blood;donor_id=CPCG0464;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.5;Sample=CPCG0464-B1;Tissue=Blood;donor_id=CPCG0464;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.5;Sample=CPCG0464-B1;Tissue=Blood;donor_id=CPCG0464;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.1;Sample=CPCG0465-B1;Tissue=Blood;donor_id=CPCG0465;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.1;Sample=CPCG0465-B1;Tissue=Blood;donor_id=CPCG0465;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.1;Sample=CPCG0465-B1;Tissue=Blood;donor_id=CPCG0465;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.1;Sample=CPCG0465-B1;Tissue=Blood;donor_id=CPCG0465;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.1;Sample=CPCG0465-B1;Tissue=Blood;donor_id=CPCG0465;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.1;Sample=CPCG0465-B1;Tissue=Blood;donor_id=CPCG0465;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.1;Sample=CPCG0465-B1;Tissue=Blood;donor_id=CPCG0465;ENA-CHECKLIST=ERC000026;
Age at Treatment=49.9;gender=male;phenotype=OBI_0000747;PreTreatment PSA=4.1;Sample=CPCG0465-B1;Tissue=Blood;donor_id=CPCG0465;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.7;Sample=CPCG0466-B1;Tissue=Blood;donor_id=CPCG0466;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.7;Sample=CPCG0466-B1;Tissue=Blood;donor_id=CPCG0466;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.7;Sample=CPCG0466-B1;Tissue=Blood;donor_id=CPCG0466;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.7;Sample=CPCG0466-B1;Tissue=Blood;donor_id=CPCG0466;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.7;Sample=CPCG0466-B1;Tissue=Blood;donor_id=CPCG0466;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.7;Sample=CPCG0466-B1;Tissue=Blood;donor_id=CPCG0466;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.7;Sample=CPCG0466-B1;Tissue=Blood;donor_id=CPCG0466;ENA-CHECKLIST=ERC000026;
Age at Treatment=54.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=5.7;Sample=CPCG0466-B1;Tissue=Blood;donor_id=CPCG0466;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.7;Sample=CPCG0467-B1;Tissue=Blood;donor_id=CPCG0467;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.7;Sample=CPCG0467-B1;Tissue=Blood;donor_id=CPCG0467;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.7;Sample=CPCG0467-B1;Tissue=Blood;donor_id=CPCG0467;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.7;Sample=CPCG0467-B1;Tissue=Blood;donor_id=CPCG0467;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.7;Sample=CPCG0467-B1;Tissue=Blood;donor_id=CPCG0467;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.7;Sample=CPCG0467-B1;Tissue=Blood;donor_id=CPCG0467;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.7;Sample=CPCG0467-B1;Tissue=Blood;donor_id=CPCG0467;ENA-CHECKLIST=ERC000026;
Age at Treatment=65.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=6.7;Sample=CPCG0467-B1;Tissue=Blood;donor_id=CPCG0467;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.7;Sample=CPCG0468-B1;Tissue=Blood;donor_id=CPCG0468;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.7;Sample=CPCG0468-B1;Tissue=Blood;donor_id=CPCG0468;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.7;Sample=CPCG0468-B1;Tissue=Blood;donor_id=CPCG0468;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.7;Sample=CPCG0468-B1;Tissue=Blood;donor_id=CPCG0468;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.7;Sample=CPCG0468-B1;Tissue=Blood;donor_id=CPCG0468;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.7;Sample=CPCG0468-B1;Tissue=Blood;donor_id=CPCG0468;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.7;Sample=CPCG0468-B1;Tissue=Blood;donor_id=CPCG0468;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.0;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.7;Sample=CPCG0468-B1;Tissue=Blood;donor_id=CPCG0468;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.1;Sample=CPCG0470-B1;Tissue=Blood;donor_id=CPCG0470;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.1;Sample=CPCG0470-B1;Tissue=Blood;donor_id=CPCG0470;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.1;Sample=CPCG0470-B1;Tissue=Blood;donor_id=CPCG0470;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.1;Sample=CPCG0470-B1;Tissue=Blood;donor_id=CPCG0470;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.1;Sample=CPCG0470-B1;Tissue=Blood;donor_id=CPCG0470;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.1;Sample=CPCG0470-B1;Tissue=Blood;donor_id=CPCG0470;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.1;Sample=CPCG0470-B1;Tissue=Blood;donor_id=CPCG0470;ENA-CHECKLIST=ERC000026;
Age at Treatment=59.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=3.1;Sample=CPCG0470-B1;Tissue=Blood;donor_id=CPCG0470;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.6;Sample=CPCG0471-B1;Tissue=Blood;donor_id=CPCG0471;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.6;Sample=CPCG0471-B1;Tissue=Blood;donor_id=CPCG0471;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.6;Sample=CPCG0471-B1;Tissue=Blood;donor_id=CPCG0471;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.6;Sample=CPCG0471-B1;Tissue=Blood;donor_id=CPCG0471;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.6;Sample=CPCG0471-B1;Tissue=Blood;donor_id=CPCG0471;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.6;Sample=CPCG0471-B1;Tissue=Blood;donor_id=CPCG0471;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.6;Sample=CPCG0471-B1;Tissue=Blood;donor_id=CPCG0471;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.3;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.6;Sample=CPCG0471-B1;Tissue=Blood;donor_id=CPCG0471;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.7;Sample=CPCG0472-B1;Tissue=Blood;donor_id=CPCG0472;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.7;Sample=CPCG0472-B1;Tissue=Blood;donor_id=CPCG0472;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.7;Sample=CPCG0472-B1;Tissue=Blood;donor_id=CPCG0472;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.7;Sample=CPCG0472-B1;Tissue=Blood;donor_id=CPCG0472;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.7;Sample=CPCG0472-B1;Tissue=Blood;donor_id=CPCG0472;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.7;Sample=CPCG0472-B1;Tissue=Blood;donor_id=CPCG0472;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.7;Sample=CPCG0472-B1;Tissue=Blood;donor_id=CPCG0472;ENA-CHECKLIST=ERC000026;
Age at Treatment=45.7;gender=male;phenotype=OBI_0000747;PreTreatment PSA=10.7;Sample=CPCG0472-B1;Tissue=Blood;donor_id=CPCG0472;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-B1;Tissue=Blood;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-B1;Tissue=Blood;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-B1;Tissue=Blood;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-B1;Tissue=Blood;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-B1;Tissue=Blood;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-B1;Tissue=Blood;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-B1;Tissue=Blood;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-B1;Tissue=Blood;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0482-B1;Tissue=Blood;donor_id=CPCG0482;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0482-B1;Tissue=Blood;donor_id=CPCG0482;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0482-B1;Tissue=Blood;donor_id=CPCG0482;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0482-B1;Tissue=Blood;donor_id=CPCG0482;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0482-B1;Tissue=Blood;donor_id=CPCG0482;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0482-B1;Tissue=Blood;donor_id=CPCG0482;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0482-B1;Tissue=Blood;donor_id=CPCG0482;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.3;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.0;Sample=CPCG0482-B1;Tissue=Blood;donor_id=CPCG0482;ENA-CHECKLIST=ERC000026;
Age at Treatment=42.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0483-B1;Tissue=Blood;donor_id=CPCG0483;ENA-CHECKLIST=ERC000026;
Age at Treatment=42.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0483-B1;Tissue=Blood;donor_id=CPCG0483;ENA-CHECKLIST=ERC000026;
Age at Treatment=42.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0483-B1;Tissue=Blood;donor_id=CPCG0483;ENA-CHECKLIST=ERC000026;
Age at Treatment=42.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0483-B1;Tissue=Blood;donor_id=CPCG0483;ENA-CHECKLIST=ERC000026;
Age at Treatment=42.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0483-B1;Tissue=Blood;donor_id=CPCG0483;ENA-CHECKLIST=ERC000026;
Age at Treatment=42.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0483-B1;Tissue=Blood;donor_id=CPCG0483;ENA-CHECKLIST=ERC000026;
Age at Treatment=42.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0483-B1;Tissue=Blood;donor_id=CPCG0483;ENA-CHECKLIST=ERC000026;
Age at Treatment=42.1;gender=male;phenotype=OBI_0000922;PreTreatment PSA=6.2;Sample=CPCG0483-B1;Tissue=Blood;donor_id=CPCG0483;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-B1;Tissue=Blood;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-B1;Tissue=Blood;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-B1;Tissue=Blood;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-B1;Tissue=Blood;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-B1;Tissue=Blood;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-B1;Tissue=Blood;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-B1;Tissue=Blood;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-B1;Tissue=Blood;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-F1;Tissue=Prostate Tumour;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-F1;Tissue=Prostate Tumour;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-F1;Tissue=Prostate Tumour;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-F1;Tissue=Prostate Tumour;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-F1;Tissue=Prostate Tumour;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-F1;Tissue=Prostate Tumour;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-F1;Tissue=Prostate Tumour;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-F1;Tissue=Prostate Tumour;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-F1;Tissue=Prostate Tumour;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-F1;Tissue=Prostate Tumour;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
Age at Treatment=62.2;gender=male;Gleason Score=3+4;phenotype=OBI_0000922;PreTreatment PSA=5.6;Sample=CPCG0484-F1;Tissue=Prostate Tumour;donor_id=CPCG0484;ENA-CHECKLIST=ERC000026;
